

VILLAGECAREMAX

**MEDICARE TOTAL ADVANTAGE PLAN
(HMO D-SNP)**

**MEDICARE HEALTH ADVANTAGE PLAN
(HMO D-SNP)**



FORMULARIO 2026 (LISTA DE MEDICAMENTOS CUBIERTOS)

**POR FAVOR LEA: ESTE DOCUMENTO CONTIENE INFORMACIÓN ACERCA DE LOS
MEDICAMENTOS QUE CUBRIMOS EN ESTE PLAN**

Este formulario fue actualizado el 01/23/2026. Si desea información más reciente o tiene otras preguntas, por favor llame a Servicios a Miembros de VillageCareMAX al 855-296-8800 (usuarios de TTY llaman al 711), de 8:00 am a 8:00 pm, los 7 días de la semana o visite www.villagecaremax.org.

Nº de identificación de la entrega del archivo del formulario aprobado: 00026370

**VillageCareMAX Medicare Total Advantage Plan (HMO D-SNP)
VillageCareMAX Medicare Health Advantage Plan (HMO D-SNP)**

Formulario 2026

**(Lista de medicamentos cubiertos o
“Lista de medicamentos”)**

**POR FAVOR LEA: ESTE DOCUMENTO CONTIENE INFORMACIÓN
ACERCA DE LOS MEDICAMENTOS QUE CUBRIMOS EN ESTE PLAN**

N.º de identificación de la entrega del archivo del formulario aprobado: 00026370

Este formulario fue actualizado el 01/23/2026. Si desea información más reciente o tiene otras preguntas, por favor llame a Servicios a VillageCareMAX al 1-855-296-8800 (usuarios de TTY llaman al 711), de 8:00 am a 8:00 pm, los 7 días de la semana o visite www.villagecaremax.org.

Mensaje importante sobre lo que usted paga por las vacunas - Nuestro plan cubre la mayoría de las vacunas de la Parte D sin costo alguno para usted, incluso si usted no ha pagado su deducible. Llame a Servicios para miembros para obtener más información.

Mensaje importante sobre lo que usted paga por la insulina – Usted no pagará más de \$35 por un suministro mensual de cada producto de insulina que cubre nuestro plan, sin importar el nivel de compartición de costos en que está, incluso si usted no ha pagado su deducible.

Nota a miembros actuales: Este Formulario ha cambiado desde el año pasado. Por favor revise este documento para asegurarse de que aun contiene los medicamentos que usted toma.

Cuando esta Lista de Medicamentos (Formulario) se refiera a “nosotros”, “nuestra” o “nuestro”, significa Village Senior Services Corporation. Cuando se refiera al “plan” o “nuestro plan”, significa VillageCareMAX.

Este documento incluye la Lista de medicamentos (Formulario) para nuestro plan que es válida a partir del 01/23/2026. Contáctenos si desea una la Lista de medicamentos (Formulario) actualizada. Nuestra información de contacto, junto con la fecha en que actualizamos la Lista de medicamentos (Formulario) por última vez, aparece en la portada y contraportada.

Generalmente, debe acudir a farmacias de la red para utilizar su beneficio de medicamentos de receta. Los beneficios, el formulario, la red de farmacias y/o los copagos o el coaseguro pueden cambiar el 1º de enero de 2026 y de vez en cuando durante el año. Recibirá un aviso cuando sea necesario.

¿Qué es el Formulario de VillageCareMAX?

En este documento, usamos los términos Lista de medicamentos y Formulario para hacer referencia a lo mismo. Un formulario es una lista de medicamentos cubiertos que VillageCareMAX ha seleccionado tras consultar con un equipo de proveedores del cuidado de la salud que representa las terapias de receta que se cree son una parte necesaria de un programa de tratamiento de calidad. Por lo general, VillageCareMAX cubrirá los medicamentos incluidos en nuestro formulario siempre y cuando el medicamento sea médicamente necesario, la receta sea despachada en una farmacia de la red de VillageCareMAX's y se sigan otras reglas del plan. Si desea más información sobre cómo se surten sus recetas, consulte nuestra Evidencia de Cobertura.

¿Puede cambiar el formulario?

Aunque la mayoría de los cambios en la cobertura de medicamentos se realizan el 1º de enero, “nosotros” podríamos agregar medicamentos al formulario o quitarlos durante el año, moverlos a distintos niveles de costo compartido o añadir nuevas restricciones. Tenemos que seguir las reglas de Medicare cuando realizamos estos cambios. Las actualizaciones del formulario se publican mensualmente en nuestro sitio web aquí: www.villagecaremax.org.

Cambios que pueden afectarle este año: en los casos a continuación, usted será afectado por cambios a la cobertura durante el año:

- **Cambios inmediatos de ciertas versiones nuevas de medicamentos de marca y productos biológicos originales.** Es posible que eliminemos de inmediato un medicamento de nuestro formulario si lo reemplazamos con una determinada versión específica de ese medicamento que aparecerá en el mismo nivel de costo compartido o en uno más bajo y con las mismas restricciones o menos. Cuando se añade una nueva versión de un medicamento a nuestro formulario, podemos decidir mantener el medicamento de marca o el producto biológico original en nuestro formulario, pero inmediatamente moverlo a un nivel de costo compartido diferente o añadir nuevas restricciones. Podemos realizar estos cambios inmediatos solo si vamos a añadir una nueva versión genérica de un medicamento de marca o ciertas nuevas versiones biosimilares de un producto biológico original que ya estaba en el formulario (por ejemplo, un biosimilar intercambiable que puede cambiarse por un producto biológico original por una farmacia sin una nueva receta).
 - Si actualmente está tomando ese medicamento de marca o producto biológico original, es posible que no le informemos con anticipación antes de realizar un cambio inmediato, pero luego le proporcionaremos información sobre el o los cambios específicos que hemos realizado. Si realizamos dicho cambio, usted o su recetador pueden solicitarnos que hagamos una excepción y continuar cubriendo el medicamento de marca para usted. El aviso que le proporcionamos también incluirá información sobre cómo solicitar una excepción, y también puede encontrar información en la sección a continuación titulada "¿Cómo le solicito una excepción al formulario VillageCareMAX's?":

Puede que algunos de estos tipos de medicamentos le resulten nuevos. Para obtener más información, consulte la siguiente sección titulada “¿Qué son productos biológicos originales y cómo se relacionan con los biosimilares?”

- **Medicamentos retirados del mercado.** Si la Administración de Alimentos y Medicamentos (FDA) considera que un medicamento en nuestro formulario no es seguro o si el fabricante del medicamento retira su producto del mercado, nosotros lo quitaremos de inmediato de nuestro formulario y avisaremos a los miembros que toman ese medicamento.
- **Otros cambios.** Podremos hacer otros cambios que afectan a miembros que estén tomando medicamentos en este momento. Por ejemplo, podemos añadir un medicamento genérico el cual no es nuevo en el mercado para reemplazar uno de marca que esté actualmente en el formulario o añadir nuevas restricciones a medicamentos de marca o mover el medicamento a un nivel de copago diferente o ambas cosas. O podemos hacer cambios basados en nuevas reglas clínicas. Si quitamos medicamentos de nuestro formulario o añadimos autorización previa, limitamos la cantidad y/o tenemos restricciones de terapia escalonada para un medicamento, tenemos que notificarles a los miembros afectados del cambio por lo menos 30 días antes de que el cambio entre en vigencia o al momento en que el miembro solicite que se le vuelva a despachar el medicamento y entonces se le surtirá por 30 días, en cuyo momento el miembro recibirá un suministro del medicamento para 60 días.
 - Si realizamos estos otros cambios, usted o su recetador pueden solicitarnos que hagamos una excepción y continuar cubriendo el medicamento de marca para usted. El aviso que le proporcionamos también incluirá información sobre cómo solicitar una excepción, y también puede encontrar información en la sección a continuación titulada "¿Cómo le solicito una excepción al formulario VillageCareMAX's?":

Cambios que no le afectarán si actualmente usted está tomando el medicamento. Generalmente, si usted está tomando un medicamento de nuestro formulario 2026 que estuvo cubierto a principios del año, no descontinuaremos ni reduciremos la cobertura del medicamento durante el año de cobertura 2026, excepto en los casos mencionados anteriormente. Esto significa que estos medicamentos continuarán estando disponibles al mismo costo compartido para aquellos miembros que lo tomen por el resto del año de cobertura. Este año, usted no será avisado sobre cambios que no le afectan. Sin embargo, el 1º de enero del próximo año, tales cambios podrían afectarle y es importante revisar la Lista de Medicamentos para el nuevo año de beneficios para ver todo cambio a los medicamentos.

El formulario adjunto es válido a partir del 01/23/2026. Por favor contáctenos para obtener información actualizada sobre los medicamentos que cubre VillageCareMAX. Nuestra información de contacto se encuentra en la portada y contraportada.

En caso de que a la mitad del año el plan realice un cambio al formulario que no es de mantenimiento, le notificaremos sobre el cambio por correo. El aviso contendrá información concreta sobre el cambio al formulario que no es de mantenimiento y le será enviado por lo menos 30 días antes de la fecha de entrada en vigor del cambio. Puede ver los cambios más recientes y el formulario en nuestro sitio web (www.villagecaremax.org) o llame a Servicios a Miembros para pedir más información.

¿Cómo uso el formulario?

Hay dos maneras para encontrar su medicamento dentro del formulario:

Enfermedad

El formulario comienza en la página 3. Los medicamentos en este formulario están agrupados en categorías según el tipo de enfermedades que tratan. Por ejemplo, los medicamentos utilizados para tratar enfermedades del corazón se encuentran bajo la categoría “Agentes cardiovasculares”. Si sabe para lo que se utiliza su medicamento, busque el nombre de la categoría en la lista que comienza abajo en la página 3. Luego, busque bajo el nombre de la categoría para encontrar su medicamento.

Lista alfabética

Si no está seguro bajo cuál categoría buscar, debe tratar de encontrar su medicamento en el índice que comienza en la página I-1. El índice contiene la lista alfabética de todos los medicamentos de marca y genéricos incluidos en este documento. Busque en el índice y encuentre su medicamento. Al lado de su medicamento, verá el número de la página donde está la información sobre cobertura. Pase a la página enumerada en el índice y encuentre el nombre de su medicamento en la primera columna de la lista.

¿Qué son medicamentos genéricos?

VillageCareMAX cubre tanto los medicamentos con nombre de marca como los genéricos. Un medicamento genérico es aprobado por la FDA por tener el mismo principio activo que el de marca. Por lo general, los medicamentos genéricos cuestan menos que los medicamentos de marca.

¿Hay cualquier tipo de restricciones en mi cobertura?

Algunos medicamentos cubiertos pueden tener más requerimientos o límites en su cobertura. Estos requerimientos o límites pueden ser:

- **Autorización previa:** VillageCareMAX le exige a usted o su médico obtener autorización previa para ciertos medicamentos, o sea que la aprobación de VillageCareMAX es necesaria antes de que le surtan sus recetas. Si no obtiene la aprobación, VillageCareMAX podría no cubrir el medicamento.
- **Límites en la cantidad:** Para ciertos medicamentos, VillageCareMAX limita la cantidad de medicamento que cubrirá. Por ejemplo, VillageCareMAX proporciona 60 cápsulas de Celebrex por cada receta. Esto podría ser además del suministro estándar de un mes o tres meses.
- **Terapia escalonada:** En algunos casos, VillageCareMAX le exige que primero pruebe cierto medicamento que trate su enfermedad antes de que cubramos otro medicamento para esa enfermedad. Por ejemplo, si tanto el Medicamento A como el Medicamento B tratan su enfermedad, es posible que VillageCareMAX no cubra el Medicamento B a menos que usted pruebe el Medicamento A primero. Si el Medicamento A no le funciona, entonces VillageCareMAX cubrirá el Medicamento B.

Puede averiguar si su medicamento tiene algún requerimiento o límite extra buscándolo en el formulario que comienza en la página 3. También puede obtener más información sobre las restricciones aplicadas a medicamentos específicos cubiertos visitando nuestro sitio Web en www.villagecaremax.org. Hemos publicado documentos en línea que explican nuestra autorización previa y las restricciones de la terapia escalonada. También puede pedirnos que le enviemos una copia. Nuestra información de contacto y la fecha en que actualizamos este formulario por última vez aparecen en la portada y contraportada.

Puede pedirle a VillageCareMAX que haga una excepción a estas restricciones o límites o que le mande una lista de otros medicamentos similares que podrían tratar su padecimiento de salud. Consulte la sección “¿Cómo le solicito una excepción al formulario de VillageCareMAX’s?” en la página v abajo para obtener información sobre cómo solicitar una excepción.

¿Qué son medicamentos de venta directa (OTC)?

Los medicamentos OTC, los cuales se venden sin receta, son aquéllos que un Plan de Medicamentos de Receta de Medicare normalmente no cubre. VillageCareMAX paga por ciertos medicamentos OTC.

Bajo el beneficio OTC, el plan cubre algunos medicamentos OTC para tratar varios padecimientos, entre ellos:

- Aspirina para adultos y alivio del dolor
- Líquidos o tabletas para la tos, el resfriado y la gripe en adultos
- Medicamentos para las alergias y los senos nasales
- Medicamentos antidiarreicos
- Medicamentos antimicóticos
- Medicamentos contra los gases
- Medicamentos contra la comezón
- Suplementos para la diabetes
- Auxiliares digestivos
- Prebióticos y probióticos para la salud digestiva
- Salud cardíaca
- Somníferos
- Vitaminas y minerales
- Control del peso (tabletas, cápsulas, etc.)

VillageCareMAX le proporcionará estos medicamentos OTC drugs sin costo alguno para usted. El costo de estos medicamentos OTC para VillageCareMAX no contará para sus costos totales de medicamentos de la Parte D (es decir, el costo de los medicamentos OTC no cuenta para la brecha de cobertura).

¿Qué pasa si mi medicamento no está en el formulario?

Si este formulario (lista de medicamentos cubiertos) no incluye su medicamento, debe llamar a Servicios a Miembros primero y preguntar si su medicamento está cubierto.

Si averigua que VillageCareMAX no cubre su medicamento, tiene dos opciones:

Puede pedirle a Servicios a Miembros una lista de medicamentos similares cubiertos por VillageCareMAX. Cuando reciba la lista, muéstresela a su doctor y pídale que le recete un medicamento similar cubierto por VillageCareMAX.

- Puede pedirle a VillageCareMAX que haga una excepción y cubra su medicamento. Vea abajo las instrucciones para solicitar una excepción.

¿Cómo le solicito una excepción al formulario VillageCareMAX?

Puede pedirle a VillageCareMAX que haga una excepción a las reglas de nuestra cobertura. Hay varios tipos de excepciones que puede pedirnos que hagamos.

- Puede pedirnos que cubramos un medicamento incluso si no está en nuestro formulario. Si lo aprobamos, cubriremos este medicamento a su nivel apropiado de costo compartido y usted no podría pedirnos que le proporcionemos el medicamento a un nivel inferior de costo compartido.
- Puede pedirnos que cubramos un medicamento en el formulario a un nivel de costo compartido más bajo, que el medicamento este en un nivel especial.
- Puede pedirnos que no apliquemos las restricciones o los límites de cobertura para su medicamento. Por ejemplo, para ciertos medicamentos, el plan limita la cantidad del medicamento que cubriremos. Si su medicamento tiene un límite de cantidad, puede pedirnos que no apliquemos el límite y cubramos una cantidad mayor.

Generalmente, VillageCareMAX solamente aprobará su solicitud para una excepción si los medicamentos alternativos incluidos en el formulario del plan o las restricciones adicionales de utilización no serían tan eficaces para tratar su enfermedad y/o le causarían efectos médicos adversos.

Debe contactarnos para pedirnos una decisión de cobertura inicial para un formulario o excepción a la utilización de la restricción. **Cuando solicite una excepción al formulario o a la restricción de utilización debe presentar una declaración de su recetante o médico que justifica su solicitud.** Generalmente, tenemos que decidir dentro de 72 horas tras recibir la declaración justificante de su recetante. Puede solicitar una excepción agilizada (rápida) si usted o su doctor creen que peligraría mucho su salud si esperara hasta 72 horas para la decisión. Si aprobamos la agilización de su solicitud, tenemos que darle nuestra decisión a más tardar 24 horas tras recibir la declaración justificante de su doctor u otro recetante.

¿Qué hago antes de poder hablar con mi doctor acerca de cambiar mis medicamentos o solicitar una excepción?

Como miembro nuevo o uno que continúa en nuestro plan, es posible que esté tomando medicamentos que no están en nuestro formulario. Por el otro lado, podría estar tomando un medicamento que sí está en nuestro formulario, pero le es difícil obtenerlo. Por ejemplo, quizás necesita una autorización previa de nosotros antes de que le puedan surtir su receta. Debe hablar con su doctor para decidir si debe cambiar a un medicamento apropiado que cubrimos o solicitar una excepción al formulario para que cubramos el medicamento que toma. Mientras habla con su doctor para determinar la forma indicada de proceder para usted, podríamos cubrir su medicamento en ciertos casos durante los primeros 90 días en que es miembro de nuestro plan.

Para cada medicamento suyo que no está en nuestro formulario o si se le dificulta obtener sus medicamentos, le cubriremos un suministro temporal de 30 días. Si su receta está escrita para menos días, le permitiremos suministros a un máximo de 30 días. Después de su primer suministro de 30 días, no pagaremos por esos medicamentos, incluso si ha sido miembro del plan por menos de 90 días.

Si es residente en un centro de cuidados a largo plazo, y si necesita un medicamento que no está en nuestro

formulario o si su capacidad para obtener un medicamento es limitada pero ya has pasado los primeros 90 días de membresía en nuestro plan, cubriremos un suministro de emergencia de 31 días de ese medicamento mientras usted intenta que le aprueben una excepción al formulario.

VillageCareMAX tiene una póliza de transición que asegura de que se siga proporcionando la continuación de la cobertura del medicamento a miembros nuevos y actuales. Hay veces cuando usted puede sentir un cambio en su nivel de atención, como ingreso a un centro de cuidados a largo plazo u hospital (o alta de estos lugares). En estos casos, le proporcionaremos un solo suministro de emergencia de un medicamento que no está en el formulario. Los medicamentos que no están en el formulario son aquéllos que no están en el formulario del plan y los medicamentos que sí están en nuestro formulario, pero requieren autorización previa o terapia escalonada bajo las reglas de manejo de la utilización del plan.

Para más información

Para información más detallada sobre su cobertura de medicamentos de receta de VillageCareMAX, sírvase consultar su Evidencia de Cobertura y otros documentos del plan.

Si tiene preguntas acerca de VillageCareMAX, por favor contáctenos. Nuestra información de contacto, junto con la fecha en que actualizamos el formulario por última vez, aparece en la portada y contraportada.

Si tiene preguntas generales acerca de los medicamentos de receta que cubre Medicare, llame a Medicare al 1-800-MEDICARE (1-800-633-4227) las 24 horas del día y los 7 días de la semana (los usuarios de TTY deben llamar al 1-877-486-2048) o bien visite <http://www.medicare.gov>.

El formulario de VillageCareMAX's

El formulario a continuación informa sobre los medicamentos que cubre VillageCareMAX. Si tiene dificultades para encontrar su medicamento en la lista, consulte el índice que comienza en la página I-1.

La primera columna del cuadro contiene el nombre del medicamento. Los medicamentos con nombre de marca se escriben con mayúsculas (p. ej., BENICAR) y los genéricos con minúsculas (p. ej., *losartan*).

La información dada en la columna de Requerimientos/Límites le indica si el plan tiene cualquier requerimiento especial para la cobertura de su medicamento.

El siguiente cuadro contiene las definiciones para las abreviaturas que aparecen en la columna de “Requerimientos /Límites” en la lista de medicamentos abajo que comienza en la página 3.

| ABREVIATURA O SÍMBOLO | DESCRIPCIÓN | EXPLICACIÓN |
|---|--|---|
| Restricciones en el manejo de la utilización | | |
| PA | Restricción de autorización previa | Se le exige a usted (o a su médico) obtener autorización previa de VillageCareMAX antes de que le surtan su receta para este medicamento. Sin aprobación previa, VillageCareMAX podría no cubrir este medicamento. |
| PA BvD | Restricción de autorización previa para la determinación de la Parte B vs. Parte D | Este medicamento puede satisfacer las condiciones de pago bajo la Parte B o D de Medicare. Se le exige a usted (o a su médico) obtener autorización previa de VillageCareMAX para determinar que este medicamento lo cubre la Parte D de Medicare antes de que le surtan su receta para este medicamento. Sin aprobación previa, VillageCareMAX podría no cubrir este medicamento. |
| PA-HRM | Restricción de autorización previa para los Medicamentos de Alto Riesgo | CMS considera que este medicamento es posiblemente dañino y por lo tanto, es un Medicamento de Alto Riesgo para los beneficiarios de Medicare mayores de 65 años. Los miembros mayores de 65 años tienen que obtener autorización previa de VillageCareMAX antes de que les surtan su receta para este medicamento. Sin aprobación previa, VillageCareMAX podría no cubrir este medicamento |

| ABREVIATURA O SÍMBOLO | DESCRIPCIÓN | EXPLICACIÓN |
|--|---|--|
| PA NSO | Restricción de autorización previa para nuevos miembros solamente | Si es nuevo miembro o no ha tomado este medicamento antes, se le exige a usted (o su médico) obtener autorización previa de VillageCareMAX antes de que le surtan su receta para este medicamento. Sin aprobación previa, VillageCareMAX podría no cubrir este medicamento. |
| QL | Restricción que limita la cantidad | VillageCareMAX limita la cantidad de este medicamento cubierto por cada receta o dentro de un plazo específico. |
| ST | Restricción de la terapia escalonada | Antes de que VillageCareMAX pueda cubrir este medicamento, usted primero tiene que probar otro(s) medicamento(s) para tratar su enfermedad. Este medicamento puede cubrirse solo si otro(s) medicamento(s) no funciona(n) para usted. |
| OTROS REQUERIMIENTOS ESPECIALES PARA LA COBERTURA | | |
| LA | Medicamento de acceso restringido | Esta receta puede estar disponible solo en ciertas farmacias. Para más información, consulte su Directorio de Proveedores y Farmacias o llame a Servicios Farmacéuticos a Miembros al 1-888-807-6806, las 24 horas del día y los días de la semana. Los usuarios de TTY deben llamar al 711. |
| NM | Medicamento que no es de venta por correo | Quizás pueda recibir un suministro mayor de 1 mes de la mayoría de los medicamentos en nuestro formulario si los compra por correo a un costo compartido menor. Los medicamentos <u>no</u> disponibles mediante su beneficio de venta por correo se indican con “NM” en la columna de Requerimientos/Limites de su formulario. |

Availability of Language Assistance Services and Auxiliary Aids and Services

English: ATTENTION: If you speak English, free language assistance services are available to you. Appropriate auxiliary aids and services to provide information in accessible formats are also available free of charge. Call 1-855-296-8800 (TTY: 711) or speak to your provider.

Spanish: ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. También están disponibles' de forma gratuita' ayuda y servicios auxiliares adecuados para proporcionar información en formatos accesibles. Llame al 1-855-296-8800 (TTY:711) o hable con su proveedor.

Simplified Chinese: 中文

注意：如果您说[中文]，我们将免费为您提供语言协助服务。我们还免费提供适当的辅助工具和服务，以无障碍格式提供信息。致电 1-855-296-8800（文本电话：711）或咨询您的服务提供商。

Traditional Chinese: 台語

注意：如果您說[台語]，我們可以為您提供免費語言協助服務。也可以免費提供適當的輔助工具與服務，以無障礙格式提供資訊。請致電 1-855-296-8800（TTY：711）或與您的提供者討論。

Tagalog: PAALALA: Kung nagsasalita ka ng Tagalog, magagamit mo ang mga libreng serbisyong tulong sa wika. Magagamit din nang libre ang mga naaangkop na auxiliary na tulong at serbisyo pero magbigay ng impormasyon sa mga naa-access na format. Tumawag sa 1-855-296-8800 (TTY:711) o makipag-usap sa iyong provider.

French: ATTENTION : Si vous parlez français, des services d'assistance linguistique gratuits sont à votre disposition. Des aides et services auxiliaires appropriés pour fournir des informations dans des formats accessibles sont également disponibles gratuitement. Appelez le 1-855-296-8800 (TTY :711) ou adressez-vous à votre prestataire.

Vietnamese: LƯU Ý: Nếu quý vị nói tiếng Việt, chúng tôi cung cấp miễn phí các dịch vụ hỗ trợ ngôn ngữ. Các hỗ trợ dịch vụ phù hợp để cung cấp thông tin theo các định dạng dễ tiếp cận cũng được cung cấp miễn phí. Vui lòng gọi theo số 1-855-296-8800 (Người khuyết tật: 711) hoặc trao đổi với người cung cấp dịch vụ của quý vị.

German: ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlose

Sprachassistentenzdienste zur Verfügung.
Entsprechende Hilfsmittel und Dienste zur
Bereitstellung von Informationen zugänglichen
Formaten stehen ebenfalls kostenlos zur
Verfügung. Rufen Sie 1-855-296-8800 (TTY:711)
an oder sprechen Sie mit Ihrem Provider.

Korean: 주의: 한국어를 사용하시는 경우 무료 언어 지원 서비스를 이용하실 수 있습니다. 이용 가능한 형식으로 정보를 제공하는 적절한 보조 기구 및 서비스도 무료로 제공됩니다. 1-855-296-8800 (TTY: 711)번으로 전화하거나 서비스 제공업체에 문의하십시오.

Russian: ВНИМАНИЕ! Если вы говорите на русском языке, вы можете бесплатно воспользоваться услугами языковой поддержки. Также бесплатно предоставляются соответствующие вспомогательные средства и услуги, обеспечивающие доступ к информации в удобном формате. Позвоните по телефону 1-855-296-8800 (TTY: 711) или обратитесь к своему поставщику стоматологических услуг.

(Arabic)تنبيه: إذا كنت تتحدث اللغة العربية، فستتوفر لك خدمات المساعدة اللغوية المجانية. كما تتوفر وسائل مساعدة وخدمات مناسبة لتوفير المعلومات بتنسيقات يمكن الوصول إليها مجانًا. اتصل على الرقم 1-855-296-8800 (711) أو تحدث إلى مقدم الخدمة".

Hindi: ध्यान दें: यदि आप हिंदी बोलते हैं, तो आपके लिए निःशुल्क भाषा सहायता सेवाएं उपलब्ध होती हैं। सुलभ प्रारूपों में जानकारी प्रदान करने के लिए उपयुक्त सहायक साधन और सेवाएँ भी निःशुल्क उपलब्ध हैं। 1-855-296-8800 (TTY: 711) पर कॉल करें या अपने प्रदाता से बात करें।”

Italian: ATTENZIONE: se parli Italiano, sono disponibili servizi di assistenza linguistica gratuiti. Sono inoltre disponibili gratuitamente ausili e servizi ausiliari adeguati per fornire informazioni in formati accessibili. Chiama l'1-855-296-8800 (tty: 711) o parla con il tuo fornitore.

Portuguese: ATENÇÃO: Se você fala português, serviços gratuitos de assistência linguística estão disponíveis para você. Auxílios e serviços auxiliares apropriados para fornecer informações em formatos acessíveis também estão disponíveis gratuitamente. Ligue para 1-855-296-8800 (TTY: 711) ou fale com seu provedor.

French Creole: ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd ki disponib pou ou gratis nan lang ou pale a. Èd ak sèvis anplis apwopriye pou bay enfòmasyon nan fòm aksèsib yo

disponib gratis tou. Rele nan 1-855-296-8800 (TTY: 711) oswa pale avèk founisè w la.

Polish: UWAGA: Osoby mówiące po polsku mogą skorzystać z bezpłatnej pomocy językowej. Dodatkowe pomoce i usługi zapewniające informacje w dostępnych formatach są również dostępne bezpłatnie. Prosimy zadzwonić pod numer 1-855-296-8800 (TTY:711) lub porozmawiać ze swoim świadczeniodawcą.

Japanese: 注：日本語を話される場合、無料の言語支援サービスをご利用いただけます。アクセシブル（誰もが利用できるよう配慮された）な形式で情報を提供するための適切な補助支援やサービスも無料でご利用いただけます。1-855-296-8800（TTY：711）までお電話ください。または、ご利用の事業者にご相談ください。

Table of Contents

| | |
|--|-----|
| Analgesics | 3 |
| Anesthetics | 8 |
| Anti-Addiction/Substance Abuse Treatment Agents | 8 |
| Antianxiety Agents | 9 |
| Antibacterials | 11 |
| Anticancer Agents | 19 |
| Anticonvulsants | 38 |
| Antidementia Agents | 44 |
| Antidepressants | 45 |
| Antidiabetic Agents | 48 |
| Antifungals | 54 |
| Antigout Agents | 56 |
| Antihistamines | 57 |
| Anti-Infectives (Skin And Mucous Membrane) | 57 |
| Antimigraine Agents | 58 |
| Antimycobacterials | 59 |
| Antinausea Agents | 59 |
| Antiparasite Agents | 61 |
| Antiparkinsonian Agents | 62 |
| Antipsychotic Agents | 64 |
| Antivirals (Systemic) | 70 |
| Blood Products/Modifiers/Volume Expanders | 77 |
| Caloric Agents | 81 |
| Cardiovascular Agents | 82 |
| Central Nervous System Agents | 94 |
| Contraceptives | 99 |
| Dental And Oral Agents | 109 |

| | |
|---|-----|
| Dermatological Agents | 109 |
| Devices | 115 |
| Enzyme Cofactors/Chaperones | 160 |
| Enzyme Replacement/Modifiers | 160 |
| Eye, Ear, Nose, Throat Agents | 161 |
| Gastrointestinal Agents | 166 |
| Genitourinary Agents | 170 |
| Heavy Metal Antagonists | 171 |
| Hormonal Agents, Stimulant/Replacement/Modifying | 171 |
| Immunological Agents | 177 |
| Inflammatory Bowel Disease Agents | 190 |
| Metabolic Bone Disease Agents | 190 |
| Miscellaneous Therapeutic Agents | 192 |
| Ophthalmic Agents | 194 |
| Replacement Preparations | 195 |
| Respiratory Tract Agents | 197 |
| Skeletal Muscle Relaxants | 202 |
| Sleep Disorder Agents | 202 |
| Vasodilating Agents | 203 |
| Vitamins And Minerals | 204 |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--|
| Analgesics | | |
| Analgesics, Miscellaneous | | |
| <i>acetaminophen-codeine 300-30 mg/12.5 ml cup inner 300 mg-30 mg /12.5 ml</i> | 1 | QL (4500 per 30 days) |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | 1 | QL (4500 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg</i> | 2 | QL (360 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i> | 2 | QL (180 per 30 days) |
| <i>ascomp with codeine oral capsule 30-50-325-40 mg</i> (codeine-butalbital-asa-caff) | 2 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>buprenorphine transdermal patch weekly 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour</i> (Butrans) | 3 | QL (4 per 28 days) |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg</i> | 4 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg</i> | 2 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-acetaminophen-caff oral capsule 50-300-40 mg</i> (Fioricet) | 4 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-acetaminophen-caff oral capsule 50-325-40 mg</i> | 4 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> | 2 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40 mg</i> | 2 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butorphanol nasal spray, non-aerosol 10 mg/ml</i> | 2 | QL (5 per 28 days) |
| <i>codeine sulfate oral tablet 15 mg, 60 mg</i> | 4 | QL (180 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| <i>codeine sulfate oral tablet 30 mg</i> | 2 | QL (180 per 30 days) |
| <i>codeine-butalbital-asa-caff oral capsule 30-50-325-40 mg</i> (Ascomp with Codeine) | 2 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>endocet oral tablet 10-325 mg</i> (oxycodone-acetaminophen) | 2 | QL (180 per 30 days) |
| <i>endocet oral tablet 2.5-325 mg, 5-325 mg</i> (oxycodone-acetaminophen) | 2 | QL (360 per 30 days) |
| <i>endocet oral tablet 7.5-325 mg</i> (oxycodone-acetaminophen) | 2 | QL (240 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg</i> | 5 | PA; NDS; QL (120 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg</i> | 2 | PA; QL (120 per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | 2 | QL (10 per 30 days) |
| <i>fioricet oral capsule 50-300-40 mg</i> (butalbital-acetaminophen-caff) | 4 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>hydrocodone-acetaminophen oral solution 10-300 mg/15 ml, 10-325 mg/15 ml, 7.5-325 mg/15 ml</i> | 2 | QL (2700 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-300 mg, 7.5-300 mg</i> | 4 | QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 7.5-325 mg</i> | 2 | QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 5-300 mg</i> | 4 | QL (240 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 5-325 mg</i> | 2 | QL (240 per 30 days) |
| <i>hydrocodone-ibuprofen 5-200 mg</i> | 2 | QL (150 per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg</i> | 4 | QL (150 per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 5-200 mg, 7.5-200 mg</i> | 2 | QL (150 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml</i> | 2 | |
| <i>hydromorphone oral liquid 1 mg/ml</i> (Dilaudid) | 2 | QL (1200 per 30 days) |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i> (Dilaudid) | 2 | QL (180 per 30 days) |
| <i>methadone oral solution 10 mg/5 ml</i> | 2 | QL (600 per 30 days) |
| <i>methadone oral solution 5 mg/5 ml</i> | 2 | QL (1200 per 30 days) |
| <i>methadone oral tablet 10 mg</i> | 2 | QL (120 per 30 days) |
| <i>methadone oral tablet 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i> | 2 | PA; QL (180 per 30 days) |
| <i>morphine oral solution 10 mg/5 ml</i> | 2 | QL (700 per 30 days) |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | QL (300 per 30 days) |
| MORPHINE ORAL TABLET 15 MG | 4 | QL (180 per 30 days) |
| MORPHINE ORAL TABLET 30 MG | 4 | QL (120 per 30 days) |
| <i>morphine oral tablet extended release 100 mg</i> | 2 | QL (60 per 30 days) |
| <i>morphine oral tablet extended release 15 mg, 30 mg</i> (MS Contin) | 2 | QL (90 per 30 days) |
| <i>morphine oral tablet extended release 200 mg</i> | 4 | QL (60 per 30 days) |
| <i>morphine oral tablet extended release 60 mg</i> (MS Contin) | 2 | QL (60 per 30 days) |
| <i>oxycodone oral capsule 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>oxycodone oral concentrate 20 mg/ml</i> | 4 | PA; QL (120 per 30 days) |
| <i>oxycodone oral solution 5 mg/5 ml</i> | 2 | QL (1300 per 30 days) |
| <i>oxycodone oral tablet 10 mg, 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>oxycodone oral tablet 15 mg, 30 mg</i> (Roxicodone) | 2 | QL (120 per 30 days) |
| <i>oxycodone oral tablet 20 mg</i> | 2 | QL (120 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i> (Endocet) | 2 | QL (180 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg</i> (Endocet) | 2 | QL (360 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--|
| <i>oxycodone-acetaminophen oral tablet</i> (Endocet) 7.5-325 mg | 2 | QL (240 per 30 days) |
| <i>oxymorphone oral tablet 10 mg</i> | 3 | QL (120 per 30 days) |
| <i>oxymorphone oral tablet 5 mg</i> | 3 | QL (180 per 30 days) |
| <i>oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg</i> | 3 | QL (60 per 30 days) |
| <i>tencon oral tablet 50-325 mg</i> (butalbital-acetaminophen) | 2 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>tramadol oral tablet 50 mg</i> | 1 | QL (240 per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 2 | QL (300 per 30 days) |
| <i>zebutal oral capsule 50-325-40 mg</i> (butalbital-acetaminophen-caff) | 4 | PA; QL (180 per 30 days); AGE (Max 64 Years) |
| Nonsteroidal Anti-Inflammatory Agents | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> (Celebrex) | 2 | QL (60 per 30 days) |
| <i>diclofenac epolamine transdermal patch 12 hour 1.3 %</i> (Flector) | 4 | PA; QL (60 per 30 days) |
| <i>diclofenac potassium oral tablet 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet extended release 24 hr 100 mg</i> | 2 | |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 25 mg</i> | 2 | |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 75 mg</i> | 2 | QL (60 per 30 days) |
| <i>diclofenac sodium topical drops 1.5 %</i> | 3 | QL (300 per 30 days) |
| <i>diclofenac sodium topical gel 3 %</i> | 3 | PA; QL (100 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---|
| <i>diclofenac sodium topical solution in metered-dose pump 20 mg/gram /actuation(2 %)</i> | 5 | PA; NDS; QL (224 per 28 days) |
| <i>diclofenac-misoprostol oral tablet,ir,delayed rel,biphasic 50-200 mg-mcg</i> (Arthrotec 50) | 2 | |
| <i>diclofenac-misoprostol oral tablet,ir,delayed rel,biphasic 75-200 mg-mcg</i> (Arthrotec 75) | 2 | |
| <i>diflunisal oral tablet 500 mg</i> | 2 | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 2 | |
| <i>etodolac oral tablet 400 mg</i> (Lodine) | 2 | |
| <i>etodolac oral tablet 500 mg</i> | 2 | |
| <i>fenoprofen oral tablet 600 mg</i> (Nalfon) | 4 | |
| <i>flurbiprofen oral tablet 100 mg</i> (Lurbiro) | 2 | |
| <i>ibu oral tablet 400 mg</i> (ibuprofen) | 1 | QL (240 per 30 days) |
| <i>ibu oral tablet 600 mg, 800 mg</i> (ibuprofen) | 1 | |
| <i>ibuprofen oral suspension 100 mg/5 ml</i> (Children's Advil) | 2 | |
| <i>ibuprofen oral tablet 400 mg</i> (IBU) | 1 | QL (240 per 30 days) |
| <i>ibuprofen oral tablet 600 mg, 800 mg</i> (IBU) | 1 | |
| <i>ibuprofen-famotidine oral tablet 800-26.6 mg</i> | 4 | PA; QL (90 per 30 days) |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | 2 | PA; AGE (Max 64 Years) |
| <i>indomethacin oral capsule, extended release 75 mg</i> | 2 | |
| <i>ketoprofen oral capsule,ext rel. pellets 24 hr 200 mg</i> | 4 | |
| <i>ketorolac oral tablet 10 mg</i> | 2 | PA; QL (20 per 30 days); AGE (Max 64 Years) |
| <i>mefenamic acid oral capsule 250 mg</i> | 4 | |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 1 | |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>naproxen oral tablet 250 mg, 375 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| <i>naproxen oral tablet 500 mg</i> (Naprosyn) | 1 | |
| <i>naproxen oral tablet, delayed release (dr/ec) 375 mg</i> (EC-Naprosyn) | 2 | |
| <i>naproxen oral tablet, delayed release (dr/ec) 500 mg</i> (EC-Naprosyn) | 4 | |
| <i>piroxicam oral capsule 10 mg</i> | 2 | |
| <i>piroxicam oral capsule 20 mg</i> (Feldene) | 2 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 2 | |
| Anesthetics | | |
| Local Anesthetics | | |
| <i>dermacinrx lidocan 5% patch outer</i> (lidocaine) | 3 | PA; QL (90 per 30 days) |
| <i>glydo mucous membrane jelly in applicator 2 %</i> (lidocaine hcl) | 2 | QL (30 per 30 days) |
| <i>lidocaine hcl mucous membrane jelly in applicator 2 %</i> (Glydo) | 2 | QL (30 per 30 days) |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | 2 | PA |
| <i>lidocaine topical adhesive patch, medicated 5 %</i> (DermacinRx Lidocan) | 3 | PA; QL (90 per 30 days) |
| <i>lidocaine topical ointment 5 %</i> | 2 | PA; QL (240 per 30 days) |
| <i>lidocaine viscous mucous membrane solution 2 %</i> (lidocaine hcl) | 2 | |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i> | 2 | PA; QL (30 per 30 days) |
| <i>lidocan iii topical adhesive patch, medicated 5 %</i> (lidocaine) | 3 | PA; QL (90 per 30 days) |
| <i>tridacaine ii topical adhesive patch, medicated 5 %</i> (lidocaine) | 3 | PA; QL (90 per 30 days) |
| ZTLIDO TOPICAL ADHESIVE PATCH, MEDICATED 1.8 % | 3 | PA; QL (90 per 30 days) |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| <i>acamprosate oral tablet, delayed release (dr/ec) 333 mg</i> | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i> | 2 | |
| <i>buprenorphine-naloxone sublingual film 12-3 mg, 2-0.5 mg, 4-1 mg, 8-2 mg</i> (Suboxone) | 4 | |
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i> | 2 | |
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | 2 | |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | 2 | |
| KLOXXADO NASAL SPRAY, NON-AEROSOL 8 MG/ACTUATION | 3 | QL (4 per 30 days) |
| <i>naloxone injection solution 0.4 mg/ml</i> | 2 | |
| <i>naloxone injection syringe 0.4 mg/ml, 0.4 mg/ml (prefilled syringe), 1 mg/ml</i> | 2 | |
| <i>naloxone nasal spray, non-aerosol 4 mg/actuation</i> (Narcan) | 2 | QL (4 per 30 days) |
| <i>naltrexone oral tablet 50 mg</i> | 2 | |
| NICOTROL INHALATION CARTRIDGE 10 MG | 4 | |
| NICOTROL NS NASAL SPRAY, NON-AEROSOL 10 MG/ML | 4 | QL (240 per 180 days) |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg</i> (Chantix) | 3 | QL (336 per 365 days) |
| <i>varenicline tartrate oral tablet 1 mg (56 pack)</i> | 3 | QL (336 per 365 days) |
| <i>varenicline tartrate oral tablets, dose pack 0.5 mg (11)- 1 mg (42)</i> (Chantix Starting Month Box) | 3 | |
| Antianxiety Agents | | |
| Benzodiazepines | | |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg</i> (Xanax) | 1 | QL (120 per 30 days) |
| <i>alprazolam oral tablet 2 mg</i> (Xanax) | 1 | QL (150 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>alprazolam oral tablet extended release 24 hr 0.5 mg</i> | 2 | QL (120 per 30 days) |
| <i>alprazolam oral tablet extended release 24 hr 1 mg, 2 mg</i> (Xanax XR) | 2 | QL (120 per 30 days) |
| <i>alprazolam oral tablet extended release 24 hr 3 mg</i> | 2 | QL (90 per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 2 | QL (120 per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> (Klonopin) | 1 | QL (90 per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> (Klonopin) | 1 | QL (300 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 2 | QL (90 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 2 mg</i> | 2 | QL (300 per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 4 | QL (180 per 30 days) |
| <i>diazepam injection solution 5 mg/ml</i> | 2 | QL (10 per 28 days) |
| <i>diazepam injection syringe 5 mg/ml</i> | 3 | |
| <i>diazepam intensol oral concentrate 5 mg/ml</i> (diazepam) | 2 | QL (1200 per 30 days) |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | 2 | QL (1200 per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> (Valium) | 1 | QL (120 per 30 days) |
| <i>estazolam oral tablet 1 mg</i> | 2 | QL (60 per 30 days) |
| <i>estazolam oral tablet 2 mg</i> | 2 | QL (30 per 30 days) |
| <i>flurazepam oral capsule 15 mg</i> | 2 | QL (60 per 30 days) |
| <i>flurazepam oral capsule 30 mg</i> | 2 | QL (30 per 30 days) |
| <i>lorazepam 2 mg/ml oral concent</i> (Lorazepam Intensol) | 2 | QL (150 per 30 days) |
| <i>lorazepam 4 mg/ml vial inner</i> (Ativan) | 1 | QL (2 per 30 days) |
| <i>lorazepam injection solution 2 mg/ml</i> (Ativan) | 1 | QL (2 per 30 days) |
| <i>lorazepam injection solution 4 mg/ml</i> (Ativan) | 4 | QL (2 per 30 days) |
| <i>lorazepam injection syringe 2 mg/ml</i> | 1 | QL (2 per 30 days) |
| <i>lorazepam intensol oral concentrate 2 mg/ml</i> (lorazepam) | 2 | QL (150 per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> (Ativan) | 1 | QL (90 per 30 days) |
| <i>lorazepam oral tablet 2 mg</i> (Ativan) | 1 | QL (150 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------|
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 2 | QL (120 per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> (Restoril) | 1 | QL (30 per 30 days) |
| <i>temazepam oral capsule 22.5 mg</i> (Restoril) | 2 | QL (30 per 30 days) |
| <i>temazepam oral capsule 7.5 mg</i> (Restoril) | 2 | QL (120 per 30 days) |
| <i>triazolam oral tablet 0.125 mg</i> | 2 | QL (120 per 30 days) |
| <i>triazolam oral tablet 0.25 mg</i> (Halcion) | 2 | QL (60 per 30 days) |
| Antibacterials | | |
| Aminoglycosides | | |
| <i>amikacin injection solution 500 mg/2 ml</i> | 2 | |
| ARIKAYCE INHALATION SUSPENSION FOR NEBULIZATION 590 MG/8.4 ML | 5 | PA; NDS; QL (235.2 per 28 days) |
| <i>gentamicin injection solution 40 mg/ml</i> | 2 | |
| <i>gentamicin sulfate (ped) (pf) injection solution 20 mg/2 ml</i> | 2 | |
| <i>gentamicin sulfate (pf) intravenous solution 100 mg/10 ml, 60 mg/6 ml</i> | 2 | |
| <i>neomycin oral tablet 500 mg</i> | 2 | |
| <i>streptomycin intramuscular recon soln 1 gram</i> | 5 | NDS |
| TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE 28 MG | 5 | NDS; QL (224 per 28 days) |
| <i>tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml</i> (Tobi) | 5 | PA BvD; NDS |
| <i>tobramycin inhalation solution for nebulization 300 mg/4 ml</i> (Bethkis) | 5 | PA BvD; NDS |
| <i>tobramycin sulfate injection solution 10 mg/ml, 40 mg/ml</i> | 3 | |
| Antibacterials, Miscellaneous | | |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i> (Cleocin HCl) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>clindamycin pediatric oral recon soln</i> (clindamycin palmitate hcl) 75 mg/5 ml | 2 | |
| <i>clindamycin phosphate injection solution</i> 150 (mg/ml) (4 ml), 150 (mg/ml) (6 ml) | 2 | |
| <i>clindamycin phosphate injection solution</i> 150 mg/ml (Cleocin) | 2 | |
| <i>colistin (colistimethate na) injection recon soln</i> 150 mg (Coly-Mycin M Parenteral) | 5 | NDS |
| <i>daptomycin intravenous recon soln</i> 350 mg, 500 mg | 5 | NDS |
| <i>fosfomycin tromethamine oral packet</i> 3 gram | 2 | |
| <i>linezolid in dextrose 5% intravenous piggyback</i> 600 mg/300 ml (Zyvox) | 3 | |
| <i>linezolid oral suspension for reconstitution</i> 100 mg/5 ml (Zyvox) | 5 | NDS |
| <i>linezolid oral tablet</i> 600 mg | 3 | |
| <i>methenamine hippurate oral tablet</i> 1 gram | 2 | |
| <i>metronidazole in nacl (iso-os) intravenous piggyback</i> 500 mg/100 ml (Metro I.V.) | 2 | |
| <i>metronidazole oral tablet</i> 250 mg, 500 mg | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule</i> 100 mg, 50 mg | 2 | QL (120 per 30 days) |
| <i>nitrofurantoin monohyd/m-cryst oral capsule</i> 100 mg (Macrobid) | 2 | QL (60 per 30 days) |
| <i>polymyxin b sulfate injection recon soln</i> 500,000 unit | 2 | |
| <i>trimethoprim oral tablet</i> 100 mg | 2 | |
| <i>vancomycin intravenous recon soln</i> 1,000 mg, 1.25 gram, 10 gram, 5 gram, 500 mg, 750 mg | 3 | |
| <i>vancomycin oral capsule</i> 125 mg (Vancocin) | 3 | QL (56 per 14 days) |
| <i>vancomycin oral capsule</i> 250 mg (Vancocin) | 3 | QL (112 per 14 days) |
| <i>vancomycin oral recon soln</i> 25 mg/ml (Firvanq) | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| XIFAXAN ORAL TABLET 200 MG | 3 | PA; QL (9 per 30 days) |
| XIFAXAN ORAL TABLET 550 MG | 5 | PA; NDS; QL (90 per 30 days) |
| Cephalosporins | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>cefaclor oral tablet extended release 12 hr 500 mg</i> | 3 | |
| <i>cefadroxil oral capsule 500 mg</i> | 2 | |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i> | 2 | |
| <i>cefadroxil oral tablet 1 gram</i> | 4 | |
| <i>cefazolin injection recon soln 1 gram, 10 gram, 500 mg</i> | 2 | |
| <i>cefdinir oral capsule 300 mg</i> | 2 | |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cefepime injection recon soln 1 gram, 2 gram</i> | 3 | |
| <i>cefixime oral capsule 400 mg</i> | 4 | |
| <i>cefixime oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | 4 | |
| <i>cefixime oral tablet 400 mg</i> | 4 | |
| <i>cefoxitin intravenous recon soln 1 gram, 10 gram, 2 gram</i> | 3 | |
| <i>cefpodoxime oral suspension for reconstitution 100 mg/5 ml, 50 mg/5 ml</i> | 4 | |
| <i>cefpodoxime oral tablet 100 mg, 200 mg</i> | 4 | |
| <i>cefprozil oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ceftazidime injection recon soln 1 gram, 2 gram, 6 gram</i> (Tazicef) | 3 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime sodium injection recon soln 750 mg</i> | 2 | |
| <i>cefuroxime sodium intravenous recon soln 1.5 gram, 7.5 gram</i> | 2 | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>cephalexin oral capsule 750 mg</i> | 4 | |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cephalexin oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>tazicef injection recon soln 1 gram, 2 gram, 6 gram</i> (ceftazidime) | 3 | |
| TEFLARO INTRAVENOUS RECON SOLN 400 MG, 600 MG | 5 | NDS |
| Macrolides | | |
| <i>azithromycin intravenous recon soln 500 mg</i> (Zithromax) | 2 | |
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml</i> | 2 | |
| <i>azithromycin oral suspension for reconstitution 200 mg/5 ml</i> (Zithromax) | 2 | |
| <i>azithromycin oral tablet 250 mg (6 pack), 500 mg (3 pack), 600 mg</i> | 1 | |
| <i>azithromycin oral tablet 250 mg, 500 mg</i> (Zithromax) | 1 | |
| <i>clarithromycin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>clarithromycin oral tablet extended release 24 hr 500 mg</i> | 4 | |
| DIFICID ORAL SUSPENSION FOR RECONSTITUTION 40 MG/ML | 5 | NDS; QL (136 per 10 days) |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml</i> (E.E.S. Granules) | 4 | |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 400 mg/5 ml</i> (EryPed 400) | 4 | |
| <i>erythromycin oral tablet 250 mg, 500 mg</i> | 4 | |
| <i>fidaxomicin oral tablet 200 mg</i> (Dificid) | 5 | NDS; QL (20 per 10 days) |
| Miscellaneous B-Lactam Antibiotics | | |
| <i>aztreonam injection recon soln 1 gram, 2 gram</i> (Azactam) | 3 | |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML | 5 | PA; LA; NDS |
| <i>ertapenem injection recon soln 1 gram</i> | 3 | |
| <i>imipenem-cilastatin intravenous recon soln 250 mg</i> | 3 | |
| <i>imipenem-cilastatin intravenous recon soln 500 mg</i> (Primaxin IV) | 3 | |
| <i>meropenem intravenous recon soln 1 gram, 500 mg</i> | 2 | |
| <i>meropenem intravenous recon soln 2 gram</i> | 4 | |
| Penicillins | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 400-57 mg/5 ml</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 250-62.5 mg/5 ml</i> (Augmentin) | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 600-42.9 mg/5 ml</i> (Augmentin ES-600) | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 875-125 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet 500-125 mg</i> (Augmentin) | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet extended release 12 hr 1,000-62.5 mg</i> (Augmentin XR) | 4 | |
| <i>amoxicillin-pot clavulanate oral tablet, chewable 200-28.5 mg, 400-57 mg</i> | 4 | |
| <i>ampicillin oral capsule 500 mg</i> | 2 | |
| <i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg</i> | 2 | |
| <i>ampicillin-sulbactam injection recon soln 1.5 gram, 15 gram, 3 gram</i> (Unasyn) | 3 | |
| BICILLIN L-A INTRAMUSCULAR SYRINGE 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML | 4 | |
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i> | 2 | |
| EXTENCILLINE INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 1.2 MILLION UNIT, 2.4 MILLION UNIT | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| LENTOCILIN S INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 1.2 MILLION UNIT | 4 | |
| <i>nafcillin injection recon soln 1 gram, 10 gram, 2 gram</i> | 3 | |
| <i>penicillin g potassium injection recon (Pfizerpen-G) soln 20 million unit</i> | 3 | |
| <i>penicillin g procaine intramuscular syringe 1.2 million unit/2 ml, 600,000 unit/ml</i> | 2 | |
| <i>penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i> | 3 | |
| Quinolones | | |
| <i>ciprofloxacin hcl oral tablet 250 mg, (Cipro) 500 mg</i> | 1 | |
| <i>ciprofloxacin hcl oral tablet 750 mg</i> | 1 | |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 2 | |
| <i>levofloxacin in d5w intravenous piggyback 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml</i> | 2 | |
| <i>levofloxacin oral solution 250 mg/10 ml</i> | 4 | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>moxifloxacin 400 mg/250 ml bag suv, p/f, inner</i> | 3 | |
| <i>moxifloxacin oral tablet 400 mg</i> | 2 | |
| <i>moxifloxacin-sod.chloride(iso) (Avelox in NaCl (iso- intravenous piggyback 400 mg/250 osmotic)) ml</i> | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Sulfonamides | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 3 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i> (Sulfatrim) | 2 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg</i> (Bactrim) | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 800-160 mg</i> (Bactrim DS) | 1 | |
| Tetracyclines | | |
| <i>demeclocycline oral tablet 150 mg, 300 mg</i> | 4 | |
| <i>doxy-100 intravenous recon soln 100 mg</i> (doxycycline hyclate) | 3 | |
| <i>doxycycline hyclate intravenous recon soln 100 mg</i> (Doxy-100) | 3 | |
| <i>doxycycline hyclate oral capsule 100 mg</i> | 2 | |
| <i>doxycycline hyclate oral capsule 50 mg</i> (Morgidox) | 2 | |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | 2 | |
| <i>doxycycline hyclate oral tablet, delayed release (dr/ec) 100 mg, 150 mg, 50 mg, 75 mg</i> | 4 | |
| <i>doxycycline hyclate oral tablet, delayed release (dr/ec) 200 mg</i> (Doryx) | 4 | |
| <i>doxycycline monohydrate oral capsule 100 mg</i> (Mondoxyne NL) | 2 | |
| <i>doxycycline monohydrate oral capsule 50 mg</i> | 2 | |
| <i>doxycycline monohydrate oral suspension for reconstitution 25 mg/5 ml</i> | 2 | |
| <i>doxycycline monohydrate oral tablet 100 mg</i> (Avidoxy) | 2 | |
| <i>doxycycline monohydrate oral tablet 150 mg, 50 mg, 75 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| <i>minocycline oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | |
| <i>minocycline oral tablet 100 mg, 50 mg, 75 mg</i> | 4 | |
| <i>tetracycline oral capsule 250 mg, 500 mg</i> | 4 | |
| <i>tigecycline intravenous recon soln 50 mg</i> (Tygacil) | 3 | |
| Anticancer Agents | | |
| Anticancer Agents | | |
| <i>abiraterone oral tablet 250 mg</i> (Abirtega) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| <i>abiraterone oral tablet 500 mg</i> (Zytiga) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| <i>abiraterone, submicronized oral tablet 125 mg</i> (Yonsa) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| <i>abirtega oral tablet 250 mg</i> (abiraterone) | 2 | PA NSO; QL (120 per 30 days) |
| <i>adrucil intravenous solution 2.5 gram/50 ml</i> (fluorouracil) | 2 | PA BvD |
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK 90 MG (7)-180 MG (23) | 5 | PA NSO; NDS |
| <i>anastrozole oral tablet 1 mg</i> (Arimidex) | 1 | |
| ANKTIVA INTRAVESICAL SOLUTION 400 MCG/0.4 ML | 5 | PA NSO; NDS; QL (1.6 per 28 days) |
| AUGTYRO ORAL CAPSULE 160 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| AUGTYRO ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| AVMAPKI ORAL CAPSULE 0.8 MG | 5 | PA NSO; NDS; QL (24 per 28 days) |
| AVMAPKI-FAKZYNJA ORAL COMBO PACK 0.8-200 MG | 5 | PA NSO; NDS; QL (66 per 28 days) |
| AXTLE INTRAVENOUS RECON SOLN 100 MG, 500 MG | 5 | NDS |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>azacitidine injection recon soln 100 mg</i> (Vidaza) | 5 | NDS |
| BALVERSA ORAL TABLET 3 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| BALVERSA ORAL TABLET 4 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| BALVERSA ORAL TABLET 5 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| <i>bendamustine intravenous recon soln 100 mg, 25 mg</i> (Treanda) | 5 | PA NSO; NDS |
| BENDAMUSTINE INTRAVENOUS SOLUTION 25 MG/ML (Bendeka) | 5 | PA NSO; NDS |
| BENDEKA INTRAVENOUS SOLUTION 25 MG/ML (bendamustine) | 5 | PA NSO; NDS |
| <i>bexarotene oral capsule 75 mg</i> (Targretin) | 5 | PA NSO; NDS |
| <i>bexarotene topical gel 1 %</i> (Targretin) | 5 | PA NSO; NDS |
| <i>bicalutamide oral tablet 50 mg</i> (Casodex) | 2 | |
| BIZENGRI INTRAVENOUS SOLUTION 375 MG/18.75 ML (20 MG/ML) | 5 | PA NSO; NDS; QL (75 per 28 days) |
| <i>bleomycin injection recon soln 15 unit, 30 unit</i> | 2 | |
| <i>bortezomib injection recon soln 1 mg, 2.5 mg</i> | 4 | PA NSO |
| <i>bortezomib injection recon soln 3.5 mg</i> (Velcade) | 5 | PA NSO; NDS |
| BORUZU INJECTION SOLUTION 2.5 MG/ML | 4 | PA NSO |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| BOSULIF ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| BOSULIF ORAL CAPSULE 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| BOSULIF ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| BRUKINSA ORAL TABLET 160 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 60 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| CABOMETYX ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CALQUENCE (ACALABRUTINIB MAL) ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CALQUENCE ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CAMCEVI (6 MONTH) SUBCUTANEOUS SYRINGE 42 MG | 4 | PA NSO |
| CAPRELSA ORAL TABLET 100 MG (vandetanib) | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 300 MG (vandetanib) | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>carboplatin intravenous solution 10 mg/ml</i> (Kyxata) | 2 | |
| <i>cladribine intravenous solution 10 mg/10 ml</i> | 2 | PA BvD |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 60 MG/DAY (20 MG X 3/DAY) | 5 | PA NSO; NDS |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3) | 5 | PA NSO; NDS; QL (112 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------------|
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| COTELLIC ORAL TABLET 20 MG | 5 | PA NSO; LA; NDS; QL (63 per 28 days) |
| <i>cyclophosphamide intravenous recon soln 1 gram, 2 gram, 500 mg</i> | 5 | PA BvD; NDS |
| <i>cyclophosphamide intravenous solution 100 mg/ml, 200 mg/ml</i> | 5 | PA BvD; NDS |
| <i>cyclophosphamide intravenous solution 500 mg/ml</i> (Frindovyx) | 5 | PA BvD; NDS |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | 3 | PA BvD; ST |
| <i>cyclophosphamide oral tablet 25 mg, 50 mg</i> | 3 | PA BvD; ST |
| DANYELZA INTRAVENOUS SOLUTION 4 MG/ML | 5 | PA NSO; NDS; QL (120 per 28 days) |
| DANZITEN ORAL TABLET 71 MG, 95 MG | 5 | PA NSO; NDS; QL (112 per 28 days) |
| DARZALEX FASPRO SUBCUTANEOUS SOLUTION 1,800 MG-30,000 UNIT/15 ML | 5 | PA NSO; NDS |
| DARZALEX INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; LA; NDS |
| <i>dasatinib oral tablet 100 mg, 140 mg, 50 mg, 70 mg, 80 mg</i> (Phyrago) | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>dasatinib oral tablet 20 mg</i> (Phyrago) | 5 | PA NSO; NDS; QL (90 per 30 days) |
| DATROWAY INTRAVENOUS RECON SOLN 100 MG | 5 | PA NSO; NDS |
| DAURISMO ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| DAURISMO ORAL TABLET 25 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>decitabine intravenous recon soln 50 mg</i> | 5 | NDS |
| <i>doxorubicin, peg-liposomal intravenous suspension 2 mg/ml</i> (Caelyx) | 5 | PA BvD; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| ELAHERE INTRAVENOUS SOLUTION 5 MG/ML | 5 | PA NSO; NDS |
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG | 4 | PA NSO |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG | 4 | PA NSO |
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG | 4 | PA NSO |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH) | 4 | PA NSO |
| ELREXFIO 44 MG/1.1 ML VIAL INNER, SUV, P/F 40 MG/ML | 5 | PA NSO; NDS |
| ELREXFIO SUBCUTANEOUS SOLUTION 40 MG/ML | 5 | PA NSO; NDS; QL (9.5 per 28 days) |
| EMCYT ORAL CAPSULE 140 MG | 5 | NDS |
| EMRELIS INTRAVENOUS RECON SOLN 100 MG, 20 MG | 5 | PA NSO; NDS |
| EPKINLY SUBCUTANEOUS SOLUTION 4 MG/0.8 ML, 48 MG/0.8 ML | 5 | PA NSO; NDS |
| ERBITUX INTRAVENOUS SOLUTION 100 MG/50 ML, 200 MG/100 ML | 5 | PA NSO; NDS |
| ERIVEDGE ORAL CAPSULE 150 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| ERLEADA ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| <i>erlotinib oral tablet 100 mg, 25 mg</i> | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>erlotinib oral tablet 150 mg</i> | 5 | PA NSO; NDS; QL (90 per 30 days) |
| ETOPOPHOS INTRAVENOUS RECON SOLN 100 MG | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>etoposide intravenous solution 20 mg/ml</i> | 2 | |
| EULEXIN ORAL CAPSULE 125 MG (flutamide) | 5 | NDS |
| <i>everolimus (antineoplastic) oral tablet 10 mg</i> (Torpenz) | 5 | PA NSO; NDS; QL (56 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet 2.5 mg</i> (Torpenz) | 5 | PA NSO; NDS; QL (28 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet 5 mg, 7.5 mg</i> (Torpenz) | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg</i> (Afinitor Disperz) | 5 | PA NSO; NDS; QL (112 per 28 days) |
| <i>exemestane oral tablet 25 mg</i> (Aromasin) | 2 | |
| FAKZYNJA ORAL TABLET 200 MG | 5 | PA NSO; NDS; QL (42 per 28 days) |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG | 5 | PA BvD; NDS |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG | 3 | PA BvD |
| <i>floxuridine injection recon soln 0.5 gram</i> | 2 | PA BvD |
| <i>fluorouracil intravenous solution 1 gram/20 ml, 5 gram/100 ml, 500 mg/10 ml</i> | 2 | PA BvD |
| <i>flutamide oral capsule 125 mg</i> (Eulexin) | 3 | |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| FRUZAQLA ORAL CAPSULE 5 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| <i>fulvestrant intramuscular syringe 250 mg/5 ml</i> (Faslodex) | 5 | NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| FYARRO INTRAVENOUS SUSPENSION FOR RECONSTITUTION 100 MG | 5 | PA NSO; NDS |
| GAVRETO ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> (Iressa) | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>gemcitabine intravenous recon soln 1 gram, 2 gram, 200 mg</i> | 3 | PA BvD |
| <i>gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml)</i> (Avegmsi) | 3 | PA BvD |
| <i>gemcitabine intravenous solution 200 mg/5.26 ml (38 mg/ml)</i> | 3 | PA BvD |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| GOMEKLI ORAL CAPSULE 1 MG | 5 | PA NSO; NDS; QL (224 per 28 days) |
| GOMEKLI ORAL CAPSULE 2 MG | 5 | PA NSO; NDS; QL (112 per 28 days) |
| GOMEKLI ORAL TABLET FOR SUSPENSION 1 MG | 5 | PA NSO; NDS; QL (224 per 28 days) |
| HERCEPTIN HYLECTA SUBCUTANEOUS SOLUTION 600 MG-10,000 UNIT/5 ML | 5 | PA NSO; NDS; QL (5 per 21 days) |
| HERNEXEOS ORAL TABLET 60 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| <i>hydroxyurea oral capsule 500 mg</i> (Hydrea) | 2 | |
| HYRNUO ORAL TABLET 10 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| IBTROZI ORAL CAPSULE 200 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| IDHIFA ORAL TABLET 100 MG, 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>ifosfamide intravenous recon soln 1 gram</i> (Ifex) | 2 | |
| <i>ifosfamide intravenous solution 1 gram/20 ml, 3 gram/60 ml</i> | 2 | |
| <i>imatinib oral tablet 100 mg</i> (Gleevec) | 2 | PA NSO; QL (180 per 30 days) |
| <i>imatinib oral tablet 400 mg</i> (Gleevec) | 2 | PA NSO; QL (60 per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML | 5 | PA NSO; NDS; QL (216 per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG, 560 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| IMDELLTRA INTRAVENOUS RECON SOLN 1 MG, 10 MG | 5 | PA NSO; NDS |
| IMJUDO INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NDS |
| IMKELDI ORAL SOLUTION 80 MG/ML | 5 | PA NSO; NDS; QL (280 per 28 days) |
| INLEXZO INTRAVESICAL IMPLANT 225 MG | 5 | PA BvD; NDS |
| INLURIYO ORAL TABLET 200 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| INLYTA ORAL TABLET 1 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| INLYTA ORAL TABLET 5 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| INQOVI ORAL TABLET 35-100 MG | 5 | PA NSO; NDS; QL (5 per 28 days) |
| INREBIC ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| <i>irinotecan intravenous solution 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml</i> (Camptosar) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>irinotecan intravenous solution 500 mg/25 ml</i> | 2 | |
| ITOVEBI ORAL TABLET 3 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| ITOVEBI ORAL TABLET 9 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| IWILFIN ORAL TABLET 192 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| JEMPERLI INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NDS |
| JYLAMVO ORAL SOLUTION 2 MG/ML | 4 | PA BvD; ST |
| KEYTRUDA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NDS |
| KEYTRUDA QLEX SUBCUTANEOUS SOLUTION 395 MG-4,800 UNIT/2.4 ML, 790 MG-9,600 UNIT/4.8 ML | 5 | PA NSO; NDS |
| KIMMTRAK INTRAVENOUS SOLUTION 100 MCG/0.5 ML | 5 | PA NSO; NDS; QL (2 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | 5 | PA NSO; NDS; QL (49 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | 5 | PA NSO; NDS; QL (70 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | 5 | PA NSO; NDS; QL (91 per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NDS; QL (21 per 28 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | 5 | PA NSO; NDS; QL (42 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | 5 | PA NSO; NDS; QL (63 per 28 days) |
| KOSELUGO ORAL CAPSULE 10 MG | 5 | PA NSO; NDS; QL (300 per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| KOSELUGO ORAL CAPSULE, SPRINKLE 5 MG | 5 | PA NSO; NDS; QL (600 per 30 days) |
| KOSELUGO ORAL CAPSULE, SPRINKLE 7.5 MG | 5 | PA NSO; NDS; QL (390 per 30 days) |
| KRAZATI ORAL TABLET 200 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>lapatinib oral tablet 250 mg</i> (Tykerb) | 5 | PA NSO; NDS |
| LAZCLUZE ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| LAZCLUZE ORAL TABLET 80 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i> (Revlimid) | 5 | PA NSO; NDS; QL (28 per 28 days) |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2) | 5 | PA NSO; NDS |
| <i>letrozole oral tablet 2.5 mg</i> (Femara) | 2 | |
| LEUKERAN ORAL TABLET 2 MG | 5 | NDS |
| <i>leuprolide acetate (3 month) intramuscular suspension for reconstitution 22.5 mg</i> (Lutrate Depot (3 month)) | 4 | PA NSO |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | 3 | PA NSO |
| <i>lomustine oral capsule 10 mg</i> (Gleostine) | 3 | |
| <i>lomustine oral capsule 100 mg, 40 mg</i> (Gleostine) | 5 | NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| LONSURF ORAL TABLET 15-6.14 MG | 5 | PA NSO; NDS; QL (100 per 28 days) |
| LONSURF ORAL TABLET 20-8.19 MG | 5 | PA NSO; NDS; QL (80 per 28 days) |
| LOQTORZI INTRAVENOUS SOLUTION 240 MG/6 ML (40 MG/ML) | 5 | PA NSO; NDS |
| LORBRENA ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| LUMAKRAS ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| LUMAKRAS ORAL TABLET 320 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| LUNSUMIO INTRAVENOUS SOLUTION 1 MG/ML | 5 | PA NSO; NDS |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 22.5 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 7.5 MG | 5 | PA NSO; NDS |
| LUTRATE DEPOT (3 MONTH) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 22.5 MG (leuprolide acetate (3 month)) | 4 | PA NSO |
| LYNOZYFIC INTRAVENOUS SOLUTION 2 MG/ML | 5 | PA NSO; NDS; QL (15 per 8 days) |
| LYNOZYFIC INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NDS; QL (40 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------------|
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 5 | NDS |
| LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) | 5 | PA NSO; NDS; QL (140 per 28 days) |
| MARGENZA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NDS |
| MATULANE ORAL CAPSULE 50 MG | 5 | NDS |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | 2 | PA NSO; AGE (Max 64 Years) |
| MEKINIST ORAL RECON SOLN 0.05 MG/ML | 5 | PA NSO; NDS; QL (1260 per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>mercaptopurine oral suspension 20 mg/ml</i> (Purixan) | 5 | NDS |
| <i>mercaptopurine oral tablet 50 mg</i> | 2 | |
| <i>methotrexate sodium (pf) injection recon soln 1 gram</i> | 2 | |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | 2 | |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | 2 | |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 2 | PA BvD; ST |
| <i>mitoxantrone intravenous concentrate 2 mg/ml</i> | 2 | |
| MODEYSO ORAL CAPSULE 125 MG | 5 | PA NSO; NDS; QL (20 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| NERLYNX ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>nilutamide oral tablet 150 mg</i> | 5 | NDS |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 5 | PA NSO; NDS; QL (3 per 28 days) |
| NUBEQA ORAL TABLET 300 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 5 | PA NSO; LA; NDS |
| OGIVRI INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NDS |
| OGSIVEO ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| OGSIVEO ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| OJEMDA ORAL SUSPENSION FOR RECONSTITUTION 25 MG/ML | 5 | PA NSO; NDS; QL (96 per 28 days) |
| OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6) | 5 | PA NSO; NDS; QL (24 per 28 days) |
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ONUREG ORAL TABLET 200 MG, 300 MG | 5 | PA NSO; NDS; QL (14 per 28 days) |
| OPDIVO INTRAVENOUS SOLUTION 100 MG/10 ML, 120 MG/12 ML, 240 MG/24 ML, 40 MG/4 ML | 5 | PA NSO; NDS |
| OPDIVO QVANTIG SUBCUTANEOUS SOLUTION 600 MG-10,000 UNIT/5 ML | 5 | PA NSO; NDS |
| OPDUALAG INTRAVENOUS SOLUTION 240-80 MG/20 ML | 5 | PA NSO; NDS |
| ORSERDU ORAL TABLET 345 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| <i>oxaliplatin intravenous recon soln</i> 100 mg, 50 mg | 2 | |
| <i>oxaliplatin intravenous solution</i> 100 mg/20 ml, 200 mg/40 ml, 50 mg/10 ml (5 mg/ml) | 2 | |
| <i>paclitaxel intravenous concentrate</i> 6 mg/ml | 2 | PA BvD |
| <i>paclitaxel protein-bound intravenous</i> (Abraxane) <i>suspension for reconstitution</i> 100 mg | 5 | PA BvD; NDS |
| <i>pazopanib oral tablet</i> 200 mg (Votrient) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| <i>pazopanib oral tablet</i> 400 mg | 5 | PA NSO; NDS; QL (60 per 30 days) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>pemetrexed disodium intravenous</i> <i>recon soln</i> 1,000 mg, 750 mg | 5 | NDS |
| <i>pemetrexed disodium intravenous</i> (Alimta) <i>recon soln</i> 100 mg, 500 mg | 5 | NDS |
| <i>pemetrexed disodium intravenous</i> <i>solution</i> 25 mg/ml | 5 | NDS |
| PEMRYDI RTU INTRAVENOUS SOLUTION 10 MG/ML | 5 | NDS |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NDS; QL (28 per 28 days) |
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 5 | PA NSO; NDS; QL (56 per 28 days) |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| QINLOCK ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| RETEVMO ORAL TABLET 120 MG, 160 MG, 80 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| RETEVMO ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| REVUFORJ ORAL TABLET 110 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| REVUFORJ ORAL TABLET 160 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| REVUFORJ ORAL TABLET 25 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| REZLIDHIA ORAL CAPSULE 150 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| RITUXAN HYCELA SUBCUTANEOUS SOLUTION 1400 MG/11.7 ML (120 MG/ML), 1600 MG/13.4 ML (120 MG/ML) | 5 | PA NSO; NDS |
| ROMVIMZA ORAL CAPSULE 14 MG, 20 MG, 30 MG | 5 | PA NSO; NDS; QL (8 per 28 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| ROZLYTREK ORAL PELLETS IN PACKET 50 MG | 5 | PA NSO; NDS; QL (360 per 30 days) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| RYBREVANT FASPRO SUBCUTANEOUS SOLUTION 1,600 MG-20,000 UNIT/10 ML, 2,240 MG-28,000 UNIT/14 ML | 5 | PA NSO; NDS |
| RYBREVANT INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NDS |
| RYDAPT ORAL CAPSULE 25 MG | 5 | PA NSO; NDS; QL (224 per 28 days) |
| RYTELO INTRAVENOUS RECON SOLN 188 MG, 47 MG | 5 | PA NSO; NDS |
| SCEMBLIX ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| SCEMBLIX ORAL TABLET 20 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------------|
| SCSEMBLIX ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (300 per 30 days) |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML | 5 | NDS |
| <i>sorafenib oral tablet 200 mg</i> (Nexavar) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> (Sutent) | 5 | PA NSO; NDS; QL (28 per 28 days) |
| SYNRIBO SUBCUTANEOUS RECON SOLN 3.5 MG | 5 | PA NSO; NDS |
| TABLOID ORAL TABLET 40 MG (thioguanine) | 5 | NDS |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5 | PA NSO; NDS; QL (112 per 28 days) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| TAFINLAR ORAL TABLET FOR SUSPENSION 10 MG | 5 | PA NSO; NDS; QL (900 per 30 days) |
| TAGRISSE ORAL TABLET 40 MG, 80 MG | 5 | PA NSO; LA; NDS; QL (30 per 30 days) |
| TALVEY SUBCUTANEOUS SOLUTION 2 MG/ML, 40 MG/ML | 5 | PA NSO; NDS |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | 2 | |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG (nilotinib hcl) | 5 | PA NSO; NDS; QL (112 per 28 days) |
| TASIGNA ORAL CAPSULE 50 MG (nilotinib hcl) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| TECENTRIQ HYBREZA SUBCUTANEOUS SOLUTION 1,875 MG-30,000 UNIT/15 ML | 5 | PA NSO; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| TECENTRIQ INTRAVENOUS SOLUTION 1,200 MG/20 ML (60 MG/ML), 840 MG/14 ML (60 MG/ML) | 5 | PA NSO; NDS |
| TECVAYLI SUBCUTANEOUS SOLUTION 10 MG/ML, 90 MG/ML | 5 | PA NSO; NDS |
| TEPMETKO ORAL TABLET 225 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| TEVIMBRA INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NDS |
| TIBSOVO ORAL TABLET 250 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION 50 MG | 4 | |
| TIVDAK INTRAVENOUS RECON SOLN 40 MG | 5 | PA NSO; NDS; QL (5 per 21 days) |
| <i>toposar intravenous solution 20 mg/ml</i> (etoposide) | 2 | |
| <i>toremifene oral tablet 60 mg</i> (Fareston) | 5 | NDS |
| <i>torpenz oral tablet 10 mg</i> (everolimus (antineoplastic)) | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>torpenz oral tablet 2.5 mg, 5 mg, 7.5 mg</i> (everolimus (antineoplastic)) | 5 | PA NSO; NDS; QL (30 per 30 days) |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG, 22.5 MG, 3.75 MG | 4 | PA NSO |
| <i>tretinoin (antineoplastic) oral capsule 10 mg</i> | 5 | NDS |
| TRUQAP ORAL TABLET 160 MG, 200 MG | 5 | PA NSO; NDS; QL (64 per 28 days) |
| TRUXIMA INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NDS |
| TUKYSA ORAL TABLET 150 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| TUKYSA ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (300 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| TURALIO ORAL CAPSULE 125 MG, 200 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG | 5 | PA NSO; NDS |
| VENCLEXTA ORAL TABLET 10 MG | 3 | PA NSO; LA; QL (60 per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG | 5 | PA NSO; LA; NDS; QL (180 per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | 5 | PA NSO; LA; NDS; QL (30 per 30 days) |
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG- 100 MG | 5 | PA NSO; LA; NDS |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| <i>vinblastine intravenous solution 1 mg/ml</i> | 2 | PA BvD |
| <i>vincasar pfs intravenous solution 1 mg/ml, 2 mg/2 ml</i> (vincristine) | 2 | PA BvD |
| <i>vincristine intravenous solution 1 mg/ml, 2 mg/2 ml</i> (Vincasar PFS) | 2 | PA BvD |
| <i>vinorelbine intravenous solution 10 mg/ml, 50 mg/5 ml</i> | 3 | |
| VITRAKVI ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 5 | PA NSO; NDS; QL (300 per 30 days) |
| VIVIMUSTA INTRAVENOUS SOLUTION 25 MG/ML (bendamustine) | 5 | PA NSO; NDS |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| VONJO ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| VORANIGO ORAL TABLET 10 MG, 40 MG | 5 | PA NSO; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| VYLOY INTRAVENOUS RECON SOLN 100 MG, 300 MG | 5 | PA NSO; NDS |
| WELIREG ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XALKORI ORAL PELLETT 150 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| XALKORI ORAL PELLETT 20 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| XALKORI ORAL PELLETT 50 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 4 | PA BvD; ST |
| XOSPATA ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2), 80 MG/WEEK (80 MG X 1) | 5 | PA NSO; NDS; QL (8 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (10 MG X 4) | 5 | PA NSO; NDS; QL (16 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) | 5 | PA NSO; NDS; QL (4 per 28 days) |
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | 5 | PA NSO; NDS; QL (24 per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | 5 | PA NSO; NDS; QL (32 per 28 days) |
| XTANDI ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 80 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| YERVOY INTRAVENOUS SOLUTION 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) | 5 | PA NSO; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| YONSA ORAL TABLET 125 MG (abiraterone, submicronized) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ZEJULA ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| ZIIHERA INTRAVENOUS RECON SOLN 300 MG | 5 | PA NSO; NDS |
| ZIRABEV INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NDS |
| ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG | 4 | PA NSO |
| ZOLINZA ORAL CAPSULE 100 MG | 5 | NDS |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| ZYNLONTA INTRAVENOUS RECON SOLN 10 MG | 5 | PA NSO; NDS |
| ZYNYZ INTRAVENOUS SOLUTION 500 MG/20 ML | 5 | PA NSO; NDS; QL (20 per 28 days) |
| Anticonvulsants | | |
| Anticonvulsants | | |
| BRIVIACT INTRAVENOUS SOLUTION 50 MG/5 ML | 5 | NDS; QL (80 per 30 days) |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 5 | NDS; QL (600 per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG (brivaracetam) | 5 | NDS; QL (60 per 30 days) |
| <i>carbamazepine 100 mg/5 ml cup outer 100 mg/5 ml (5 ml)</i> | 2 | |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> (Carbatrol) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>carbamazepine oral suspension 100 mg/5 ml</i> (Tegretol) | 2 | |
| <i>carbamazepine oral tablet 200 mg</i> (Tegretol) | 2 | |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> (Tegretol XR) | 2 | |
| <i>carbamazepine oral tablet, chewable 100 mg, 200 mg</i> | 2 | |
| <i>clobazam oral suspension 2.5 mg/ml</i> (Onfi) | 3 | QL (480 per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg</i> (Onfi) | 3 | QL (60 per 30 days) |
| DIACOMIT ORAL CAPSULE 250 MG | 5 | PA NSO; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL CAPSULE 500 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 250 MG | 5 | PA NSO; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 5-7.5-10 mg</i> | 3 | |
| <i>diazepam rectal kit 2.5 mg</i> | 4 | |
| DILANTIN ORAL CAPSULE 30 MG | 4 | |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> (Depakote Sprinkles) | 2 | |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> (Depakote ER) | 2 | |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> (Depakote) | 2 | |
| ELEPSIA XR ORAL TABLET EXTENDED RELEASE 24 HR 1,000 MG | 5 | ST; NDS; QL (90 per 30 days) |
| ELEPSIA XR ORAL TABLET EXTENDED RELEASE 24 HR 1,500 MG | 5 | ST; NDS; QL (60 per 30 days) |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 5 | PA NSO; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| <i>epitol oral tablet 200 mg</i> (carbamazepine) | 2 | |
| <i>eslicarbazepine oral tablet 200 mg, 400 mg</i> (Aptiom) | 5 | ST; NDS; QL (30 per 30 days) |
| <i>eslicarbazepine oral tablet 600 mg, 800 mg</i> (Aptiom) | 5 | ST; NDS; QL (60 per 30 days) |
| <i>ethosuximide oral capsule 250 mg</i> (Zarontin) | 2 | |
| <i>ethosuximide oral solution 250 mg/5 ml</i> (Zarontin) | 2 | |
| <i>felbamate oral suspension 600 mg/5 ml</i> | 3 | |
| <i>felbamate oral tablet 400 mg, 600 mg</i> (Felbatol) | 3 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 5 | PA NSO; NDS |
| <i>fosphephenytoin injection solution 100 mg pe/2 ml, 500 mg pe/10 ml</i> (Cerebyx) | 2 | |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML (perampanel) | 5 | ST; NDS; QL (720 per 30 days) |
| <i>gabapentin oral capsule 100 mg, 300 mg</i> (Neurontin) | 2 | QL (360 per 30 days) |
| <i>gabapentin oral capsule 400 mg</i> (Neurontin) | 2 | QL (270 per 30 days) |
| <i>gabapentin oral solution 250 mg/5 ml</i> (Neurontin) | 2 | QL (2160 per 30 days) |
| <i>gabapentin oral tablet 600 mg</i> (Neurontin) | 2 | QL (180 per 30 days) |
| <i>gabapentin oral tablet 800 mg</i> (Neurontin) | 2 | QL (120 per 30 days) |
| <i>lacosamide intravenous solution 200 mg/20 ml</i> (Vimpat) | 2 | QL (200 per 5 days) |
| <i>lacosamide oral solution 10 mg/ml</i> (Vimpat) | 3 | QL (1200 per 30 days) |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> (Vimpat) | 3 | QL (60 per 30 days) |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> (Subvenite) | 1 | |
| <i>lamotrigine oral tablet disintegrating, dose pk 25 mg (21) - 50 mg (7)</i> (Lamictal ODT Starter (Blue)) | 3 | |
| <i>lamotrigine oral tablet disintegrating, dose pk 25 mg(14)-50 mg (14)-100 mg (7)</i> (Lamictal ODT Starter (Orange)) | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|--------------------------------|------------------|-------------------------------|
| <i>lamotrigine oral tablet disintegrating, dose pk 50 mg (42) - 100 mg (14)</i> | (Lamictal ODT Starter (Green)) | 3 | |
| <i>lamotrigine oral tablet extended release 24hr 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | (Lamictal XR) | 4 | |
| <i>lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg</i> | (Lamictal) | 2 | |
| <i>lamotrigine oral tablet, disintegrating 100 mg, 200 mg, 25 mg, 50 mg</i> | (Lamictal ODT) | 3 | |
| <i>levetiracetam intravenous solution 500 mg/5 ml</i> | (Keppra) | 2 | |
| <i>levetiracetam oral solution 100 mg/ml</i> | (Keppra) | 2 | |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i> | (Keppra) | 2 | |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i> | (Keppra XR) | 2 | |
| <i>levetiracetam oral tablet for suspension 250 mg</i> | (Spritam) | 3 | ST |
| LIBERVANT BUCCAL FILM 10 MG, 12.5 MG, 15 MG, 5 MG, 7.5 MG | | 4 | QL (10 per 30 days) |
| <i>methsuximide oral capsule 300 mg</i> | (Celontin) | 3 | |
| NAYZILAM NASAL SPRAY, NON-AEROSOL 5 MG/SPRAY (0.1 ML) | | 4 | QL (10 per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml)</i> | (Trileptal) | 3 | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | (Trileptal) | 2 | |
| <i>perampanel oral suspension 0.5 mg/ml</i> | (Fycompa) | 5 | ST; NDS; QL (720 per 30 days) |
| <i>perampanel oral tablet 10 mg, 12 mg, 8 mg</i> | (Fycompa) | 5 | ST; NDS; QL (30 per 30 days) |
| <i>perampanel oral tablet 2 mg</i> | (Fycompa) | 3 | ST; QL (30 per 30 days) |
| <i>perampanel oral tablet 4 mg, 6 mg</i> | (Fycompa) | 5 | ST; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | 2 | PA NSO; AGE (Max 64 Years) |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 2 | PA NSO; AGE (Max 64 Years) |
| <i>phenytek oral capsule 200 mg, 300 mg</i> (phenytoin sodium extended) | 2 | |
| <i>phenytoin oral suspension 125 mg/5 ml</i> (Dilantin-125) | 2 | |
| <i>phenytoin oral tablet, chewable 50 mg</i> (Dilantin Infatabs) | 2 | |
| <i>phenytoin sodium extended oral capsule 100 mg</i> (Dilantin Extended) | 2 | |
| <i>phenytoin sodium extended oral capsule 200 mg, 300 mg</i> (Phenytek) | 2 | |
| <i>phenytoin sodium intravenous solution 50 mg/ml</i> | 2 | |
| <i>phenytoin sodium intravenous syringe 50 mg/ml</i> | 2 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> (Lyrica) | 2 | QL (90 per 30 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> (Lyrica) | 2 | QL (60 per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> (Lyrica) | 3 | QL (900 per 30 days) |
| <i>primidone oral tablet 125 mg</i> | 2 | |
| <i>primidone oral tablet 250 mg, 50 mg</i> (Mysoline) | 2 | |
| <i>rufinamide oral suspension 40 mg/ml</i> (Banzel) | 5 | ST; NDS |
| <i>rufinamide oral tablet 200 mg</i> (Banzel) | 3 | ST |
| <i>rufinamide oral tablet 400 mg</i> (Banzel) | 5 | ST; NDS |
| SEZABY INTRAVENOUS RECON SOLN 100 MG | 5 | PA BvD; NDS |
| SPRITAM ORAL TABLET FOR SUSPENSION 1,000 MG, 500 MG, 750 MG | 4 | ST |
| SPRITAM ORAL TABLET FOR SUSPENSION 250 MG (levetiracetam) | 4 | ST |
| <i>subvenite oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> (lamotrigine) | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------------|
| SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 3 | |
| <i>topiramate oral capsule, sprinkle 15 (Topamax) mg, 25 mg</i> | 2 | |
| <i>topiramate oral capsule, sprinkle 50 mg</i> | 3 | |
| <i>topiramate oral solution 25 mg/ml (Eprontia)</i> | 3 | ST |
| <i>topiramate oral tablet 100 mg, 200 (Topamax) mg, 25 mg, 50 mg</i> | 1 | |
| <i>valproate sodium intravenous solution 500 mg/5 ml (100 mg/ml)</i> | 2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | 2 | |
| <i>valproic acid oral capsule 250 mg</i> | 2 | |
| VALTOCO NASAL SPRAY, NON- AEROSOL 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) | 5 | NDS; QL (10 per 30 days) |
| <i>vigabatrin oral powder in packet 500 (Vigadrone) mg</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigabatrin oral tablet 500 mg (Vigadrone)</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigadrone oral powder in packet 500 (vigabatrin) mg</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigadrone oral tablet 500 mg (vigabatrin)</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigpoder oral powder in packet 500 (vigabatrin) mg</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) | 5 | NDS; QL (56 per 28 days) |
| XCOPRI ORAL TABLET 100 MG, 25 MG, 50 MG | 5 | NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------------|
| XCOPRI ORAL TABLET 150 MG, 200 MG | 5 | NDS; QL (60 per 30 days) |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14) | 4 | |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | 5 | NDS |
| ZONISADE ORAL SUSPENSION 100 MG/5 ML | 4 | |
| <i>zonisamide oral capsule 100 mg, 25 mg</i> (Zonegran) | 2 | |
| <i>zonisamide oral capsule 50 mg</i> | 2 | |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 5 | PA NSO; NDS; QL (1080 per 30 days) |
| Antidementia Agents | | |
| Antidementia Agents | | |
| <i>donepezil oral tablet 10 mg, 5 mg</i> (Aricept) | 1 | QL (30 per 30 days) |
| <i>donepezil oral tablet 23 mg</i> (Aricept) | 2 | QL (30 per 30 days) |
| <i>donepezil oral tablet,disintegrating 10 mg</i> | 2 | |
| <i>donepezil oral tablet,disintegrating 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>ergoloid oral tablet 1 mg</i> | 2 | |
| <i>galantamine oral capsule,ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i> | 2 | QL (30 per 30 days) |
| <i>galantamine oral solution 4 mg/ml</i> | 3 | QL (200 per 30 days) |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i> | 2 | QL (60 per 30 days) |
| <i>memantine oral capsule,sprinkle,er 24hr 14 mg, 21 mg, 28 mg</i> | 2 | ST; QL (30 per 30 days) |
| <i>memantine oral capsule,sprinkle,er 24hr 7 mg</i> (Namenda XR) | 2 | ST; QL (30 per 30 days) |
| <i>memantine oral solution 2 mg/ml</i> | 3 | QL (300 per 30 days) |
| <i>memantine oral tablet 10 mg, 5 mg</i> | 2 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>memantine-donepezil oral capsule, sprinkle, er 24hr 14-10 mg, 21-10 mg, 28-10 mg</i> (Namzaric) | 3 | ST; QL (30 per 30 days) |
| NAMZARIC ORAL CAP, SPRINKLE, ER 24HR DOSE PACK 7/14/21/28 MG-10 MG | 4 | ST |
| NAMZARIC ORAL CAPSULE, SPRINKLE, ER 24HR 7-10 MG | 4 | ST; QL (30 per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 2 | |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour</i> (Exelon Patch) | 3 | QL (30 per 30 days) |
| Antidepressants | | |
| Antidepressants | | |
| <i>amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>amitriptyline-chlordiazepoxide oral tablet 12.5-5 mg, 25-10 mg</i> | 2 | |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 2 | |
| AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 45-105 MG | 5 | ST; NDS |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | 2 | |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg, 300 mg</i> (Wellbutrin XL) | 2 | |
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg</i> (Wellbutrin SR) | 2 | |
| <i>citalopram oral solution 10 mg/5 ml</i> | 2 | |
| <i>citalopram oral tablet 10 mg</i> (Celexa) | 1 | QL (120 per 30 days) |
| <i>citalopram oral tablet 20 mg, 40 mg</i> (Celexa) | 1 | QL (30 per 30 days) |
| <i>clomipramine oral capsule 25 mg, 50 mg, 75 mg</i> (Anafranil) | 4 | |
| <i>desipramine oral tablet 10 mg, 25 mg</i> (Norpramin) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>desipramine oral tablet 100 mg, 150 mg, 50 mg, 75 mg</i> | 4 | |
| <i>desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg</i> (Pristiq) | 2 | QL (30 per 30 days) |
| <i>doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>doxepin oral concentrate 10 mg/ml</i> | 2 | |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 60 MG | 4 | ST; QL (60 per 30 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG | 4 | ST; QL (30 per 30 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 30 mg, 60 mg</i> | 2 | QL (60 per 30 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 40 mg</i> | 4 | QL (30 per 30 days) |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR | 5 | ST; NDS; QL (30 per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5 ml</i> | 3 | |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> (Lexapro) | 1 | |
| EXXUA ORAL TABLET EXTENDED RELEASE 24 HR 18.2 MG, 36.3 MG, 54.5 MG, 72.6 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| EXXUA ORAL TABLET, EXT REL 24HR DOSE PACK 18.2 MG (32 TABS) | 5 | PA NSO; NDS |
| FETZIMA ORAL CAPSULE, EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) | 4 | ST |
| FETZIMA ORAL CAPSULE, EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 4 | ST; QL (30 per 30 days) |
| <i>fluoxetine oral capsule 10 mg, 20 mg</i> (Prozac) | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------------|
| <i>fluoxetine oral capsule 40 mg</i> | 1 | |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine pamoate oral capsule 100 mg, 125 mg, 150 mg, 75 mg</i> | 4 | |
| MARPLAN ORAL TABLET 10 MG | 4 | |
| <i>mirtazapine oral tablet 15 mg, 30 mg (Remeron)</i> | 2 | |
| <i>mirtazapine oral tablet 45 mg, 7.5 mg</i> | 2 | |
| <i>mirtazapine oral tablet, disintegrating (Remeron SolTab) 15 mg, 30 mg, 45 mg</i> | 2 | |
| <i>nefazodone oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 2 | |
| <i>nortriptyline oral capsule 10 mg, 25 mg, 50 mg, 75 mg (Pamelor)</i> | 1 | |
| <i>nortriptyline oral solution 10 mg/5 ml</i> | 4 | |
| <i>paroxetine hcl oral suspension 10 mg/5 ml (Paxil)</i> | 4 | PA NSO; AGE (Max 64 Years) |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg (Paxil)</i> | 1 | PA NSO; AGE (Max 64 Years) |
| <i>paroxetine hcl oral tablet extended release 24 hr 12.5 mg, 25 mg, 37.5 mg (Paxil CR)</i> | 4 | PA NSO; AGE (Max 64 Years) |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg</i> | 2 | |
| <i>phenelzine oral tablet 15 mg (Nardil)</i> | 2 | |
| <i>protriptyline oral tablet 10 mg, 5 mg</i> | 4 | |
| RALDESY ORAL SOLUTION 10 MG/ML | 5 | PA NSO; NDS; QL (1200 per 30 days) |
| <i>sertraline oral concentrate 20 mg/ml (Zoloft)</i> | 2 | |
| <i>sertraline oral tablet 100 mg, 25 mg, 50 mg (Zoloft)</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| SPRAVATO NASAL SPRAY, NON-AEROSOL 28 MG, 56 MG (28 MG X 2), 84 MG (28 MG X 3) | 5 | PA NSO; NDS |
| <i>tranylcypromine oral tablet 10 mg</i> (Parnate) | 4 | |
| <i>trazodone oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | 1 | |
| <i>trimipramine oral capsule 100 mg, 25 mg, 50 mg</i> | 4 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>venlafaxine besylate oral tablet extended release 24hr 112.5 mg</i> | 4 | QL (60 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 150 mg</i> (Effexor XR) | 2 | QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 37.5 mg, 75 mg</i> (Effexor XR) | 2 | QL (90 per 30 days) |
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 2 | |
| <i>venlafaxine oral tablet extended release 24hr 150 mg, 225 mg, 37.5 mg</i> | 4 | QL (30 per 30 days) |
| <i>venlafaxine oral tablet extended release 24hr 75 mg</i> | 4 | QL (90 per 30 days) |
| <i>vilazodone oral tablet 10 mg, 20 mg, 40 mg</i> (Viibryd) | 2 | QL (30 per 30 days) |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG | 5 | PA NSO; NDS; QL (28 per 14 days) |
| ZURZUVAE ORAL CAPSULE 30 MG | 5 | PA NSO; NDS; QL (14 per 14 days) |
| Antidiabetic Agents | | |
| Antidiabetic Agents, Miscellaneous | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> (Precose) | 2 | |
| <i>dapagliflozin propanediol oral tablet 10 mg, 5 mg</i> (Farxiga) | 3 | QL (30 per 30 days) |
| FARXIGA ORAL TABLET 10 MG, 5 MG (dapagliflozin propanediol) | 3 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG | 3 | QL (30 per 30 days) |
| JANUMET ORAL TABLET 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG | 3 | QL (30 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 3 | QL (30 per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 3 | QL (30 per 30 days) |
| JENTADUETO ORAL TABLET (linagliptin-metformin) 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | 3 | QL (30 per 30 days) |
| <i>metformin oral solution 500 mg/5 ml</i> (Riomet) | 4 | QL (765 per 30 days) |
| <i>metformin oral tablet 1,000 mg</i> | 6 | QL (75 per 30 days) |
| <i>metformin oral tablet 500 mg</i> | 6 | QL (150 per 30 days) |
| <i>metformin oral tablet 750 mg, 850 mg</i> | 6 | QL (90 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 500 mg</i> | 6 | QL (120 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 750 mg</i> | 6 | QL (60 per 30 days) |
| <i>mifepristone oral tablet 300 mg</i> (Korlym) | 5 | PA; NDS; QL (112 per 28 days) |
| <i>miglitol oral tablet 100 mg, 25 mg, 50 mg</i> | 4 | QL (90 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| MOUNJARO SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML | 3 | PA; QL (2 per 28 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 6 | QL (90 per 30 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 0.25 MG OR 0.5 MG(2 MG/1.5 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | 3 | PA; QL (3 per 28 days) |
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i> (Actos) | 6 | QL (30 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-500 mg</i> | 6 | QL (90 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-850 mg</i> (Actoplus MET) | 6 | QL (90 per 30 days) |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | 6 | QL (120 per 30 days) |
| <i>repaglinide oral tablet 2 mg</i> | 6 | QL (240 per 30 days) |
| RYBELSUS ORAL TABLET 1.5 MG, 14 MG, 3 MG, 4 MG, 7 MG, 9 MG | 3 | PA; QL (30 per 30 days) |
| SYNJARDY ORAL TABLET 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG | 3 | QL (30 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-1,000 MG, 5-1,000 MG | 3 | QL (60 per 30 days) |
| TRADJENTA ORAL TABLET 5 MG | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG | 3 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--|
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML | 3 | PA; QL (2 per 28 days) |
| XIGDUO XR ORAL TABLET, IR - (dapaglifloz propaned- ER, BIPHASIC 24HR 10-1,000 MG metformin) | 3 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-500 MG | 3 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - (dapaglifloz propaned- ER, BIPHASIC 24HR 5-1,000 MG metformin) | 3 | QL (60 per 30 days) |
| Insulins | | |
| FIASP FLEXTOUCH U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| FIASP PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| FIASP PUMPCART SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (1.6 ML) | 3 | max \$35 copay per month supply |
| FIASP U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (24 per 28 days) |
| <i>insulin asp prt-insulin aspart</i> (Novolog Mix 70- <i>subcutaneous insulin pen 100 unit/ml</i> 30FlexPen U-100) (70-30) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|----------------------------------|------------------|--|
| <i>insulin asp prt-insulin aspart subcutaneous solution 100 unit/ml (70-30)</i> | (Novolog Mix 70-30 U-100 Insuln) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin aspart u-100 subcutaneous cartridge 100 unit/ml</i> | (Novolog PenFill U-100 Insulin) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous insulin pen 100 unit/ml (3 ml)</i> | (Novolog FlexPen U-100 Insulin) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous solution 100 unit/ml</i> | (Novolog U-100 Insulin aspart) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin glargine-yfgn subcutaneous insulin pen 100 unit/ml (3 ml)</i> | (Semglee(insulin glarg-yfgn)Pen) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin glargine-yfgn subcutaneous solution 100 unit/ml</i> | (Semglee(insulin glargine-yfgn)) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin lispro subcutaneous solution 100 unit/ml</i> | (Admelog U-100 Insulin lispro) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| LANTUS SOLOSTAR U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | (insulin glargine) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| LANTUS U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | (insulin glargine) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) | | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN 70-30 FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | | 3 | max \$35 copay per month supply; QL (30 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| NOVOLIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN R FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN R REGULAR U100 INSULIN INJECTION SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLOG FLEXPEN U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) (insulin aspart u-100) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLOG MIX 70-30 U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML (70-30) (insulin asp prt-insulin aspart) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLOG MIX 70-30FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) (insulin asp prt-insulin aspart) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLOG PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (insulin aspart u-100) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLOG U-100 INSULIN ASPART SUBCUTANEOUS SOLUTION 100 UNIT/ML (insulin aspart u-100) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| SOLIQUA 100/33 SUBCUTANEOUS INSULIN PEN 100 UNIT-33 MCG/ML | 3 | max \$35 copay per month supply; QL (30 per 30 days) |
| TOUJEO MAX U-300 SOLOSTAR SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (3 ML) (insulin glargine u-300 conc) | 3 | max \$35 copay per month supply; QL (18 per 28 days) |
| TOUJEO SOLOSTAR U-300 INSULIN SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML) (insulin glargine u-300 conc) | 3 | max \$35 copay per month supply; QL (13.5 per 28 days) |
| XULTOPHY 100/3.6 SUBCUTANEOUS INSULIN PEN 100 UNIT-3.6 MG /ML (3 ML) | 3 | max \$35 copay per month supply; QL (15 per 28 days) |
| Sulfonylureas | | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>glimepiride oral tablet 1 mg, 2 mg</i> | 6 | QL (30 per 30 days) |
| <i>glimepiride oral tablet 4 mg</i> | 6 | QL (60 per 30 days) |
| <i>glipizide oral tablet 10 mg</i> | 6 | QL (120 per 30 days) |
| <i>glipizide oral tablet 2.5 mg</i> | 6 | QL (90 per 30 days) |
| <i>glipizide oral tablet 5 mg</i> | 6 | QL (240 per 30 days) |
| <i>glipizide oral tablet extended release 24hr 10 mg</i> | 6 | QL (60 per 30 days) |
| <i>glipizide oral tablet extended release 24hr 2.5 mg, 5 mg</i> | 6 | QL (30 per 30 days) |
| <i>glipizide-metformin oral tablet 2.5-250 mg</i> | 6 | QL (240 per 30 days) |
| <i>glipizide-metformin oral tablet 2.5-500 mg, 5-500 mg</i> | 6 | QL (120 per 30 days) |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | 6 | PA; AGE (Max 64 Years) |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | 6 | PA; AGE (Max 64 Years) |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | 6 | PA; AGE (Max 64 Years) |
| Antifungals | | |
| Antifungals | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 4 | PA BvD |
| <i>amphotericin b injection recon soln 50 mg</i> | 2 | PA BvD |
| <i>amphotericin b liposome intravenous suspension for reconstitution 50 mg</i> (AmBisome) | 5 | PA BvD; NDS |
| <i>ciclopirox topical cream 0.77 %</i> (Ciclodan) | 2 | QL (180 per 30 days) |
| <i>ciclopirox topical gel 0.77 %</i> | 4 | |
| <i>ciclopirox topical shampoo 1 %</i> | 4 | |
| <i>ciclopirox topical solution 8 %</i> (Ciclodan) | 2 | QL (19.8 per 30 days) |
| <i>ciclopirox topical suspension 0.77 %</i> (Loprox (as olamine)) | 4 | QL (180 per 30 days) |
| <i>clotrimazole mucous membrane troche 10 mg</i> | 2 | |
| <i>clotrimazole topical cream 1 %</i> (Antifungal (clotrimazole)) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>clotrimazole topical solution 1 %</i> (Athlete's Foot (clotrimazole)) | 2 | |
| <i>clotrimazole-betamethasone topical cream 1-0.05 %</i> | 2 | QL (90 per 30 days) |
| <i>clotrimazole-betamethasone topical lotion 1-0.05 %</i> | 4 | |
| CRESEMBA INTRAVENOUS RECON SOLN 372 MG | 5 | NDS |
| CRESEMBA ORAL CAPSULE 186 MG, 74.5 MG | 5 | PA; NDS |
| <i>econazole nitrate topical cream 1 %</i> | 2 | QL (170 per 30 days) |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 2 | |
| <i>fluconazole oral suspension for reconstitution 10 mg/ml</i> | 2 | |
| <i>fluconazole oral suspension for reconstitution 40 mg/ml</i> (Diflucan) | 2 | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 2 | |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> (Ancobon) | 5 | NDS |
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | 3 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 4 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 165 mg, 250 mg</i> | 4 | |
| <i>itraconazole oral capsule 100 mg</i> (Sporanox) | 3 | |
| <i>itraconazole oral solution 10 mg/ml</i> | 5 | PA; NDS |
| <i>ketoconazole oral tablet 200 mg</i> | 2 | |
| <i>ketoconazole topical cream 2 %</i> | 2 | QL (180 per 30 days) |
| <i>ketoconazole topical foam 2 %</i> (Extina) | 4 | ST; QL (100 per 30 days) |
| <i>ketoconazole topical shampoo 2 %</i> | 2 | QL (360 per 30 days) |
| <i>miconazole intravenous recon soln 100 mg, 50 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>miconazole-3 vaginal suppository 200 mg</i> | 2 | |
| NOXAFIL ORAL SUSP,DELAYED RELEASE FOR RECON 300 MG | 5 | PA; NDS |
| <i>nyamyc topical powder 100,000 unit/gram</i> (nystatin) | 2 | QL (60 per 30 days) |
| <i>nystatin oral suspension 100,000 unit/ml</i> | 2 | |
| <i>nystatin oral tablet 500,000 unit</i> | 2 | |
| <i>nystatin topical cream 100,000 unit/gram</i> | 2 | QL (60 per 30 days) |
| <i>nystatin topical ointment 100,000 unit/gram</i> | 2 | QL (60 per 30 days) |
| <i>nystatin topical powder 100,000 unit/gram</i> (Nyamyc) | 2 | QL (60 per 30 days) |
| <i>nystatin-triamcinolone topical cream 100,000-0.1 unit/g-%</i> | 2 | |
| <i>nystatin-triamcinolone topical ointment 100,000-0.1 unit/gram-%</i> | 2 | |
| <i>nystop topical powder 100,000 unit/gram</i> (nystatin) | 2 | QL (60 per 30 days) |
| <i>posaconazole oral suspension 200 mg/5 ml (40 mg/ml)</i> (Noxafil) | 5 | PA; NDS |
| <i>posaconazole oral tablet, delayed release (dr/ec) 100 mg</i> | 5 | PA; NDS |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | |
| <i>voriconazole intravenous recon soln 200 mg</i> (Vfend IV) | 5 | PA BvD; NDS |
| <i>voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml)</i> (Vfend) | 5 | PA; NDS |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | 4 | |
| Antigout Agents | | |
| Antigout Agents, Other | | |
| <i>allopurinol oral tablet 100 mg</i> (Zyloprim) | 1 | |
| <i>allopurinol oral tablet 300 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| <i>colchicine oral capsule 0.6 mg</i> (Mitigare) | 3 | QL (60 per 30 days) |
| <i>colchicine oral tablet 0.6 mg</i> (Colcrys) | 2 | QL (120 per 30 days) |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> (Uloric) | 4 | ST; QL (30 per 30 days) |
| <i>probenecid oral tablet 500 mg</i> | 2 | |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i> | 2 | |
| Antihistamines | | |
| Antihistamines | | |
| <i>carbinoxamine maleate oral liquid 4 mg/5 ml</i> (Carbzah) | 4 | PA; AGE (Max 64 Years) |
| <i>clemastine oral tablet 2.68 mg</i> (Clemsza) | 2 | PA; AGE (Max 64 Years) |
| <i>clemasz oral tablet 2.68 mg</i> (clemastine) | 2 | PA; AGE (Max 64 Years) |
| <i>clemsza oral tablet 2.68 mg</i> (clemastine) | 2 | PA; AGE (Max 64 Years) |
| <i>cyproheptadine oral syrup 2 mg/5 ml</i> | 2 | PA; AGE (Max 64 Years) |
| <i>cyproheptadine oral tablet 4 mg</i> | 2 | PA; AGE (Max 64 Years) |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> | 2 | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |
| <i>levocetirizine oral solution 2.5 mg/5 ml</i> (Xyzal) | 4 | |
| <i>levocetirizine oral tablet 5 mg</i> (24HR Allergy Relief) | 1 | |
| <i>promethazine oral syrup 6.25 mg/5 ml</i> | 2 | PA; AGE (Max 64 Years) |
| Anti-Infectives (Skin And Mucous Membrane) | | |
| Anti-Infectives (Skin And Mucous Membrane) | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> (Cleocin) | 4 | |
| <i>metronidazole vaginal gel 0.75 % (37.5mg/5 gram)</i> (Vandazole) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------------|
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 2 | |
| <i>terconazole vaginal suppository 80 mg</i> | 4 | |
| Antimigraine Agents | | |
| Antimigraine Agents | | |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO- INJECTOR 140 MG/ML, 70 MG/ML | 3 | PA; QL (1 per 30 days) |
| <i>dihydroergotamine nasal spray, non- (Migranal)</i> <i>aerosol 0.5 mg/pump act. (4 mg/ml)</i> | 5 | ST; NDS; QL (8 per 28 days) |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | 3 | PA; QL (3 per 30 days) |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i> | 2 | QL (9 per 30 days) |
| NURTEC ODT ORAL TABLET, DISINTEGRATING 75 MG | 3 | PA; QL (18 per 30 days) |
| QULIPTA ORAL TABLET 10 MG, 30 MG, 60 MG | 3 | PA; QL (30 per 30 days) |
| <i>rizatriptan oral tablet 10 mg (Maxalt)</i> | 2 | QL (18 per 30 days) |
| <i>rizatriptan oral tablet 5 mg</i> | 2 | QL (18 per 30 days) |
| <i>rizatriptan oral tablet, disintegrating (Maxalt-MLT)</i> <i>10 mg</i> | 2 | QL (18 per 30 days) |
| <i>rizatriptan oral tablet, disintegrating</i> <i>5 mg</i> | 2 | QL (18 per 30 days) |
| <i>sumatriptan 4 mg/0.5 ml inject outer, (Imitrex STATdose Pen)</i> <i>suv</i> | 3 | QL (4 per 28 days) |
| <i>sumatriptan nasal spray, non-aerosol</i> <i>20 mg/actuation, 5 mg/actuation</i> | 3 | QL (12 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>sumatriptan succinate oral tablet 100 mg</i> (Imitrex) | 2 | QL (9 per 30 days) |
| <i>sumatriptan succinate oral tablet 25 mg, 50 mg</i> (Imitrex) | 2 | QL (18 per 30 days) |
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml, 6 mg/0.5 ml</i> (Imitrex STATdose Pen) | 4 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i> | 2 | QL (5 per 28 days) |
| <i>sumatriptan-naproxen oral tablet 85-500 mg</i> (Treximet) | 4 | QL (9 per 27 days) |
| UBRELVY ORAL TABLET 100 MG, 50 MG | 3 | PA; QL (16 per 30 days) |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> (Zomig) | 2 | QL (12 per 30 days) |
| <i>zolmitriptan oral tablet, disintegrating 2.5 mg, 5 mg</i> | 3 | QL (12 per 30 days) |
| Antimycobacterials | | |
| Antimycobacterials | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 2 | |
| <i>ethambutol oral tablet 100 mg, 400 mg</i> | 2 | |
| <i>isoniazid oral solution 50 mg/5 ml</i> | 4 | |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | |
| PRIFTIN ORAL TABLET 150 MG | 4 | |
| <i>pyrazinamide oral tablet 500 mg</i> | 3 | |
| <i>rifabutin oral capsule 150 mg</i> | 4 | |
| <i>rifampin intravenous recon soln 600 mg</i> (Rifadin) | 3 | |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 2 | |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 5 | PA; NDS |
| TRECTOR ORAL TABLET 250 MG | 4 | |
| Antinausea Agents | | |
| Antinausea Agents | | |
| <i>aprepitant oral capsule 125 mg</i> | 3 | PA BvD; QL (2 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>aprepitant oral capsule 40 mg</i> | 3 | PA BvD; QL (1 per 28 days) |
| <i>aprepitant oral capsule 80 mg</i> (Emend) | 3 | PA BvD; QL (4 per 28 days) |
| <i>aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)</i> (Emend) | 3 | PA BvD |
| <i>compro rectal suppository 25 mg</i> (prochlorperazine) | 3 | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> (Marinol) | 4 | PA; QL (60 per 30 days) |
| EMEND ORAL SUSPENSION FOR RECONSTITUTION 125 MG (25 MG/ ML FINAL CONC.) | 4 | PA BvD; QL (6 per 28 days) |
| <i>granisetron hcl oral tablet 1 mg</i> | 4 | PA BvD |
| <i>meclizine oral tablet 12.5 mg</i> | 1 | |
| <i>meclizine oral tablet 25 mg</i> (Dramamine (meclizine)) | 1 | |
| <i>ondansetron hcl oral solution 4 mg/5 ml</i> | 2 | PA BvD |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>ondansetron oral tablet, disintegrating 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>prochlorperazine edisylate injection solution 10 mg/2 ml (5 mg/ml)</i> | 2 | |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> (Compazine) | 2 | |
| <i>prochlorperazine rectal suppository 25 mg</i> (Compro) | 3 | |
| <i>promethazine injection solution 25 mg/ml</i> (Phenergan) | 2 | PA; AGE (Max 64 Years) |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | PA; AGE (Max 64 Years) |
| <i>promethazine rectal suppository 12.5 mg</i> (Promethegan) | 3 | PA; AGE (Max 64 Years) |
| <i>promethazine rectal suppository 25 mg</i> (Promethegan) | 2 | PA; AGE (Max 64 Years) |
| <i>promethazine rectal suppository 50 mg</i> (Promethegan) | 4 | PA; AGE (Max 64 Years) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---|
| <i>promethegan rectal suppository 12.5 mg, 25 mg</i> (promethazine) | 2 | PA; AGE (Max 64 Years) |
| <i>promethegan rectal suppository 50 mg</i> (promethazine) | 4 | PA; AGE (Max 64 Years) |
| <i>scopolamine base transdermal patch 3 day 1 mg over 3 days</i> (Transderm-Scop) | 4 | PA; QL (10 per 30 days); AGE (Max 64 Years) |
| Antiparasite Agents | | |
| Antiparasite Agents | | |
| <i>albendazole oral tablet 200 mg</i> | 3 | |
| <i>atovaquone oral suspension 750 mg/5 ml</i> (Mepron) | 3 | |
| <i>atovaquone-proguanil oral tablet 250-100 mg</i> (Malarone) | 2 | |
| <i>atovaquone-proguanil oral tablet 62.5-25 mg</i> (Malarone Pediatric) | 2 | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 2 | |
| COARTEM ORAL TABLET 20-120 MG | 4 | |
| <i>hydroxychloroquine oral tablet 100 mg</i> | 2 | QL (180 per 30 days) |
| <i>hydroxychloroquine oral tablet 200 mg</i> (Plaquenil) | 2 | QL (90 per 30 days) |
| <i>hydroxychloroquine oral tablet 300 mg</i> (Sovuna) | 2 | QL (60 per 30 days) |
| <i>hydroxychloroquine oral tablet 400 mg</i> | 2 | QL (60 per 30 days) |
| IMPAVIDO ORAL CAPSULE 50 MG | 5 | PA; NDS; QL (84 per 28 days) |
| <i>ivermectin oral tablet 3 mg</i> (Stromectol) | 2 | |
| <i>ivermectin oral tablet 6 mg</i> | 2 | |
| <i>mefloquine oral tablet 250 mg</i> | 2 | |
| <i>nitazoxanide oral tablet 500 mg</i> (Alinia) | 5 | NDS; QL (60 per 30 days) |
| <i>pentamidine inhalation recon soln 300 mg</i> (Nebupent) | 3 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>pentamidine injection recon soln 300 mg</i> (Pentam) | 3 | |
| <i>praziquantel oral tablet 600 mg</i> (Biltricide) | 3 | |
| PRIMAQUINE ORAL TABLET 26.3 MG (15 MG BASE) | 4 | |
| <i>pyrimethamine oral tablet 25 mg</i> (Daraprim) | 5 | PA; NDS |
| <i>quinine sulfate oral capsule 324 mg</i> (Qualaquin) | 2 | PA |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 2 | |
| Antiparkinsonian Agents | | |
| Antiparkinsonian Agents | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 2 | |
| <i>amantadine hcl oral solution 50 mg/5 ml</i> | 2 | |
| <i>amantadine hcl oral tablet 100 mg</i> | 2 | |
| <i>apomorphine subcutaneous cartridge 10 mg/ml</i> (APOKYN) | 5 | PA; NDS; QL (60 per 30 days) |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |
| <i>bromocriptine oral capsule 5 mg</i> | 4 | |
| <i>bromocriptine oral tablet 2.5 mg</i> | 2 | |
| <i>cabergoline oral tablet 0.5 mg</i> | 2 | |
| <i>carbidopa oral tablet 25 mg</i> (Lodosyn) | 2 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg</i> (Sinemet) | 2 | |
| <i>carbidopa-levodopa oral tablet 25-100 mg</i> (Dhivy) | 2 | |
| <i>carbidopa-levodopa oral tablet 25-250 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet, disintegrating 10-100 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet, disintegrating 25-100 mg, 25-250 mg</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 4 | |
| <i>entacapone oral tablet 200 mg</i> | 3 | |
| INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE 42 MG | 5 | PA; NDS; QL (300 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NDS; QL (150 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10-15-20-25-30 MG | 5 | PA; NDS |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR | 4 | ST; QL (30 per 30 days) |
| ONAPGO SUBCUTANEOUS CARTRIDGE 4.9 MG/ ML | 5 | PA; NDS; QL (600 per 30 days) |
| ONGENTYS ORAL CAPSULE 25 MG, 50 MG | 4 | PA; QL (30 per 30 days) |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 129 MG, 193 MG, 258 MG, 322 MG/DAY(129 MG X1-193MG X1) | 4 | ST |
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 2 | |
| <i>rasagiline oral tablet 0.5 mg, 1 mg</i> (Azilect) | 4 | |
| <i>ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 2 | |
| <i>ropinirole oral tablet extended release 24 hr 12 mg, 2 mg, 4 mg, 6 mg, 8 mg</i> | 2 | |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | |
| <i>selegiline hcl oral tablet 5 mg</i> | 4 | |
| <i>trihexyphenidyl oral elixir 0.4 mg/ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | 2 | |
| VYALEV CONTIN. SUBCUTANEOUS INFUSION SOLUTION 12-240 MG/ML | 5 | PA; NDS; QL (560 per 28 days) |
| Antipsychotic Agents | | |
| Antipsychotic Agents | | |
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 720 MG/2.4 ML | 5 | NDS; QL (2.4 per 42 days) |
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 960 MG/3.2 ML | 5 | NDS; QL (3.2 per 42 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG | 5 | NDS; QL (2 per 28 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 300 MG, 400 MG | 5 | NDS; QL (2 per 28 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 3 | |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> (Abilify) | 2 | |
| <i>aripiprazole oral tablet,disintegrating 10 mg</i> | 4 | ST; QL (90 per 30 days) |
| <i>aripiprazole oral tablet,disintegrating 15 mg</i> | 4 | ST; QL (60 per 30 days) |
| ARISTADA INITIO INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 675 MG/2.4 ML | 5 | NDS; QL (4.8 per 365 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 1,064 MG/3.9 ML | 5 | NDS; QL (3.9 per 14 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 441 MG/1.6 ML | 5 | NDS; QL (1.6 per 14 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 662 MG/2.4 ML | 5 | NDS; QL (2.4 per 14 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 882 MG/3.2 ML | 5 | NDS; QL (3.2 per 14 days) |
| <i>asenapine maleate sublingual tablet</i> (Saphris) <i>10 mg, 2.5 mg, 5 mg</i> | 4 | QL (60 per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 5 | ST; NDS; QL (30 per 30 days) |
| <i>chlorpromazine injection solution 25 mg/ml</i> | 2 | |
| <i>chlorpromazine oral concentrate 100 mg/ml, 30 mg/ml</i> | 3 | |
| <i>chlorpromazine oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 4 | |
| <i>clozapine oral tablet 100 mg, 200</i> (Clozaril) <i>mg, 25 mg, 50 mg</i> | 2 | |
| <i>clozapine oral tablet,disintegrating 100 mg, 12.5 mg, 25 mg</i> | 4 | ST; QL (90 per 30 days) |
| <i>clozapine oral tablet,disintegrating 150 mg</i> | 4 | ST; QL (180 per 30 days) |
| <i>clozapine oral tablet,disintegrating 200 mg</i> | 4 | ST; QL (120 per 30 days) |
| COBENFY ORAL CAPSULE 100- 20 MG, 125-30 MG, 50-20 MG | 5 | ST; NDS; QL (60 per 30 days) |
| COBENFY STARTER PACK ORAL CAPSULE,DOSE PACK 50 MG-20 MG /100 MG-20 MG | 5 | ST; NDS |
| ERZOFRI INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 5 | NDS; QL (0.75 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 156 MG/ML | 5 | NDS; QL (1 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 5 | NDS; QL (1.5 per 21 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| ERZOFRI INTRAMUSCULAR SYRINGE 351 MG/2.25 ML | 5 | NDS; QL (2.25 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 5 | NDS; QL (0.25 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 5 | NDS; QL (0.5 per 21 days) |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 5 | ST; NDS; QL (60 per 30 days) |
| FANAPT TITRATION PACK A ORAL TABLETS,DOSE PACK 1MG(2)-2MG(2)- 4MG(2)-6MG(2) | 4 | ST |
| FANAPT TITRATION PACK B ORAL TABLETS,DOSE PACK 1 MG(6)-2MG(2)- 6 MG(2)-8 MG(2) | 4 | ST |
| FANAPT TITRATION PACK C ORAL TABLETS,DOSE PACK 1 MG(4)-2 MG(2) -6 MG (2) | 4 | ST |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 2 | |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 3 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 3 | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i> | 3 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 4 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml (1 ml), 50 mg/ml, 50 mg/ml(1ml)</i> | 2 | |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate intramuscular syringe 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 2 | |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML | 5 | NDS; QL (3.5 per 166 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML | 5 | NDS; QL (5 per 166 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 5 | NDS; QL (0.75 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | 5 | NDS; QL (1 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 5 | NDS; QL (1.5 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 3 | QL (0.25 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 5 | NDS; QL (0.5 per 21 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML | 5 | NDS; QL (0.88 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML | 5 | NDS; QL (1.32 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | 5 | NDS; QL (1.75 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML | 5 | NDS; QL (2.63 per 70 days) |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>lurasidone oral tablet 120 mg</i> (Latuda) | 4 | QL (30 per 30 days) |
| <i>lurasidone oral tablet 20 mg, 40 mg, 60 mg</i> (Latuda) | 3 | QL (30 per 30 days) |
| <i>lurasidone oral tablet 80 mg</i> (Latuda) | 3 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG | 5 | NDS; QL (30 per 30 days) |
| <i>molindone oral tablet 10 mg</i> | 2 | QL (240 per 30 days) |
| <i>molindone oral tablet 25 mg</i> | 2 | QL (270 per 30 days) |
| <i>molindone oral tablet 5 mg</i> | 5 | NDS; QL (120 per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| NUPLAZID ORAL TABLET 10 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>olanzapine intramuscular recon soln (Zyprexa) 10 mg</i> | 3 | QL (30 per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 7.5 mg</i> | 2 | |
| <i>olanzapine oral tablet 2.5 mg, 20 mg, 5 mg (Zyprexa)</i> | 2 | |
| <i>olanzapine oral tablet, disintegrating 10 mg, 15 mg, 20 mg, 5 mg</i> | 3 | |
| OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG | 5 | ST; NDS |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg</i> | 4 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 3 mg, 9 mg (Invega)</i> | 4 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 6 mg (Invega)</i> | 4 | QL (60 per 30 days) |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 2 | |
| PERSERIS SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 120 MG, 90 MG | 5 | NDS; QL (1 per 30 days) |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>prochlorperazine 10 mg/2 ml vial outer 10 mg/2 ml (5 mg/ml)</i> | 2 | |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg (Seroquel)</i> | 2 | |
| <i>quetiapine oral tablet 150 mg</i> | 2 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>quetiapine oral tablet extended release 24 hr 150 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> (Seroquel XR) | 2 | |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 5 | NDS; QL (30 per 30 days) |
| <i>risperidone microspheres intramuscular suspension,extended rel recon 12.5 mg/2 ml</i> (Risperdal Consta) | 2 | QL (2 per 28 days) |
| <i>risperidone microspheres intramuscular suspension,extended rel recon 25 mg/2 ml</i> (Rykindo) | 2 | QL (2 per 28 days) |
| <i>risperidone microspheres intramuscular suspension,extended rel recon 37.5 mg/2 ml, 50 mg/2 ml</i> (Rykindo) | 5 | NDS; QL (2 per 28 days) |
| <i>risperidone oral solution 1 mg/ml</i> (Risperdal) | 2 | |
| <i>risperidone oral tablet 0.25 mg</i> | 2 | |
| <i>risperidone oral tablet 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> (Risperdal) | 2 | |
| <i>risperidone oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 4 | |
| RYKINDO INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 25 MG/2 ML, 37.5 MG/2 ML, 50 MG/2 ML (risperidone microspheres) | 5 | NDS; QL (2 per 28 days) |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR | 5 | ST; NDS; QL (30 per 30 days) |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 100 MG/0.28 ML | 5 | NDS; QL (0.28 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 125 MG/0.35 ML | 5 | NDS; QL (0.35 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 150 MG/0.42 ML | 5 | NDS; QL (0.42 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 200 MG/0.56 ML | 5 | NDS; QL (0.56 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 250 MG/0.7 ML | 5 | NDS; QL (0.7 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 50 MG/0.14 ML | 5 | NDS; QL (0.14 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 75 MG/0.21 ML | 5 | NDS; QL (0.21 per 28 days) |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 5 | ST; NDS; QL (540 per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG | 5 | ST; NDS; QL (30 per 30 days) |
| VRAYLAR ORAL CAPSULE,DOSE PACK 1.5 MG (1)- 3 MG (6) | 4 | ST |
| <i>ziprasidone hcl oral capsule 20 mg, (Geodon) 40 mg, 60 mg, 80 mg</i> | 2 | |
| <i>ziprasidone mesylate intramuscular (Geodon) recon soln 20 mg/ml (final conc.)</i> | 3 | QL (6 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG | 4 | QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 300 MG | 5 | NDS; QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 405 MG | 5 | NDS; QL (1 per 28 days) |

Antivirals (Systemic)

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------|
| Antiretrovirals | | |
| <i>abacavir oral solution 20 mg/ml</i> (Ziagen) | 2 | |
| <i>abacavir oral tablet 300 mg</i> | 2 | |
| <i>abacavir-lamivudine oral tablet 600-300 mg</i> | 2 | |
| APTIVUS ORAL CAPSULE 250 MG | 5 | NDS |
| <i>atazanavir oral capsule 150 mg</i> | 2 | |
| <i>atazanavir oral capsule 200 mg, 300 mg</i> (Reyataz) | 2 | |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | 5 | NDS; QL (30 per 30 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION, EXTENDED RELEASE 400 MG/2 ML- 600 MG/2 ML, 600 MG/3 ML- 900 MG/3 ML | 5 | NDS |
| <i>cabotegravir intramuscular suspension, extended release 400 mg/2 ml (200 mg/ml)</i> | 5 | NDS; QL (24 per 365 days) |
| <i>cabotegravir intramuscular suspension, extended release 600 mg/3 ml (200 mg/ml)</i> (Apretude) | 5 | NDS; QL (24 per 365 days) |
| CIMDUO ORAL TABLET 300-300 MG | 5 | NDS |
| <i>darunavir oral tablet 600 mg</i> (Prezista) | 3 | |
| <i>darunavir oral tablet 800 mg</i> (Prezista) | 5 | NDS |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 5 | NDS |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG | 5 | NDS |
| <i>didanosine oral capsule, delayed release(dr/ec) 250 mg, 400 mg</i> | 3 | |
| DOVATO ORAL TABLET 50-300 MG | 5 | NDS |
| EDURANT ORAL TABLET 25 MG | 5 | NDS |
| EDURANT PED ORAL TABLET FOR SUSPENSION 2.5 MG | 5 | NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>efavirenz oral capsule 200 mg</i> | 3 | |
| <i>efavirenz oral capsule 50 mg</i> | 2 | |
| <i>efavirenz oral tablet 600 mg</i> | 3 | |
| <i>efavirenz-emtricitabin-tenofov oral tablet 600-200-300 mg</i> | 2 | |
| <i>efavirenz-lamivu-tenofov disop oral tablet 400-300-300 mg</i> | 5 | NDS |
| <i>efavirenz-lamivu-tenofov disop oral tablet 600-300-300 mg</i> (Symfi) | 5 | NDS |
| <i>emtricitabine oral capsule 200 mg</i> (Emtriva) | 3 | |
| <i>emtricitabine-tenofov (tdf) oral tablet 100-150 mg, 167-250 mg</i> (Truvada) | 3 | |
| <i>emtricitabine-tenofov (tdf) oral tablet 133-200 mg</i> (Truvada) | 5 | NDS |
| <i>emtricitabine-tenofov (tdf) oral tablet 200-300 mg</i> (Truvada) | 2 | |
| <i>emtricitabine-tenofov (tdf) oral tablet 200-25-300 mg</i> (Complera) | 5 | NDS |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 4 | |
| EPIVIR HBV ORAL SOLUTION 25 MG/5 ML (5 MG/ML) | 4 | |
| <i>etravirine oral tablet 100 mg, 200 mg</i> (Intelence) | 5 | NDS |
| EVOTAZ ORAL TABLET 300-150 MG | 5 | NDS |
| <i>fosamprenavir oral tablet 700 mg</i> | 5 | NDS |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG | 5 | NDS |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 5 | NDS |
| INTELENCE ORAL TABLET 25 MG | 4 | |
| ISENTRESS HD ORAL TABLET 600 MG | 5 | NDS |
| ISENTRESS ORAL POWDER IN PACKET 100 MG | 5 | NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| ISENTRESS ORAL TABLET 400 MG | 5 | NDS |
| ISENTRESS ORAL TABLET,CHEWABLE 100 MG | 5 | NDS |
| ISENTRESS ORAL TABLET,CHEWABLE 25 MG | 3 | |
| JULUCA ORAL TABLET 50-25 MG | 5 | NDS |
| KALETRA ORAL SOLUTION 400-100 MG/5 ML (lopinavir-ritonavir) | 4 | QL (480 per 30 days) |
| <i>lamivudine oral solution 10 mg/ml</i> (Epivir) | 2 | |
| <i>lamivudine oral tablet 100 mg</i> | 2 | |
| <i>lamivudine oral tablet 150 mg, 300 mg</i> (Epivir) | 2 | |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 3 | |
| LEXIVA ORAL SUSPENSION 50 MG/ML | 4 | |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5 ml</i> (Kaletra) | 2 | QL (480 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> (Kaletra) | 3 | QL (300 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> (Kaletra) | 3 | QL (120 per 30 days) |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> (Selzentry) | 5 | NDS |
| <i>nevirapine oral suspension 50 mg/5 ml</i> | 3 | QL (1200 per 30 days) |
| <i>nevirapine oral tablet 200 mg</i> | 2 | QL (60 per 30 days) |
| <i>nevirapine oral tablet extended release 24 hr 100 mg</i> | 3 | QL (90 per 30 days) |
| <i>nevirapine oral tablet extended release 24 hr 400 mg</i> | 3 | QL (30 per 30 days) |
| NORVIR ORAL POWDER IN PACKET 100 MG | 4 | |
| NORVIR ORAL SOLUTION 80 MG/ML | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| ODEFSEY ORAL TABLET 200-25-25 MG | 5 | NDS |
| PIFELTRO ORAL TABLET 100 MG | 5 | NDS |
| PREZCOBIX ORAL TABLET 675-150 MG, 800-150 MG-MG | 5 | NDS |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 5 | NDS |
| PREZISTA ORAL TABLET 150 MG | 5 | NDS |
| PREZISTA ORAL TABLET 75 MG | 4 | |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML | 4 | |
| REYATAZ ORAL POWDER IN PACKET 50 MG | 5 | NDS |
| <i>rilpivirine intramuscular suspension, extended release 600 mg/2 ml (300 mg/ml), 900 mg/3 ml (300 mg/ml)</i> | 5 | NDS |
| <i>ritonavir oral tablet 100 mg</i> (Norvir) | 2 | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG | 5 | NDS |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 5 | NDS |
| SELZENTRY ORAL TABLET 25 MG | 3 | |
| SELZENTRY ORAL TABLET 75 MG | 5 | NDS |
| <i>stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg</i> | 2 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 5 | NDS |
| SUNLENCA ORAL TABLET 300 MG, 300 MG (4-TABLET PACK), 300 MG (5-TABLET PACK) | 5 | NDS |
| SUNLENCA SUBCUTANEOUS SOLUTION 309 MG/ML | 5 | PA BvD; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| SYMTUZA ORAL TABLET 800-150-200-10 MG | 5 | NDS |
| TEMIXYS ORAL TABLET 300-300 MG | 5 | NDS |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> (Viread) | 2 | |
| TIVICAY ORAL TABLET 10 MG | 4 | |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5 | NDS |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG | 5 | NDS |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 5 | NDS; QL (30 per 30 days) |
| TRIUMEQ PD ORAL TABLET FOR SUSPENSION 60-5-30 MG | 4 | |
| TRIZIVIR ORAL TABLET 300-150-300 MG | 5 | NDS |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33 ML (150 MG/ML) | 5 | NDS |
| VEMLIDY ORAL TABLET 25 MG | 5 | NDS; QL (30 per 30 days) |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | 5 | NDS |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM) | 5 | NDS |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 5 | NDS |
| VOCABRIA ORAL TABLET 30 MG | 4 | |
| <i>zidovudine oral capsule 100 mg</i> (Retrovir) | 2 | |
| <i>zidovudine oral syrup 10 mg/ml</i> (Retrovir) | 2 | |
| <i>zidovudine oral tablet 300 mg</i> | 2 | |
| Antivirals, Miscellaneous | | |
| LIVTENCITY ORAL TABLET 200 MG | 5 | PA; NDS |
| <i>oseltamivir oral capsule 30 mg</i> (Tamiflu) | 2 | QL (84 per 180 days) |
| <i>oseltamivir oral capsule 45 mg</i> (Tamiflu) | 2 | QL (48 per 180 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>oseltamivir oral capsule 75 mg</i> (Tamiflu) | 2 | QL (42 per 180 days) |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> (Tamiflu) | 2 | QL (540 per 180 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (10)- 100 MG (10) | 2 | QL (20 per 5 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (6)- 100 MG (5) | 2 | QL (11 per 28 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 300 MG (150 MG X 2)-100 MG | 2 | QL (30 per 5 days) |
| PREVYMIS ORAL PELLETS IN PACKET 120 MG, 20 MG | 5 | PA; NDS; QL (120 per 30 days) |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 5 | PA; NDS; QL (28 per 28 days) |
| RELENZA DISKHALER INHALATION BLISTER WITH DEVICE 5 MG/ACTUATION | 4 | QL (60 per 180 days) |
| <i>rimantadine oral tablet 100 mg</i> (Flumadine) | 3 | |
| Hcv Antivirals | | |
| EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG | 5 | PA; NDS; QL (28 per 28 days) |
| EPCLUSA ORAL PELLETS IN PACKET 200-50 MG | 5 | PA; NDS; QL (56 per 28 days) |
| EPCLUSA ORAL TABLET 200-50 MG | 5 | PA; NDS; QL (28 per 28 days) |
| EPCLUSA ORAL TABLET 400-100 (sofosbuvir-velpatasvir) MG | 5 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 33.75-150 MG | 5 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 45-200 MG | 5 | PA; NDS; QL (56 per 28 days) |
| HARVONI ORAL TABLET 45-200 MG | 5 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL TABLET 90-400 (ledipasvir-sofosbuvir) MG | 5 | PA; NDS; QL (28 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| MAVYRET ORAL TABLET 100-40 MG | 5 | PA; NDS; QL (84 per 28 days) |
| VOSEVI ORAL TABLET 400-100-100 MG | 5 | PA; NDS; QL (28 per 28 days) |
| Interferons | | |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5 | PA; NDS |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML | 5 | PA; NDS |
| Nucleosides And Nucleotides | | |
| <i>acyclovir oral capsule 200 mg</i> | 1 | |
| <i>acyclovir oral suspension 200 mg/5 ml</i> (Zovirax) | 4 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 2 | |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 3 | PA BvD |
| <i>adefovir oral tablet 10 mg</i> (Hepsera) | 3 | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> (Baraclude) | 3 | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 2 | |
| <i>lagevrio (eua) oral capsule 200 mg</i> | 4 | QL (40 per 5 days) |
| <i>ribavirin oral capsule 200 mg</i> | 2 | |
| <i>ribavirin oral tablet 200 mg</i> | 2 | |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i> (Valtrex) | 2 | |
| <i>valganciclovir oral recon soln 50 mg/ml</i> (Valcyte) | 5 | NDS |
| <i>valganciclovir oral tablet 450 mg</i> (Valcyte) | 2 | |
| Blood Products/Modifiers/Volume Expanders | | |
| Anticoagulants | | |
| <i>dabigatran etexilate oral capsule 110 mg, 150 mg, 75 mg</i> (Pradaxa) | 3 | QL (60 per 30 days) |
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS) | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| ELIQUIS ORAL TABLET 2.5 MG | 3 | QL (60 per 30 days) |
| ELIQUIS ORAL TABLET 5 MG | 3 | QL (74 per 30 days) |
| ELIQUIS ORAL TABLET FOR SUSPENSION 0.5 MG, 1.5 MG (0.5 MG X 3), 2 MG (0.5 MG X 4) | 3 | QL (960 per 30 days) |
| ELIQUIS SPRINKLE ORAL CAPSULE, SPRINKLE 0.15 MG | 3 | QL (120 per 30 days) |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 150 mg/ml</i> (Lovenox) | 3 | QL (60 per 30 days) |
| <i>enoxaparin subcutaneous syringe 120 mg/0.8 ml, 80 mg/0.8 ml</i> (Lovenox) | 3 | QL (48 per 30 days) |
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml</i> (Lovenox) | 3 | QL (18 per 30 days) |
| <i>enoxaparin subcutaneous syringe 40 mg/0.4 ml</i> (Lovenox) | 3 | QL (24 per 30 days) |
| <i>enoxaparin subcutaneous syringe 60 mg/0.6 ml</i> (Lovenox) | 3 | QL (36 per 30 days) |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml</i> (Arixtra) | 5 | NDS; QL (24 per 30 days) |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i> (Arixtra) | 2 | QL (15 per 30 days) |
| <i>fondaparinux subcutaneous syringe 5 mg/0.4 ml</i> (Arixtra) | 5 | NDS; QL (12 per 30 days) |
| <i>fondaparinux subcutaneous syringe 7.5 mg/0.6 ml</i> (Arixtra) | 5 | NDS; QL (18 per 30 days) |
| <i>heparin (porcine) injection solution 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml</i> | 2 | |
| <i>jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> (warfarin) | 1 | |
| <i>rivaroxaban oral suspension for reconstitution 1 mg/ml</i> (Xarelto) | 2 | QL (600 per 30 days) |
| <i>rivaroxaban oral tablet 2.5 mg</i> (Xarelto) | 2 | |
| <i>warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> (Jantoven) | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)- 20 MG (9) | 3 | |
| XARELTO ORAL SUSPENSION (rivaroxaban) FOR RECONSTITUTION 1 MG/ML | 3 | QL (600 per 30 days) |
| XARELTO ORAL TABLET 10 MG, (rivaroxaban) 20 MG | 3 | QL (30 per 30 days) |
| XARELTO ORAL TABLET 15 MG (rivaroxaban) | 3 | QL (60 per 30 days) |
| XARELTO ORAL TABLET 2.5 MG (rivaroxaban) | 3 | ST; QL (60 per 30 days) |
| Blood Formation Modifiers | | |
| ALVAIZ ORAL TABLET 18 MG, 36 MG, 54 MG, 9 MG | 5 | PA; NDS; QL (60 per 30 days) |
| CINRYZE INTRAVENOUS RECON SOLN 500 UNIT (5 ML) | 5 | PA; NDS |
| DOPTELET (10 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NDS; QL (60 per 30 days) |
| DOPTELET (15 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NDS; QL (60 per 30 days) |
| DOPTELET (30 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NDS; QL (60 per 30 days) |
| DOPTELET SPRINKLE ORAL CAPSULE, SPRINKLE 10 MG | 5 | PA; NDS; QL (60 per 30 days) |
| <i>eltrombopag olamine oral powder in</i> (Promacta) <i>packet 12.5 mg</i> | 5 | PA; NDS; QL (90 per 30 days) |
| <i>eltrombopag olamine oral powder in</i> (Promacta) <i>packet 25 mg</i> | 5 | PA; NDS; QL (180 per 30 days) |
| <i>eltrombopag olamine oral tablet 12.5</i> (Promacta) <i>mg</i> | 5 | PA; NDS; QL (90 per 30 days) |
| <i>eltrombopag olamine oral tablet 25</i> (Promacta) <i>mg</i> | 5 | PA; NDS; QL (30 per 30 days) |
| <i>eltrombopag olamine oral tablet 50</i> (Promacta) <i>mg, 75 mg</i> | 5 | PA; NDS; QL (60 per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT | 5 | PA; NDS; QL (30 per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 3,000 UNIT | 5 | PA; NDS; QL (20 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| LEUKINE INJECTION RECON SOLN 250 MCG | 5 | PA; NDS |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 5 | PA; NDS |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NDS |
| NYVEPRIA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NDS |
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | 3 | PA; QL (12 per 28 days) |
| RETACRIT INJECTION SOLUTION 40,000 UNIT/ML | 3 | PA; QL (4 per 28 days) |
| ROLVEDON SUBCUTANEOUS SYRINGE 13.2 MG/0.6 ML | 5 | PA; NDS |
| UDENYCA ONBODY SUBCUTANEOUS SYRINGE, W/ WEARABLE INJECTOR 6 MG/0.6 ML | 5 | PA; NDS |
| Hematologic Agents, Miscellaneous | | |
| <i>anagrelide oral capsule 0.5 mg</i> (Agrylin) | 3 | |
| <i>anagrelide oral capsule 1 mg</i> | 3 | |
| CABLIVI INJECTION KIT 11 MG | 5 | PA; NDS; QL (30 per 30 days) |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 4 | |
| TAVALISSE ORAL TABLET 100 MG, 150 MG | 5 | PA; NDS; QL (60 per 30 days) |
| <i>tranexamic acid oral tablet 650 mg</i> | 2 | |
| Platelet-Aggregation Inhibitors | | |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | 3 | |
| BRILINTA ORAL TABLET 90 MG (ticagrelor) | 3 | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>clopidogrel oral tablet 75 mg</i> (Plavix) | 1 | |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 2 | PA; AGE (Max 64 Years) |
| <i>pentoxifylline oral tablet extended release 400 mg</i> | 2 | |
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i> (Effient) | 2 | QL (30 per 30 days) |
| <i>ticagrelor oral tablet 60 mg, 90 mg</i> (Brilinta) | 2 | |
| Caloric Agents | | |
| Caloric Agents | | |
| CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX 4.25%/D10W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX 4.25%/D5W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX 5%-D20W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX 6%-D5W (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 6-5 % | 4 | PA BvD |
| CLINIMIX 8%-D10W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 8-10 % | 4 | PA BvD |
| CLINIMIX 8%-D14W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 8-14 % | 4 | PA BvD |
| CLINIMIX E 2.75%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 2.75 % | 4 | PA BvD |
| CLINIMIX E 4.25%/D10W SUL FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| CLINIMIX E 4.25%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX E 5%/D15W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX E 5%/D20W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX E 8%-D10W SULFITEFREE INTRAVENOUS PARENTERAL SOLUTION 8-10 % | 4 | PA BvD |
| CLINIMIX E 8%-D14W SULFITEFREE INTRAVENOUS PARENTERAL SOLUTION 8-14 % | 4 | PA BvD |
| <i>dextrose 5 % in water (d5w) intravenous parenteral solution</i> | 2 | |
| PROSOL 20 % INTRAVENOUS PARENTERAL SOLUTION | 4 | PA BvD |
| TRAVASOL 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| Cardiovascular Agents | | |
| Alpha-Adrenergic Agents | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | |
| <i>clonidine transdermal patch weekly (Catapres-TTS-1) 0.1 mg/24 hr</i> | 2 | |
| <i>clonidine transdermal patch weekly (Catapres-TTS-2) 0.2 mg/24 hr</i> | 2 | |
| <i>clonidine transdermal patch weekly (Catapres-TTS-3) 0.3 mg/24 hr</i> | 2 | |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> (Cardura) | 1 | |
| <i>droxidopa oral capsule 100 mg</i> (Northera) | 2 | PA; QL (180 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>droxidopa oral capsule 200 mg, 300 mg</i> (Northera) | 5 | PA; NDS; QL (180 per 30 days) |
| <i>guanfacine oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>midodrine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | 2 | |
| Angiotensin II Receptor Antagonists | | |
| <i>candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> (Atacand) | 6 | |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> (Atacand HCT) | 6 | |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG (sacubitril-valsartan) | 3 | QL (60 per 30 days) |
| ENTRESTO SPRINKLE ORAL PELLETT 15-16 MG, 6-6 MG | 3 | QL (240 per 30 days) |
| <i>irbesartan oral tablet 150 mg, 300 mg</i> (Avapro) | 6 | |
| <i>irbesartan oral tablet 75 mg</i> | 6 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> (Avalide) | 6 | |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> (Cozaar) | 6 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> (Hyzaar) | 6 | |
| <i>olmesartan oral tablet 20 mg, 40 mg, 5 mg</i> (Benicar) | 6 | |
| <i>olmesartan-amlodipin-hctiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> (Tribenzor) | 6 | |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> (Benicar HCT) | 6 | |
| <i>sacubitril-valsartan oral tablet 24-26 mg, 49-51 mg, 97-103 mg</i> (Entresto) | 2 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>telmisartan oral tablet 20 mg</i> | 6 | |
| <i>telmisartan oral tablet 40 mg, 80 mg</i> (Micardis) | 6 | |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | 4 | |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> (Micardis HCT) | 6 | |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> (Diovan) | 6 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> (Diovan HCT) | 6 | |
| Angiotensin-Converting Enzyme Inhibitors | | |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg</i> (Lotensin) | 6 | |
| <i>benazepril oral tablet 5 mg</i> | 6 | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Lotensin HCT) | 6 | |
| <i>benazepril-hydrochlorothiazide oral tablet 5-6.25 mg</i> | 6 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 6 | |
| <i>enalapril maleate oral solution 1 mg/ml</i> (Epaned) | 3 | ST; QL (1200 per 30 days) |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> (Vasotec) | 6 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg</i> (Vaseretic) | 6 | |
| <i>enalapril-hydrochlorothiazide oral tablet 5-12.5 mg</i> | 6 | |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | |
| <i>fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg</i> | 6 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> (Zestril) | 6 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Zestoretic) | 6 | |
| <i>moexipril oral tablet 15 mg, 7.5 mg</i> | 6 | |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 6 | |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 6 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 6 | |
| <i>ramipril oral capsule 1.25 mg, 2.5 mg, 5 mg</i> (Altace) | 6 | |
| <i>ramipril oral capsule 10 mg</i> | 6 | |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 6 | |
| Antiarrhythmic Agents | | |
| <i>amiodarone oral tablet 100 mg, 200 mg</i> (Pacerone) | 2 | |
| <i>amiodarone oral tablet 400 mg</i> | 2 | |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> (Norpace) | 3 | PA; AGE (Max 64 Years) |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> (Tikosyn) | 3 | |
| <i>flecainide oral tablet 100 mg, 150 mg, 50 mg</i> | 2 | |
| <i>mexiletine oral capsule 150 mg, 200 mg, 250 mg</i> | 2 | |
| MULTAQ ORAL TABLET 400 MG | 3 | |
| <i>pacerone oral tablet 100 mg, 200 mg, 400 mg</i> (amiodarone) | 2 | |
| <i>propafenone oral capsule, extended release 12 hr 225 mg, 325 mg, 425 mg</i> | 3 | |
| <i>propafenone oral tablet 150 mg, 225 mg, 300 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>quinidine gluconate oral tablet extended release 324 mg</i> | 3 | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 3 | |
| Beta-Adrenergic Blocking Agents | | |
| <i>acebutolol oral capsule 200 mg, 400 mg</i> | 2 | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> (Tenormin) | 1 | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg</i> (Tenoretic 100) | 2 | |
| <i>atenolol-chlorthalidone oral tablet 50-25 mg</i> (Tenoretic 50) | 2 | |
| <i>betaxolol oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 2 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> (Coreg) | 1 | |
| JAVADIN ORAL SOLUTION 0.02 MG/ML (20 MCG/ML) | 5 | PA; NDS; QL (3600 per 30 days) |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | 2 | |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> (Toprol XL) | 1 | |
| <i>metoprolol ta-hydrochlorothiaz oral tablet 100-25 mg, 100-50 mg</i> | 2 | |
| <i>metoprolol ta-hydrochlorothiaz oral tablet 50-25 mg</i> | 4 | |
| <i>metoprolol tartrate oral tablet 100 mg, 50 mg</i> (Lopressor) | 1 | |
| <i>metoprolol tartrate oral tablet 25 mg</i> | 1 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>nebivolol oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> (Bystolic) | 2 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>propranolol oral capsule,extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> (Inderal LA) | 2 | |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | 2 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | |
| <i>sorine oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> (sotalol) | 2 | |
| <i>sotalol af oral tablet 120 mg, 160 mg, 80 mg</i> (sotalol) | 2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 80 mg</i> (Sotalol AF) | 2 | |
| <i>sotalol oral tablet 240 mg</i> (Betapace) | 2 | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 4 | |
| Calcium-Channel Blocking Agents | | |
| <i>cartia xt oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> (diltiazem hcl) | 2 | |
| <i>diltiazem 24hr er 360 mg cap once-a-day dosage</i> (Tiadylt ER) | 2 | |
| <i>diltiazem 24hr er 420 mg cap</i> (Tiadylt ER) | 2 | |
| <i>diltiazem hcl oral capsule,extended release 12 hr 120 mg, 60 mg, 90 mg</i> | 4 | |
| <i>diltiazem hcl oral capsule,extended release 24 hr 180 mg, 360 mg, 420 mg</i> (Tiadylt ER) | 2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> (Cartia XT) | 2 | |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg</i> (Cardizem) | 2 | |
| <i>diltiazem hcl oral tablet 90 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| <i>diltiazem hcl oral tablet extended release 24 hr 120 mg</i> (Cardizem LA) | 4 | |
| <i>diltiazem hcl oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> (Matzim LA) | 4 | |
| <i>dilt-xr oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> (diltiazem hcl) | 2 | |
| <i>matzim la oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> (diltiazem hcl) | 4 | |
| <i>taztia xt oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</i> (diltiazem hcl) | 2 | |
| <i>tiadylt er oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> (diltiazem hcl) | 2 | |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | 4 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg</i> | 2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 360 mg</i> | 4 | |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg, 240 mg</i> | 2 | |
| Cardiovascular Agents, Miscellaneous | | |
| CAMZYOS ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 5 MG | 5 | PA; NDS; QL (30 per 30 days) |
| CORLANOR ORAL SOLUTION 5 MG/5 ML | 4 | QL (600 per 30 days) |
| DAWNZERA SUBCUTANEOUS AUTO-INJECTOR 80 MG/0.8 ML | 5 | PA; NDS; QL (0.8 per 28 days) |
| <i>digoxin injection syringe 250 mcg/ml (0.25 mg/ml)</i> | 3 | |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> (Digitek) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>epinephrine injection auto-injector 0.15 mg/0.15 ml</i> (Auvi-Q) | 3 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml</i> (EpiPen Jr) | 2 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.3 mg/0.3 ml</i> | 3 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.3 mg/0.3 ml</i> (Auvi-Q) | 2 | QL (4 per 30 days) |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>icatibant subcutaneous syringe 30 mg/3 ml</i> (Sajazir) | 5 | PA; NDS; QL (18 per 30 days) |
| <i>ivabradine oral tablet 5 mg, 7.5 mg</i> (Corlanor) | 3 | QL (60 per 30 days) |
| <i>metyrosine oral capsule 250 mg</i> (Demser) | 5 | PA; NDS |
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg</i> | 2 | QL (60 per 30 days) |
| <i>ranolazine oral tablet extended release 12 hr 500 mg</i> | 2 | QL (120 per 30 days) |
| <i>sajazir subcutaneous syringe 30 mg/3 ml</i> (icatibant) | 5 | PA; NDS; QL (18 per 30 days) |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG | 4 | PA; QL (30 per 30 days) |
| Dihydropyridines | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> (Norvasc) | 1 | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 5-10 mg, 5-20 mg</i> (Lotrel) | 6 | |
| <i>amlodipine-benazepril oral capsule 2.5-10 mg, 5-40 mg</i> | 6 | |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> (Azor) | 6 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> (Exforge) | 6 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>amlodipine-valsartan-hcthiazyd oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-25 mg</i> (Exforge HCT) | 3 | |
| <i>amlodipine-valsartan-hcthiazyd oral tablet 5-160-12.5 mg</i> (Exforge HCT) | 4 | |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i> | 4 | |
| KATERZIA ORAL SUSPENSION 1 MG/ML | 4 | ST; QL (300 per 30 days) |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | 4 | |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | 2 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg, 60 mg</i> (Procardia XL) | 2 | |
| <i>nifedipine oral tablet extended release 24hr 90 mg</i> | 2 | |
| <i>nifedipine oral tablet extended release 30 mg, 60 mg, 90 mg</i> | 2 | |
| Diuretics | | |
| <i>amiloride oral tablet 5 mg</i> | 1 | |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 2 | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 2 | |
| <i>furosemide injection solution 10 mg/ml</i> | 1 | |
| <i>furosemide injection syringe 10 mg/ml</i> | 1 | |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | 2 | |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> (Lasix) | 1 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | |
| JYNARQUE ORAL TABLET 15 MG, 30 MG (tolvaptan (polycys kidney dis)) | 5 | PA; NDS; QL (120 per 30 days) |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> (Aldactone) | 1 | |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | 2 | |
| <i>tolvaptan (polycys kidney dis) oral tablets, sequential 15 mg (am)/ 15 mg (pm), 30 mg (am)/ 15 mg (pm), 45 mg (am)/ 15 mg (pm), 60 mg (am)/ 30 mg (pm), 90 mg (am)/ 30 mg (pm)</i> (Jynarque) | 5 | PA; NDS; QL (56 per 28 days) |
| <i>toremide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 1 | |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | 1 | |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | |
| Dyslipidemics | | |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 5-10 mg</i> (Caduet) | 6 | |
| <i>amlodipine-atorvastatin oral tablet 10-20 mg, 10-40 mg, 10-80 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> (Caduet) | 6 | QL (30 per 30 days) |
| <i>amlodipine-atorvastatin oral tablet 2.5-10 mg, 2.5-20 mg, 2.5-40 mg</i> | 6 | |
| <i>atorvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> (Lipitor) | 6 | |
| <i>cholestyramine (with sugar) oral powder in packet 4 gram</i> (Questran) | 2 | |
| <i>cholestyramine light oral powder in packet 4 gram</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>colesevelam oral powder in packet 3.75 gram</i> (WelChol) | 4 | |
| <i>colesevelam oral tablet 625 mg</i> (WelChol) | 3 | |
| <i>colestipol oral packet 5 gram</i> | 2 | |
| <i>colestipol oral tablet 1 gram</i> (Colestid) | 2 | |
| EZALLOR SPRINKLE ORAL CAPSULE, SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG | 4 | ST |
| <i>ezetimibe oral tablet 10 mg</i> (Zetia) | 2 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg</i> (Vytorin 10-10) | 6 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-20 mg</i> (Vytorin 10-20) | 6 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-40 mg</i> (Vytorin 10-40) | 6 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-80 mg</i> (Vytorin 10-80) | 6 | QL (30 per 30 days) |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg</i> | 2 | |
| <i>fenofibrate nanocrystallized oral tablet 145 mg</i> (Tricor) | 2 | |
| <i>fenofibrate nanocrystallized oral tablet 48 mg</i> | 2 | |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | 2 | |
| <i>fenofibric acid (choline) oral capsule, delayed release(dr/ec) 135 mg, 45 mg</i> | 2 | |
| <i>fluvastatin oral capsule 20 mg, 40 mg</i> | 6 | QL (60 per 30 days) |
| <i>fluvastatin oral tablet extended release 24 hr 80 mg</i> (Lescol XL) | 6 | |
| <i>gemfibrozil oral tablet 600 mg</i> (Lopid) | 1 | |
| <i>icosapent ethyl oral capsule 0.5 gram</i> (Vascepa) | 3 | QL (240 per 30 days) |
| <i>icosapent ethyl oral capsule 1 gram</i> (Vascepa) | 3 | QL (120 per 30 days) |
| JUXTAPID ORAL CAPSULE 10 MG, 5 MG | 5 | PA; NDS; QL (28 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| JUXTAPID ORAL CAPSULE 20 MG, 30 MG | 5 | PA; NDS; QL (56 per 28 days) |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | |
| NEXLETOL ORAL TABLET 180 MG | 3 | ST; QL (30 per 30 days) |
| NEXLIZET ORAL TABLET 180-10 MG | 3 | ST; QL (30 per 30 days) |
| <i>niacin oral tablet 500 mg</i> (Niacor) | 4 | |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 500 mg</i> | 2 | |
| <i>niacin oral tablet extended release 24 hr 750 mg</i> | 4 | |
| <i>niacor oral tablet 500 mg</i> (niacin) | 4 | |
| <i>omega-3 acid ethyl esters oral capsule 1 gram</i> (Lovaza) | 2 | ST; QL (120 per 30 days) |
| <i>pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg</i> (Livalo) | 3 | QL (30 per 30 days) |
| <i>pravastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 6 | |
| <i>prevalite oral powder in packet 4 gram</i> | 2 | |
| REPATHA PUSHTRONEX SUBCUTANEOUS WEARABLE INJECTOR 420 MG/3.5 ML | 3 | ST; QL (7 per 28 days) |
| REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/ML | 3 | ST; QL (6 per 28 days) |
| REPATHA SYRINGE SUBCUTANEOUS SYRINGE 140 MG/ML | 3 | ST; QL (6 per 28 days) |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> (Crestor) | 6 | |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg</i> (Zocor) | 6 | |
| <i>simvastatin oral tablet 5 mg, 80 mg</i> | 6 | |
| Renin-Angiotensin-Aldosterone System Inhibitors | | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>aliskiren oral tablet 150 mg, 300 mg</i> (Tekturna) | 3 | |
| <i>eplerenone oral tablet 25 mg</i> (Inspra) | 2 | |
| <i>eplerenone oral tablet 50 mg</i> | 2 | |
| KERENDIA ORAL TABLET 10 MG, 20 MG, 40 MG | 3 | PA; QL (30 per 30 days) |
| <i>spironolactone oral suspension 25 mg/5 ml</i> (CaroSpir) | 2 | ST; QL (600 per 30 days) |
| Vasodilators | | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg</i> | 2 | |
| <i>isosorbide dinitrate oral tablet 5 mg</i> (Isordil Titradose) | 2 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i> | 1 | |
| <i>isosorbide-hydralazine oral tablet 20-37.5 mg</i> (BiDil) | 4 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 2 | |
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i> (Nitrostat) | 2 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> (Nitro-Dur) | 2 | |
| Central Nervous System Agents | | |
| Central Nervous System Agents | | |
| <i>atomoxetine oral capsule 10 mg</i> | 3 | QL (60 per 30 days) |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> | 2 | QL (30 per 30 days) |
| <i>atomoxetine oral capsule 18 mg, 25 mg, 40 mg</i> | 2 | QL (60 per 30 days) |
| AUSTEDO ORAL TABLET 12 MG, 9 MG | 5 | PA; NDS; QL (120 per 30 days) |
| AUSTEDO ORAL TABLET 6 MG | 5 | PA; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG | 5 | PA; NDS; QL (90 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 18 MG, 24 MG | 5 | PA; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 30 MG, 36 MG, 42 MG, 48 MG | 5 | PA; NDS; QL (30 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG | 5 | PA; NDS; QL (210 per 30 days) |
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24- 30 MG, 6 MG (14)-12 MG (14)-24 MG (14) | 5 | PA; NDS |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT 30 MCG/0.5 ML | 5 | PA; NDS; QL (1 per 28 days) |
| AVONEX INTRAMUSCULAR SYRINGE KIT 30 MCG/0.5 ML | 5 | PA; NDS; QL (1 per 28 days) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 5 | PA; NDS; QL (15 per 30 days) |
| <i>clonidine hcl oral tablet extended release 12 hr 0.1 mg</i> | 4 | |
| <i>dalfampridine oral tablet extended release 12 hr 10 mg</i> (Ampyra) | 2 | PA; QL (60 per 30 days) |
| <i>dexmethylphenidate oral tablet 10 mg, 2.5 mg, 5 mg</i> (Focalin) | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine sulfate oral capsule, extended release 10 mg, 15 mg</i> (Dexedrine Spansule) | 4 | QL (120 per 30 days) |
| <i>dextroamphetamine sulfate oral capsule, extended release 5 mg</i> | 4 | QL (120 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i> (Zenedi) | 2 | QL (180 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 15 mg, 2.5 mg, 5 mg, 7.5 mg</i> (Zenedi) | 2 | QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>dextroamphetamine sulfate oral tablet 20 mg</i> (Zenzedi) | 2 | QL (90 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 30 mg</i> (Zenzedi) | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 10 mg, 15 mg, 5 mg</i> (Adderall XR) | 2 | QL (30 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 20 mg, 25 mg, 30 mg</i> (Adderall XR) | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> (Adderall) | 2 | QL (60 per 30 days) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg</i> (Tecfidera) | 3 | PA; QL (14 per 7 days) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i> (Tecfidera) | 3 | PA |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 240 mg</i> (Tecfidera) | 5 | PA; NDS; QL (60 per 30 days) |
| ENSPRYNG SUBCUTANEOUS SYRINGE 120 MG/ML | 5 | PA; NDS |
| <i>fingolimod oral capsule 0.5 mg</i> (Gilenya) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> (Glatopa) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> (Glatopa) | 5 | PA; NDS; QL (12 per 28 days) |
| <i>glatopa subcutaneous syringe 20 mg/ml</i> (glatiramer) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>glatopa subcutaneous syringe 40 mg/ml</i> (glatiramer) | 5 | PA; NDS; QL (12 per 28 days) |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg</i> (Intuniv ER) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| INGREZZA INITIATION PK(TARDIV) ORAL CAPSULE,DOSE PACK 40 MG (7)- 80 MG (21) | 5 | PA; NDS |
| INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG | 5 | PA; NDS; QL (30 per 30 days) |
| INGREZZA SPRINKLE ORAL CAPSULE, SPRINKLE 40 MG, 60 MG, 80 MG | 5 | PA; NDS; QL (30 per 30 days) |
| KESIMPTA PEN SUBCUTANEOUS PEN INJECTOR 20 MG/0.4 ML | 5 | PA; NDS; QL (1.2 per 28 days) |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | |
| <i>lithium carbonate oral tablet extended release 300 mg</i> (Lithobid) | 2 | |
| <i>lithium carbonate oral tablet extended release 450 mg</i> | 2 | |
| <i>lithium citrate oral solution 8 meq/5 ml</i> | 2 | |
| MAVENCLAD (10 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NDS |
| MAVENCLAD (4 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NDS |
| MAVENCLAD (5 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NDS |
| MAVENCLAD (6 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NDS |
| MAVENCLAD (7 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NDS |
| MAVENCLAD (8 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NDS |
| MAVENCLAD (9 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NDS |
| MAYZENT ORAL TABLET 0.25 MG | 5 | PA; NDS; QL (112 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| MAYZENT ORAL TABLET 1 MG, 2 MG | 5 | PA; NDS; QL (30 per 30 days) |
| MAYZENT STARTER(FOR 1MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (7 TABS) | 3 | PA |
| MAYZENT STARTER(FOR 2MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (12 TABS) | 5 | PA; NDS |
| <i>metadate er oral tablet extended release 20 mg</i> (methylphenidate hcl) | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 10 mg, 20 mg, 40 mg, 50 mg, 60 mg</i> (Metadate CD) | 3 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 30 mg</i> (Metadate CD) | 3 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 10 mg, 40 mg, 60 mg</i> | 3 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 20 mg</i> (Ritalin LA) | 3 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 30 mg</i> | 3 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral solution 10 mg/5 ml, 5 mg/5 ml</i> (Methylin) | 3 | QL (900 per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> (Ritalin) | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 10 mg, 20 mg</i> | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg (bx rating), 27 mg (bx rating), 54 mg (bx rating)</i> | 3 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 27 mg, 54 mg</i> (Concerta) | 3 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 36 mg</i> (Concerta) | 3 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 36 mg (bx rating)</i> | 3 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>methylphenidate hcl oral tablet extended release 24hr 72 mg</i> (Relexxii) | 4 | QL (30 per 30 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML | 5 | PA; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 63 MCG/0.5 ML- 94 MCG/0.5 ML | 5 | PA; NDS |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML | 5 | PA; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 63 MCG/0.5 ML- 94 MCG/0.5 ML | 5 | PA; NDS |
| <i>riluzole oral tablet 50 mg</i> | 3 | |
| <i>teriflunomide oral tablet 14 mg, 7 mg</i> (Aubagio) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>tetrabenazine oral tablet 12.5 mg</i> (Xenazine) | 3 | PA; QL (112 per 28 days) |
| <i>tetrabenazine oral tablet 25 mg</i> (Xenazine) | 5 | PA; NDS; QL (112 per 28 days) |
| VUMERITY ORAL CAPSULE,DELAYED RELEASE(DR/EC) 231 MG | 5 | PA; NDS; QL (120 per 30 days) |
| Contraceptives | | |
| Contraceptives | | |
| <i>afirmelle oral tablet 0.1-20 mg-mcg</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>altavera (28) oral tablet 0.15-0.03 mg</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>alyacen 1/35 (28) oral tablet 1-35 mg-mcg</i> (norethindrone-ethin estradiol) | 2 | |
| <i>alyacen 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | |
| <i>amethia oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> (1 norgest/e.estradiol-e.estrad) | 2 | QL (91 per 84 days) |
| <i>amethyst (28) oral tablet 90-20 mcg (28)</i> (levonorgestrel-ethinyl estrad) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------------------|------------------|----------------------------|
| <i>apri oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>aranelle (28) oral tablet 0.5/1/0.5-35 mg-mcg</i> | | 2 | |
| <i>ashlyna oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (l norgest/e.estradiol-e.estrad) | 2 | QL (91 per 84 days) |
| <i>aubra eq oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>aurovela 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>aurovela 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>aurovela 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>aurovela fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>aurovela fe 1-20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>aviane oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>ayuna oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>azurette (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>balziva (28) oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>blisovi 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>blisovi fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>camila oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>chateal eq (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-------------------------------------|------------------|----------------------------|
| <i>cryselle (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>cyred eq oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>dasetta 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>dasetta 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>daysee oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (1 norgest/e.estradiol-e.estradiol) | 2 | QL (91 per 84 days) |
| <i>deblitane oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>desog-e.estradiol/e.estradiol oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (Azurette (28)) | 2 | |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.03 mg</i> | (Apri) | 2 | |
| <i>dolishale oral tablet 90-20 mcg (28)</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg</i> | (Jasmiel (28)) | 2 | |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.03 mg</i> | (Syeda) | 2 | |
| <i>elinest oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>eluryng vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>emzahh oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>enilloring vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 4 | QL (1 per 28 days) |
| <i>enpresse oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>enskyce oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>errin oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------------------|------------------|----------------------------|
| <i>estarylla oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg</i> | (Kelnor 1/35 (28)) | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-50 mg-mcg</i> | (Valtya) | 2 | |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr</i> | (EluRyng) | 2 | QL (1 per 28 days) |
| <i>falmina (28) oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>feirza oral tablet 1 mg-20 mcg (21)/75 mg (7), 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>femynor oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 1 | |
| <i>gemmily oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 3 | |
| <i>hailey 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>hailey fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>hailey fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>haloette vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>heather oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>iclevia oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>incassia oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>introvale oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>isibloom oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>jaimiess oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (1 norgest/e.estradiol-e.estrad) | 2 | QL (91 per 84 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|----------------------------------|------------------|----------------------------|
| <i>jasmiel (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>jencycla oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | |
| <i>jolessa oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 4 | QL (91 per 84 days) |
| <i>juleber oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>junel 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>junel 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>junel fe 24 oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>kelnor 1/35 (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>kelnor 1/50 (28) oral tablet 1-50 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>kurvelo (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| KYLEENA INTRAUTERINE INTRAUTERINE DEVICE 17.5 MCG/24 HR (5 YRS) 19.5 MG | | 4 | |
| <i>l norgest/e.estradiol-e.estrad oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)</i> | (Camrese Lo) | 2 | QL (91 per 84 days) |
| <i>l norgest/e.estradiol-e.estrad oral tablets,dose pack,3 month 0.15 mg-20 mcg/ 0.15 mg-25 mcg</i> | (Rosyrah) | 2 | QL (91 per 84 days) |
| <i>l norgest/e.estradiol-e.estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (Amethia) | 2 | QL (91 per 84 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|----------------------------------|------------------|----------------------------|
| <i>larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>larin 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>larin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>lessina oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>levonorgest-eth.estradiol-iron oral tablet 0.1 mg-0.02 mg (21)/iron (7)</i> | (Balcoltra) | 4 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg</i> | (Afirmelle) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.15-0.03 mg</i> | (Altavera (28)) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 90-20 mcg (28)</i> | (Amethyst (28)) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (Iclevia) | 2 | QL (91 per 84 days) |
| <i>levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (Enpresse) | 2 | |
| <i>levora-28 oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| LILETTA INTRAUTERINE INTRAUTERINE DEVICE 20.4 MCG/24 HR (8 YRS) 52 MG | | 3 | |
| <i>loryna (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>low-ogestrel (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>lo-zumandimine (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|----------------------------------|------------------|----------------------------|
| <i>luizza oral tablet 1-20 mg-mcg, 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>lutera (28) oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>lyleq oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>lyza oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>marlissa (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>meleya oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>merzee oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 3 | |
| <i>microgestin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>microgestin 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>microgestin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>microgestin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>microgestin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>mili oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| MIRENA INTRAUTERINE INTRAUTERINE DEVICE 21 MCG/24HR (UP TO 8 YRS) 52 MG | | 4 | |
| <i>mono-linyah oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 1 | |
| NEXPLANON SUBDERMAL IMPLANT 68 MG | | 3 | |
| <i>nikki (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>norelgestromin-ethin.estradiol transdermal patch weekly 150-35 mcg/24 hr</i> | (Xulane) | 2 | QL (3 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>norethindrone (contraceptive) oral tablet 0.35 mg</i> (Jencycla) | 2 | |
| <i>norethindrone ac-eth estradiol oral tablet 1.5-30 mg-mcg</i> (Aurovela 1.5/30 (21)) | 2 | |
| <i>norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg</i> (Aurovela 1/20 (21)) | 2 | |
| <i>norethindrone-e.estradiol-iron oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> (Gemmyly) | 3 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> (Aurovela Fe 1-20 (28)) | 2 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> (Aurovela Fe 1.5/30 (28)) | 2 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> (Tilia Fe) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> (Tri-Lo-Estarylla) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> (Tri-Estarylla) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.25-0.035 mg</i> (Mono-Linyah) | 2 | |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg (21)</i> | 2 | |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i> (norethindrone-ethin estradiol) | 2 | |
| <i>nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | |
| <i>nylia 1/35 (28) oral tablet 1-35 mg-mcg</i> (norethindrone-ethin estradiol) | 2 | |
| <i>nylia 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | |
| <i>nymyo oral tablet 0.25-35 mg-mcg</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>orquidea oral tablet 0.35 mg</i> (norethindrone (contraceptive)) | 2 | |
| <i>philith oral tablet 0.4-35 mg-mcg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|----------------------------------|------------------|----------------------------|
| <i>pimtreea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>portia 28 oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>reclipsen (28) oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>rosyrah oral tablets,dose pack,3 month 0.15 mg-20 mcg/ 0.15 mg-25 mcg</i> | (1 norgest/e.estradiol-e.estrad) | 2 | |
| <i>setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>sharobel oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>simliya (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>simpesse oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (1 norgest/e.estradiol-e.estrad) | 2 | QL (91 per 84 days) |
| SKYLA INTRAUTERINE INTRAUTERINE DEVICE 14 MCG/24 HR (3 YRS) 13.5 MG | | 4 | |
| <i>sprintec (28) oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>sronyx oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>syeda oral tablet 3-0.03 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>tarina 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>tarina fe 1-20 eq (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>taysofy oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 3 | |
| <i>tilia fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>tri-estarylla oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------------------|------------------|----------------------------|
| <i>tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>tri-linyah oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-marzia oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-mili oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-mili oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-nymyo oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>trivora (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-vylibra oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>turqoz (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>valtya oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>velivet triphasic regimen (28) oral tablet 0.1/.125/.15-25 mg-mcg</i> | | 2 | |
| <i>vestura (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>vienva oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>viorele (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>volnea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------------------|-----------|---------------------|
| <i>vyfemla (28) oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>vylibra oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>xarah fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>xulane transdermal patch weekly 150-35 mcg/24 hr</i> | (norelgestromin-ethin.estradiol) | 2 | QL (3 per 28 days) |
| <i>zafemy transdermal patch weekly 150-35 mcg/24 hr</i> | (norelgestromin-ethin.estradiol) | 2 | QL (3 per 28 days) |
| <i>zovia 1/35e (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>zovia 1-35 (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>zumandimine (28) oral tablet 3-0.03 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |

Dental And Oral Agents

Dental And Oral Agents

| | | | |
|---|-----------------------------|---|--|
| <i>cevimeline oral capsule 30 mg</i> | (Evoxac) | 4 | |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 %</i> | (Periogard) | 1 | |
| <i>denta 5000 plus dental cream 1.1 %</i> | (fluoride (sodium)) | 1 | |
| <i>dentagel dental gel 1.1 %</i> | (fluoride (sodium)) | 1 | |
| <i>fluoride (sodium) dental gel 1.1 %</i> | (DentaGel) | 1 | |
| <i>fluoride (sodium) dental solution 0.2 %</i> | (PreviDent) | 1 | |
| <i>periogard mucous membrane mouthwash 0.12 %</i> | (chlorhexidine gluconate) | 1 | |
| <i>pilocarpine hcl oral tablet 5 mg</i> | (Salagen (pilocarpine)) | 2 | |
| <i>pilocarpine hcl oral tablet 7.5 mg</i> | (Salagen (pilocarpine)) | 4 | |
| <i>sf 5000 plus dental cream 1.1 %</i> | (fluoride (sodium)) | 1 | |
| <i>sodium fluoride-pot nitrate dental paste 1.1-5 %</i> | (Denta 5000 Plus Sensitive) | 1 | |
| <i>triamcinolone acetonide dental paste 0.1 %</i> | (Kourzeq) | 2 | |

Dermatological Agents

Dermatological Agents, Other

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>accutane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> (isotretinoin) | 3 | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | 2 | |
| <i>acyclovir topical cream 5 %</i> (Zovirax) | 4 | QL (5 per 4 days) |
| <i>acyclovir topical ointment 5 %</i> (Zovirax) | 4 | QL (30 per 30 days) |
| <i>ammonium lactate topical cream 12 %</i> | 2 | |
| <i>ammonium lactate topical lotion 12 %</i> (AmLactin) | 2 | |
| <i>calcipotriene scalp solution 0.005 %</i> | 2 | QL (120 per 30 days) |
| <i>calcipotriene topical cream 0.005 %</i> | 3 | QL (120 per 30 days) |
| <i>calcipotriene topical ointment 0.005 %</i> | 3 | QL (120 per 30 days) |
| <i>fluorouracil topical cream 0.5 %</i> (Carac) | 5 | NDS |
| <i>fluorouracil topical cream 5 %</i> (Efudex) | 2 | |
| <i>fluorouracil topical solution 2 %</i> | 2 | |
| <i>fluorouracil topical solution 5 %</i> | 4 | |
| <i>imiquimod topical cream in packet 5 %</i> | 2 | QL (24 per 30 days) |
| KLISYRI (250 MG) TOPICAL OINTMENT IN PACKET 1 % | 5 | ST; NDS; QL (5 per 5 days) |
| <i>methoxsalen oral capsule, liqd-filled, rapid rel 10 mg</i> | 5 | NDS |
| PANRETIN TOPICAL GEL 0.1 % | 5 | NDS; QL (60 per 28 days) |
| <i>penciclovir topical cream 1 %</i> (Denavir) | 4 | |
| <i>podofilox topical solution 0.5 %</i> | 2 | |
| REGRANEX TOPICAL GEL 0.01 % | 5 | PA; NDS; QL (30 per 30 days) |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM | 4 | QL (180 per 30 days) |
| VALCHLOR TOPICAL GEL 0.016 % | 5 | PA NSO; NDS |
| <i>zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> (isotretinoin) | 3 | |
| Dermatological Antibacterials | | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>clindamycin phosphate topical foam 1 %</i> (Clindacin) | 4 | QL (100 per 30 days) |
| <i>clindamycin phosphate topical solution 1 %</i> | 2 | QL (180 per 30 days) |
| <i>clindamycin phosphate topical swab 1 %</i> (Clindacin ETZ) | 2 | |
| <i>clindamycin-benzoyl peroxide topical gel 1.2 %(1 % base) -5 %</i> (Neuac) | 2 | |
| <i>clindamycin-benzoyl peroxide topical gel 1-5 %</i> | 4 | |
| <i>ery pads topical swab 2 %</i> (erythromycin with ethanol) | 2 | |
| <i>erythromycin with ethanol topical gel 2 %</i> | 4 | |
| <i>erythromycin with ethanol topical solution 2 %</i> | 2 | |
| <i>erythromycin-benzoyl peroxide topical gel 3-5 %</i> (Benzamycin) | 4 | |
| <i>gentamicin topical cream 0.1 %</i> | 2 | QL (90 per 30 days) |
| <i>gentamicin topical ointment 0.1 %</i> | 2 | QL (120 per 30 days) |
| <i>metronidazole topical cream 0.75 %</i> (Rosadan) | 2 | |
| <i>metronidazole topical gel 0.75 %</i> (Rosadan) | 2 | |
| <i>metronidazole topical gel 1 %</i> (Metrogel) | 4 | |
| <i>metronidazole topical lotion 0.75 %</i> (MetroLotion) | 4 | |
| <i>mupirocin topical ointment 2 %</i> (Centany) | 1 | QL (220 per 30 days) |
| <i>rosadan topical cream 0.75 %</i> (metronidazole) | 2 | |
| <i>selenium sulfide topical lotion 2.5 %</i> | 2 | |
| <i>silver sulfadiazine topical cream 1 %</i> (SSD) | 2 | |
| <i>ssd topical cream 1 %</i> (silver sulfadiazine) | 4 | |
| <i>sulfacetamide sodium (acne) topical suspension 10 %</i> (Klaron) | 2 | |
| Dermatological Anti-Inflammatory Agents | | |
| <i>ala-cort topical cream 1 %</i> (hydrocortisone) | 2 | |
| <i>ala-scalp topical lotion 2 %</i> (hydrocortisone) | 4 | |
| <i>alclometasone topical cream 0.05 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>alclometasone topical ointment 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical cream 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical lotion 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | 2 | |
| <i>betamethasone valerate topical cream 0.1 %</i> | 2 | |
| <i>betamethasone valerate topical foam (Luxiq) 0.12 %</i> | 4 | |
| <i>betamethasone valerate topical lotion 0.1 %</i> | 2 | |
| <i>betamethasone valerate topical ointment 0.1 %</i> | 2 | |
| <i>betamethasone, augmented topical cream 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical gel 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical lotion 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical ointment 0.05 % (Diprolene (augmented))</i> | 2 | |
| <i>clobetasol scalp solution 0.05 %</i> | 2 | |
| <i>clobetasol topical cream 0.05 %</i> | 2 | |
| <i>clobetasol topical foam 0.05 % (Olux)</i> | 4 | |
| <i>clobetasol topical gel 0.05 %</i> | 4 | |
| <i>clobetasol topical lotion 0.05 % (Clobex)</i> | 4 | |
| <i>clobetasol topical ointment 0.05 %</i> | 2 | |
| <i>clobetasol topical shampoo 0.05 % (Clobex)</i> | 2 | |
| <i>clobetasol-emollient topical cream 0.05 %</i> | 2 | |
| <i>clobetasol-emollient topical foam 0.05 % (Olux-E)</i> | 4 | |
| <i>desonide topical cream 0.05 %</i> | 2 | |
| <i>desonide topical lotion 0.05 %</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>desonide topical ointment 0.05 %</i> | 2 | |
| <i>desoximetasone topical cream 0.05 %</i> (Topicort) | 4 | QL (120 per 30 days) |
| <i>desoximetasone topical cream 0.25 %</i> (Topicort) | 2 | QL (120 per 30 days) |
| <i>desoximetasone topical gel 0.05 %</i> (Topicort) | 4 | QL (120 per 30 days) |
| <i>desoximetasone topical ointment 0.05 %, 0.25 %</i> (Topicort) | 4 | |
| <i>diflorasone topical ointment 0.05 %</i> | 4 | QL (180 per 30 days) |
| EUCRISA TOPICAL OINTMENT 2 % | 3 | |
| <i>fluocinolone topical cream 0.01 %</i> | 2 | |
| <i>fluocinolone topical cream 0.025 %</i> (Synalar) | 2 | |
| <i>fluocinolone topical ointment 0.025 %</i> (Synalar) | 2 | |
| <i>fluocinonide topical cream 0.05 %</i> | 2 | |
| <i>fluocinonide topical gel 0.05 %</i> | 2 | |
| <i>fluocinonide topical ointment 0.05 %</i> | 2 | |
| <i>fluocinonide topical solution 0.05 %</i> | 2 | |
| <i>fluocinonide-emollient topical cream 0.05 %</i> (Fluocinonide-E) | 2 | |
| <i>fluticasone propionate topical cream 0.05 %</i> | 2 | |
| <i>fluticasone propionate topical ointment 0.005 %</i> | 2 | |
| <i>halobetasol propionate topical cream 0.05 %</i> | 2 | |
| <i>halobetasol propionate topical ointment 0.05 %</i> | 2 | |
| <i>hydrocortisone 2.5% cream</i> | 2 | |
| <i>hydrocortisone butyrate topical cream 0.1 %</i> | 4 | QL (120 per 30 days) |
| <i>hydrocortisone butyrate topical lotion 0.1 %</i> | 4 | QL (236 per 30 days) |
| <i>hydrocortisone butyrate topical ointment 0.1 %</i> | 4 | QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>hydrocortisone butyrate topical solution 0.1 %</i> | 4 | QL (120 per 30 days) |
| <i>hydrocortisone topical cream 1 %</i> (Ala-Cort) | 2 | |
| <i>hydrocortisone topical cream with perineal applicator 2.5 %</i> (Procto-Med HC) | 2 | |
| <i>hydrocortisone topical lotion 2.5 %</i> | 2 | |
| <i>hydrocortisone topical ointment 1 %</i> (Anti-Itch (HC)) | 1 | |
| <i>hydrocortisone topical ointment 2.5 %</i> | 1 | |
| <i>hydrocortisone valerate topical cream 0.2 %</i> | 2 | |
| <i>hydrocortisone valerate topical ointment 0.2 %</i> | 4 | |
| <i>mometasone topical cream 0.1 %</i> | 2 | |
| <i>mometasone topical ointment 0.1 %</i> | 2 | |
| <i>mometasone topical solution 0.1 %</i> | 2 | |
| <i>pimecrolimus topical cream 1 %</i> (Elidel) | 4 | QL (100 per 30 days) |
| <i>procto-med hc topical cream with perineal applicator 2.5 %</i> (hydrocortisone) | 2 | |
| <i>proctosol hc topical cream with perineal applicator 2.5 %</i> (hydrocortisone) | 2 | |
| <i>proctozone-hc topical cream with perineal applicator 2.5 %</i> (hydrocortisone) | 2 | |
| <i>tacrolimus topical ointment 0.03 %, 0.1 %</i> | 3 | QL (100 per 30 days) |
| <i>triamcinolone acetonide topical cream 0.025 %, 0.1 %</i> | 1 | |
| <i>triamcinolone acetonide topical cream 0.5 %</i> (Triderm) | 1 | |
| <i>triamcinolone acetonide topical lotion 0.025 %, 0.1 %</i> | 2 | |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | 2 | |
| Dermatological Retinoids | | |
| <i>adapalene topical cream 0.1 %</i> (Differin) | 4 | |
| ALTRENO TOPICAL LOTION 0.05 % | 4 | PA |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>tazarotene topical cream 0.05 %</i> (Tazorac) | 3 | |
| <i>tazarotene topical cream 0.1 %</i> (Tazorac) | 2 | |
| <i>tretinoin topical cream 0.025 %</i> (Avita) | 2 | PA |
| <i>tretinoin topical cream 0.05 %, 0.1 %</i> (Retin-A) | 2 | PA |
| <i>tretinoin topical gel 0.01 %</i> (Retin-A) | 2 | PA |
| <i>tretinoin topical gel 0.025 %</i> (Avita) | 2 | PA |
| <i>tretinoin topical gel 0.05 %</i> (Atralin) | 4 | PA |
| Scabicides And Pediculicides | | |
| <i>malathion topical lotion 0.5 %</i> (Ovide) | 4 | |
| <i>permethrin topical cream 5 %</i> (Elimite) | 2 | QL (60 per 30 days) |
| Devices | | |
| Devices | | |
| 1ST TIER UNIFINE PENTP 5MM 31G 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 6MM 31G 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 8MM 31G STRL,SINGLE-USE,SHRT 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 29GX1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 31GX3/16 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 32GX5/32 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| ABOUTTIME PEN NEEDLE NEEDLE 30 GAUGE X 5/16", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| ADVOCATE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS SYR 0.3 ML 29GX1/2 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS SYR 0.5 ML 29GX1/2 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS SYR 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE PEN NDL 12.7MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE PEN NEEDLES 5MM 31G 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| ALCOHOL PADS TOPICAL PADS, MEDICATED | (alcohol swabs) | 1 | PA; ST |
| ALCOHOL PREP SWABS TOPICAL PADS, MEDICATED | (alcohol swabs) | 1 | PA; ST |
| ALCOHOL WIPES TOPICAL PADS, MEDICATED | (alcohol swabs) | 1 | PA; ST |
| AQINJECT PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| AQINJECT PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ASSURE ID DUO PRO NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| ASSURE ID DUO-SHIELD 30GX3/16" 30 GAUGE X 3/16" | 2 | PA; ST |
| ASSURE ID DUO-SHIELD 30GX5/16" 30 GAUGE X 5/16" | 2 | PA; ST |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| ASSURE ID PEN NEEDLE 30GX3/16" 30 GAUGE X 3/16" | 2 | PA; ST |
| ASSURE ID PEN NEEDLE 30GX5/16" 30 GAUGE X 5/16" | 2 | PA; ST |
| ASSURE ID PEN NEEDLE (pen needle, diabetic, 31GX3/16" 31 GAUGE X 3/16" safety) | 2 | PA; ST |
| ASSURE ID PRO PEN NDL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| ASSURE ID SYR 0.5 ML 31GX15/64" 0.5 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| ASSURE ID SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| AUTOSHIELD DUO PEN NDL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| BD AUTOSHIELD DUO NDL 5MMX30G 30 GAUGE X 3/16" | 2 | PA; ST |
| BD ECLIPSE 30GX1/2" SYRINGE (insulin syringe-needle 1 ML 30 GAUGE X 1/2" u-100) | 2 | PA; ST |
| BD ECLIPSE NEEDLE 30GX1/2" (OTC) 30 X 1/2 " | 2 | PA; ST |
| BD INS SYR 0.3 ML 8MMX31G(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| BD INS SYR UF 0.3 ML (insulin syringe-needle 12.7MMX30G 0.3 ML 30 GAUGE u-100) X 1/2" | 2 | PA; ST |
| BD INS SYR UF 0.5 ML (insulin syringe-needle 12.7MMX30G NOT FOR RETAIL u-100) SALE 0.5 ML 30 GAUGE X 1/2" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| BD INSULIN SYR 1 ML 27GX12.7MM 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE 1 ML 27 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD LO-DOSE ULTRA-FINE SYRINGE 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD NANO 2 GEN PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| BD SAFETGLD INS 0.3 ML 29G 13MM 0.3 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| BD SAFETYGLD INS 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| BD SAFETYGLD INS 0.5 ML 30G 8MM 0.5 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| BD SAFETYGLD INS 1 ML 29G 13MM 1 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| BD SAFETYGLID INS 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD SAFETYGLIDE SYRINGE 27GX5/8 1 ML 27 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD SAFTYGLD INS 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD SAFTYGLD INS 0.5 ML 29G 13MM 0.5 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| BD SAFTYGLD INS 0.5 ML 6MMX31G 0.5 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD SINGLE USE SWAB | (alcohol swabs) | 1 | PA; ST |
| BD UF MICRO PEN NEEDLE 6MMX32G 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF MINI PEN NEEDLE 5MMX31G 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF NANO PEN NEEDLE 4MMX32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| BD UF ORIG PEN NDL 12.7MMX29G 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| BD UF SHORT PEN NEEDLE 8MMX31G 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| BD VEO INS 0.3 ML 6MMX31G (1/2) 0.3 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| BD VEO INS SYRING 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| BD VEO INS SYRN 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| BD VEO INS SYRN 0.5 ML 6MMX31G 1/2 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| BORDERED GAUZE 2"X2" 2 X 2 " (gauze bandage) | 1 | PA; ST |
| CAREFINE PEN NEEDLE 12.7MM 29G 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 5MM 32G 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 8MM 30G 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH ALCOHOL 70% PREP PAD (alcohol swabs) | 1 | PA; ST |
| CARETOUCH PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| CARETOUCH PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 1 ML 28GX5/16" 1 ML 28 X 5/16" | | 2 | PA; ST |
| CARETOUCH SYR 1 ML 29GX5/16" 1 ML 29 GAUGE X 5/16 | | 2 | PA; ST |
| CARETOUCH SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| CLICKFINE PEN NEEDLE 32GX5/32" 32GX4MM, STERILE 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ 0.3 ML 31G 15/64" 0.3 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ 0.5 ML 31G 15/64" 1/2 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ INS 0.3 ML 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ INS 1 ML 31G 15/64" 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| COMFORT EZ INS 1 ML (insulin syringe-needle 31GX5/16" 1 ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| COMFORT EZ INSULIN SYR 0.3 (insulin syringe-needle ML 0.3 ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |
| COMFORT EZ INSULIN SYR 0.5 (insulin syringe-needle ML 0.5 ML 30 GAUGE X 5/16", 0.5 u-100) ML 31 GAUGE X 5/16" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLE (pen needle, diabetic) 12MM 29G 29 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 4MM 32G SINGLE USE, MICRO 32 GAUGE X 5/32" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 4MM 33G 33 GAUGE X 5/32" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 5MM 31G MINI 31 GAUGE X 3/16" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 5MM 32G SINGLE USE,MINI,HRI 32 GAUGE X 3/16" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 5MM 33G 33 GAUGE X 3/16" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 6MM 31G 31 GAUGE X 1/4" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 6MM 32G 32 GAUGE X 1/4" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 6MM 33G 33 GAUGE X 1/4" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 8MM 31G SHORT 31 GAUGE X 5/16" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 8MM 32G 32 GAUGE X 5/16" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 33G 33 GAUGE X 5/16" | 2 | PA; ST |
| COMFORT EZ PRO PEN NDL 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| COMFORT EZ PRO PEN NDL 31G (pen needle, diabetic, 4MM 31 GAUGE X 5/32" safety) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| COMFORT EZ PRO PEN NDL 31G (pen needle, diabetic, safety) 5MM 31 GAUGE X 3/16" | 2 | PA; ST |
| COMFORT EZ SYR 0.3 ML (insulin syringe-needle u-100) 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ SYR 0.5 ML (insulin syringe-needle u-100) 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ SYR 0.5 ML (insulin syringe-needle u-100) 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ SYR 0.5 ML (insulin syringe-needle u-100) 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 27G (insulin syringe-needle u-100) 12.7MM 1 ML 27 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ SYR 1 ML (insulin syringe-needle u-100) 28GX1/2" 1 ML 28 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ SYR 1 ML (insulin syringe-needle u-100) 29GX1/2" 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ SYR 1 ML (insulin syringe-needle u-100) 30GX1/2" 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ SYR 1 ML (insulin syringe-needle u-100) 30GX5/16" 1 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| COMFORT POINT PEN NDL 31GX1/3" 31 GAUGE X 1/3" | 2 | PA; ST |
| COMFORT POINT PEN NDL 31GX1/6" 31 GAUGE X 1/6" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G (pen needle, diabetic) 4MM 31 GAUGE X 5/32" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G (pen needle, diabetic) 5MM 31 GAUGE X 3/16" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G (pen needle, diabetic) 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G (pen needle, diabetic) 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G (pen needle, diabetic) 4MM 32 GAUGE X 5/32" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| COMFORT TOUCH PEN NDL 32G (pen needle, diabetic) 5MM 32 GAUGE X 3/16" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G (pen needle, diabetic) 6MM 32 GAUGE X 1/4" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G (pen needle, diabetic) 8MM 32 GAUGE X 5/16" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 33G (pen needle, diabetic) 4MM 33 GAUGE X 5/32" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 33G (pen needle, diabetic) 6MM 33 GAUGE X 1/4" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL (pen needle, diabetic) 33GX5MM 33 GAUGE X 3/16" | 2 | PA; ST |
| CURAD GAUZE PADS 2" X 2" 2 X (gauze bandage) 2 " | 1 | PA; ST |
| CURITY ALCOHOL PREPS 2 (alcohol swabs) PLY,MEDIUM | 1 | PA; ST |
| CURITY GAUZE PADS 2 X 2 " (gauze bandage) | 1 | PA; ST |
| CURITY GAUZE SPONGES (12 PLY)-200/BAG 2 X 2 " | 1 | PA; ST |
| DERMACEA 2"X2" GAUZE 12 (gauze bandage) PLY, USP TYPE VII 2 X 2 " | 1 | PA; ST |
| DERMACEA GAUZE 2"X2" SPONGE 8 PLY 2 X 2 " | 1 | PA; ST |
| DERMACEA NON-WOVEN 2"X2" SPNGE 2 X 2 " | 1 | PA; ST |
| DROPLET 0.3 ML 29G 12.7MM(1/2) 0.3 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| DROPLET 0.3 ML 30G 12.7MM(1/2) 0.3 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| DROPLET 0.5 ML 29GX12.5MM(1/2) 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| DROPLET 0.5 ML 30GX12.5MM(1/2) 0.5 ML 30 GAUGE X 1/2" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| DROPLET INS 0.3 ML 29GX12.5MM 0.3 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.3 ML 30G 8MM(1/2) 0.3 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| DROPLET INS 0.3 ML 30GX12.5MM 0.3 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.3 ML 31G 6MM(1/2) 0.3 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPLET INS 0.3 ML 31G 8MM(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPLET INS 0.5 ML 29G 12.7MM 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.5 ML 30G 12.7MM 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.5 ML 30GX6MM(1/2) 0.5ML 30 GAUGE X 15/64" | 2 | PA; ST |
| DROPLET INS 0.5 ML 30GX8MM(1/2) 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| DROPLET INS 0.5 ML 31GX6MM(1/2) 0.5 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPLET INS 0.5 ML 31GX8MM(1/2) 0.5 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 30GX6MM 0.3 ML 30 GAUGE X 15/64" | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 30GX8MM 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| DROPLET INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 31GX8MM 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.5 ML 30G 8MM 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 29G 12.7MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 30G 8MM 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 30GX12.5MM 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 30GX6MM 1 ML 30 GAUGE X 15/64" | | 2 | PA; ST |
| DROPLET INS SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET MICRON 34G X 9/64" 34 GAUGE X 9/64" | | 2 | PA; ST |
| DROPLET PEN NEEDLE 29G 10MM 29 GAUGE X 3/8" | | 2 | PA; ST |
| DROPLET PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| DROPLET PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| DROPSAFE ALCOHOL 70% PREP PADS (alcohol swabs) | 1 | PA; ST |
| DROPSAFE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPSAFE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPSAFE INS SYR 0.5 ML 31G 6MM 0.5 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPSAFE INS SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPSAFE INSUL SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPSAFE INSUL SYR 1 ML 31G 8MM 1 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPSAFE INSULN 1 ML 29G 12.5MM 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 2 | PA; ST |
| DRUG MART ULTRA COMFORT SYR 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| EASY CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | PA; ST |
| EASY CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| EASY CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| EASY COMFORT 0.3 ML 31G 1/2" 0.3 ML 31 X 1/2" | 2 | PA; ST |
| EASY COMFORT 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 0.5 ML 32GX5/16" 1/2 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| EASY COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 1 ML 32GX5/16" 1 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| EASY COMFORT ALCOHOL 70% PAD (alcohol swabs) | 1 | PA; ST |
| EASY COMFORT INSULIN 1 ML SYR 1 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT PEN NDL 29G 4MM 29 GAUGE X 5/32" | 2 | PA; ST |
| EASY COMFORT PEN NDL 29G 5MM 29 GAUGE X 3/16" | 2 | PA; ST |
| EASY COMFORT PEN NDL 31GX1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| EASY COMFORT PEN NDL 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 32GX5/32" 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT SYR 0.5 ML 29G 8MM 1/2 ML 29 X5/16 " (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT SYR 1 ML 29G 8MM 1 ML 29 GAUGE X 5/16 | 2 | PA; ST |
| EASY COMFORT SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE INS 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE INS 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE INS 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH 0.3 ML SYR 30GX1/2" 0.3 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR 27GX1/2" 1/2 ML 27 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| EASY TOUCH 0.5 ML SYR 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR 30GX5/16 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH 1 ML SYR 27GX1/2" 1 ML 27 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH 1 ML SYR 29GX1/2" 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH 1 ML SYR 30GX1/2" 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH ALCOHOL 70% (alcohol swabs) PADS GAMMA-STERILIZED | 1 | PA; ST |
| EASY TOUCH FLIPLOK 1 ML 27GX0.5 1 ML 27 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULIN 1 ML 29GX1/2 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULIN 1 ML 30GX1/2 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 0.3 (insulin syringe-needle u-100) ML 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 0.5 (insulin syringe-needle u-100) ML 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 1 (insulin syringe-needle u-100) ML 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 1 (insulin syringe-needle u-100) ML RETRACTABLE 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULIN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULIN 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULIN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH LUER LOK INSUL 1 ML (insulin syringe needleless) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 30GX5/16 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX3/16 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX5/16 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX3/16 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX5/32 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH SAF PEN NDL 29G 5MM 29 GAUGE X 3/16" | 2 | PA; ST |
| EASY TOUCH SAF PEN NDL 29G 8MM 29 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH SAF PEN NDL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| EASY TOUCH SAF PEN NDL 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH SYR 0.5 ML 28G 12.7MM 1/2 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 0.5 ML 29G 12.7MM 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 1 ML 27G 16MM 1 ML 27 GAUGE X 5/8" (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|------------------------------------|------------------|----------------------------|
| EASY TOUCH SYR 1 ML 28G 12.7MM 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 1 ML 29G 12.7MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH UNI-SLIP SYR 1 ML | (insulin syringe needleless) | 2 | PA; ST |
| EASYTOUCH SAF PEN NDL 30G 6MM 30 GAUGE X 1/4" | | 2 | PA; ST |
| EMBRACE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| EQL INSULIN 0.5 ML SYRINGE 1/2 ML 29 | (Ultilet Insulin Syringe) | 2 | PA; ST |
| EQL INSULIN 0.5 ML SYRINGE SHORT NEEDLE 1/2 ML 30 GAUGE | (Ultra Comfort Insulin Syringe) | 2 | PA; ST |
| EXEL U100 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| FP INSULIN 1 ML SYRINGE 1 ML 28 GAUGE | | 2 | PA; ST |
| FREESTYLE PREC 0.5 ML 30GX5/16 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| FREESTYLE PREC 0.5 ML 31GX5/16 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| FREESTYLE PREC 1 ML (insulin syringe-needle 30GX5/16" 1 ML 30 GAUGE X 5/16 u-100) | 2 | PA; ST |
| FREESTYLE PREC 1 ML (insulin syringe-needle 31GX5/16" 1 ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| GAUZE PAD TOPICAL (gauze bandage) BANDAGE 2 X 2 " | 1 | PA; ST |
| GAUZE PADS 2"X2" STRL 2 X 2 " (Bordered Gauze) | 1 | PA; ST |
| GNP ALCOHOL SWAB STERILE, (Alcohol Pads) TWO PLY | 1 | PA; ST |
| GNP CLICKFINE 31G X 1/4" NDL (pen needle, diabetic) 6MM, UNIVERSAL 31 GAUGE X 1/4" | 2 | PA; ST |
| GNP CLICKFINE 31G X 5/16" NDL (pen needle, diabetic) 8MM, UNIVERSAL 31 GAUGE X 5/16" | 2 | PA; ST |
| GNP PEN NEEDLE 31G 5MM 31 (1st Tier Unifine Pentips) GAUGE X 3/16" | 2 | PA; ST |
| GNP PEN NEEDLE 32G 4MM 32 (1st Tier Unifine Pentips) GAUGE X 5/32" | 2 | PA; ST |
| GNP PEN NEEDLE 32G 6MM 32 (CareFine Pen Needle) GAUGE X 1/4" | 2 | PA; ST |
| GNP SIMPLI PEN NEEDLE 32G (pen needle, diabetic) 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT 0.3 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| GNP ULT CMFRT 0.5 ML (insulin syringe-needle 29GX1/2" 1/2 ML 29 u-100) | 2 | PA; ST |
| GNP ULTRA COMFORT 0.5 ML (insulin syringe-needle SYR 1/2 ML 30 GAUGE u-100) | 2 | PA; ST |
| GNP ULTRA COMFORT 1 ML SYRINGE 1 ML 29 GAUGE | 2 | PA; ST |
| GNP ULTRA COMFORT 1 ML (insulin syringe-needle SYRINGE 1 ML 30 GAUGE X u-100) 7/16" | 2 | PA; ST |
| GNP ULTRA COMFORT 3/10 ML (insulin syringe-needle SYR 0.3 ML 30 u-100) | 2 | PA; ST |
| GS PEN NEEDLE 31G X 8MM 31 (1st Tier Unifine Pentips) GAUGE X 5/16" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| HEALTHWISE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHWISE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHWISE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP 5MM 31G 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP 8MM 31G 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHY ACCENTS PENTP 12MM 29G 29 GAUGE X 1/2" | | 2 | PA; ST |
| HEB INCONTROL ALCOHOL 70% PADS | (alcohol swabs) | 1 | PA; ST |
| INCONTROL PEN NEEDLE 12MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| INCONTROL PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| INCONTROL PEN NEEDLE 5MM (pen needle, diabetic) 31G 31 GAUGE X 3/16" | 2 | PA; ST |
| INCONTROL PEN NEEDLE 6MM (pen needle, diabetic) 31G 31 GAUGE X 1/4" | 2 | PA; ST |
| INCONTROL PEN NEEDLE 8MM (pen needle, diabetic) 31G 31 GAUGE X 5/16" | 2 | PA; ST |
| INPEN (FOR HUMALOG) BLUE SUBCUTANEOUS INSULIN PEN | 3 | |
| INPEN (NOVOLOG OR FIASP) BLUE SUBCUTANEOUS INSULIN PEN | 3 | |
| INSULIN 1 ML SYRINGE 1 ML 30 (Ultra Comfort Insulin GAUGE X 7/16" Syringe) | 2 | PA; ST |
| INSULIN SYR 0.3 ML (UltiCare Insuln Syr(half 31GX1/4(1/2) 0.3 ML 31 GAUGE X unit)) 1/4" | 2 | PA; ST |
| INSULIN SYR 0.5 ML 28G (Comfort EZ Insulin 12.7MM (OTC) 1/2 ML 28 GAUGE Syringe) X 1/2" | 2 | PA; ST |
| INSULIN SYRIN 0.5 ML 30GX1/2" (Comfort EZ Insulin (RX) 0.5 ML 30 GAUGE X 1/2" Syringe) | 2 | PA; ST |
| INSULIN SYRING 0.5 ML 27G 1/2" (Easy Touch Insulin INNER 1/2 ML 27 GAUGE X 1/2" Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 0.3 ML 0.3 ML (insulin syringe-needle 29 GAUGE u-100) | 2 | PA; ST |
| INSULIN SYRINGE 0.3 ML (Sure Comfort Insulin 31GX1/4 0.3 ML 31 GAUGE X 1/4" Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 0.5 ML 1/2 ML (insulin syringe-needle 29 u-100) | 2 | PA; ST |
| INSULIN SYRINGE 0.5 ML (Sure Comfort Insulin 31GX1/4 1/2 ML 31 GAUGE X 1/4" Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 1 ML 29 GAUGE | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 27G 1/2" (Comfort EZ Insulin INNER 1 ML 27 GAUGE X 1/2" Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 27G (BD SafetyGlide 16MM 1 ML 27 GAUGE X 5/8" Syringe) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| INSULIN SYRINGE 1 ML 28G (Comfort EZ Insulin Syringe) 12.7MM (OTC) 1 ML 28 GAUGE X 1/2" | 2 | PA; ST |
| INSULIN SYRINGE 1 ML (BD Eclipse Luer-Lok) 30GX1/2" SHORT NEEDLE (OTC) 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| INSULIN SYRINGE 1 ML (Sure Comfort Insulin Syringe) 31GX1/4" 1 ML 31 GAUGE X 1/4" | 2 | PA; ST |
| INSULIN SYRINGE NEEDLELESS SYRINGE 1 ML (Easy Touch Luer Lock Insulin) | 2 | PA; ST |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE (Ultilet Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 1 ML 29 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 1/2 ML 28 GAUGE (Monoject Syringe) | 2 | PA; ST |
| INSULIN U-500 SYRINGE-NEEDLE SYRINGE 1/2 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| INSUPEN 30G ULTRAFIN (pen needle, diabetic) NEEDLE 30 GAUGE X 5/16" | 2 | PA; ST |
| INSUPEN 31G ULTRAFIN (pen needle, diabetic) NEEDLE 31 GAUGE X 1/4" | 2 | PA; ST |
| INSUPEN 32G 8MM PEN NEEDLE (pen needle, diabetic) 32 GAUGE X 5/16" | 2 | PA; ST |
| INSUPEN PEN NEEDLE (pen needle, diabetic) 29GX12MM 29 GAUGE X 1/2" | 2 | PA; ST |
| INSUPEN PEN NEEDLE 31G 8MM (pen needle, diabetic) 31 GAUGE X 5/16" | 2 | PA; ST |
| INSUPEN PEN NEEDLE (pen needle, diabetic) 31GX3/16" 31 GAUGE X 3/16" | 2 | PA; ST |
| INSUPEN PEN NEEDLE 32G 6MM (pen needle, diabetic) (RX) 32 GAUGE X 1/4" | 2 | PA; ST |
| INSUPEN PEN NEEDLE (pen needle, diabetic) 32GX4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| INSUPEN PEN NEEDLE (pen needle, diabetic) 33GX4MM 33 GAUGE X 5/32" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| IV ANTISEPTIC WIPES (alcohol swabs) | 1 | PA; ST |
| KENDALL ALCOHOL 70% PREP PAD (alcohol swabs) | 1 | PA; ST |
| LISCO SPONGES 100/BAG 2 X 2 " | 1 | PA; ST |
| LITE TOUCH 31GX1/4" PEN NEEDLE 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| LITE TOUCH INSULIN 0.5 ML SYR 1/2 ML 28 GAUGE, 1/2 ML 29 , 1/2 ML 30 GAUGE (insulin syringe-needle u-100) | 2 | PA; ST |
| LITE TOUCH INSULIN 1 ML SYR 1 ML 28 GAUGE, 1 ML 30 GAUGE X 7/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| LITE TOUCH INSULIN 1 ML SYR 1 ML 29 GAUGE | 2 | PA; ST |
| LITE TOUCH INSULIN SYR 1 ML 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| LITE TOUCH PEN NEEDLE 29G 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| LITE TOUCH PEN NEEDLE 31G 31 GAUGE X 3/16", 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| LITETOUCH INS 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUCH INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUCH INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUCH INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUCH SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUCH SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|--|----------------------------|
| LITETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| LITETOUCH SYRIN 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| LITETOUCH SYRIN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| LITETOUCH SYRIN 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | PA; ST |
| MAGELLAN INSUL SYRINGE 0.3 ML 0.3 ML 30 X 5/16" | 2 | PA; ST |
| MAGELLAN INSUL SYRINGE 0.5 ML 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| MAGELLAN INSULIN SYR 0.3 ML 0.3 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| MAGELLAN INSULIN SYR 0.5 ML 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| MAGELLAN INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| MAXICOMFORT II PEN NDL 31GX6MM 31 GAUGE X 1/4" | (pen needle, diabetic) 2 | PA; ST |
| MAXICOMFORT INS 0.5 ML 27GX1/2" 1/2 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| MAXI-COMFORT INS 0.5 ML 28G 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| MAXICOMFORT INS 1 ML 27GX1/2" 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| MAXI-COMFORT INS 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| MAXICOMFORT PEN NDL 29G X 5MM 29 GAUGE X 3/16" | 2 | PA; ST |
| MAXICOMFORT PEN NDL 29G X 8MM 29 GAUGE X 5/16" | 2 | PA; ST |
| MICRODOT PEN NEEDLE 31GX6MM 31 GAUGE X 1/4" | (pen needle, diabetic) 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| MICRODOT PEN NEEDLE 32GX4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| MICRODOT PEN NEEDLE 33GX4MM 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| MICRODOT READYGARD NDL 31G 5MM OUTER 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| MINI PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" | (CareFine Pen Needle) | 2 | PA; ST |
| MINI PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" | (Comfort EZ Pen Needles) | 2 | PA; ST |
| MINI PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | (Advocate Pen Needle) | 2 | PA; ST |
| MINI PEN NEEDLE 33G 5MM 33 GAUGE X 3/16" | (Comfort EZ Pen Needles) | 2 | PA; ST |
| MINI PEN NEEDLE 33G 6MM 33 GAUGE X 1/4" | (Comfort EZ Pen Needles) | 2 | PA; ST |
| MINI ULTRA-THIN II PEN NDL 31G STERILE 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| MONOJECT 0.5 ML SYRN 28GX1/2" 1/2 ML 28 GAUGE | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT 1 ML SYRN 27X1/2" 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT 1 ML SYRN 28GX1/2" (OTC) 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 (OTC) 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 .5ML,29GX1/2" (OTC) 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC) 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML 1 ML 25 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC) 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC) (insulin syringes (disposable)) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.3 ML (OTC) 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.5 ML (OTC) 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 1 ML 3'S (OTC) 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR U-100 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR U-100 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| MONOJECT SYRINGE 0.3 ML 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT SYRINGE 0.5 ML 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT SYRINGE 1 ML 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| MS INSULIN SYR 1 ML 31GX5/16" (OTC) 1 ML 31 GAUGE X 5/16 (Advocate Syringes) | 2 | PA; ST |
| MS INSULIN SYRINGE 0.3 ML 0.3 ML 30 (Ultra Comfort Insulin Syringe) | 2 | PA; ST |
| NANO 2 GEN PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| NANO PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| NOVOFINE 30 NEEDLE | 2 | PA; ST |
| NOVOFINE 32G NEEDLES 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| NOVOFINE PLUS PEN NDL 32GX1/6" 32 GAUGE X 1/6" | 2 | PA; ST |
| NOVOTWIST NEEDLE 32 GAUGE X 1/5" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| OMNIPOD 5 (G6/LIBRE 2 PLUS) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD 5 G6-G7 INTRO KT(GEN5) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD 5 G6-G7 PODS (GEN 5) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD 5 INTRO(G6/LIBRE2PLUS) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD CLASSIC PDM KIT(GEN 3) | 3 | QL (1 per 365 days) |
| OMNIPOD CLASSIC PODS (GEN 3) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD DASH INTRO KIT (GEN 4) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD DASH PDM KIT (GEN 4) | 3 | QL (1 per 365 days) |
| OMNIPOD DASH PODS (GEN 4) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| PC UNIFINE PENTIPS 8MM (pen needle, diabetic) NEEDLE SHORT 31 GAUGE X 5/16" | 2 | PA; ST |
| PEN NEEDLE 30G 5MM OUTER (Embrace Pen Needle) 30 GAUGE X 3/16" | 2 | PA; ST |
| PEN NEEDLE 30G 8MM INNER 30 (CareFine Pen Needle) GAUGE X 5/16" | 2 | PA; ST |
| PEN NEEDLE 30G X 5/16" 30 (pen needle, diabetic) GAUGE X 5/16" | 2 | PA; ST |
| PEN NEEDLE 31G X 1/4" HRI 31 (1st Tier Unifine GAUGE X 1/4" Pentips) | 2 | PA; ST |
| PEN NEEDLE 6MM 31G 6MM 31 (pen needle, diabetic) GAUGE X 1/4" | 2 | PA; ST |
| PEN NEEDLE, DIABETIC (1st Tier Unifine Pentips NEEDLE 29 GAUGE X 1/2" Plus) | 2 | PA; ST |
| PEN NEEDLES 12MM 29G (pen needle, diabetic) 29GX12MM,STRL 29 GAUGE X 1/2" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| PEN NEEDLES 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLES 5MM 31G 31GX5MM,STRL,MINI (OTC) 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC) 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 29G 1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 31G 1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 32G 1/4" 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 32GX5/32" 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| PIP PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| PIP PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| PREFPLS INS SYR 1 ML 30GX5/16" (OTC) 1 ML 30 GAUGE X 5/16 (Advocate Syringes) | 2 | PA; ST |
| PREVENT PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 2 | PA; ST |
| PREVENT PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 2 | PA; ST |
| PRO COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| PRO COMFORT 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| PRO COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-------------------------------------|----------------------------|
| PRO COMFORT 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| PRO COMFORT 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | PA; ST |
| PRO COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | PA; ST |
| PRO COMFORT ALCOHOL 70% PADS | (alcohol swabs) 1 | PA; ST |
| PRO COMFORT PEN NDL 32G 8MM 32 GAUGE X 5/16" | (pen needle, diabetic) 2 | PA; ST |
| PRO COMFORT PEN NDL 32G X 1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) 2 | PA; ST |
| PRO COMFORT PEN NDL 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) 2 | PA; ST |
| PRO COMFORT PEN NDL 5MM 32G 32 GAUGE X 3/16" | (pen needle, diabetic) 2 | PA; ST |
| PRODIGY INS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| PRODIGY SYRNG 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| PRODIGY SYRNGE 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| PURE CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) 2 | PA; ST |
| PURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| PURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| PURE COMFORT ALCOHOL 70% PADS | (alcohol swabs) 1 | PA; ST |
| PURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) 2 | PA; ST |
| PURE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" | (pen needle, diabetic) 2 | PA; ST |
| PURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| PURE COMFORT PEN NDL 32G 8MM 32 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 29G 12MM 29 GAUGE X 15/32" | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" (Comfort Touch Pen Needle) | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 5MM 31 GAUGE X 13/64" | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 6MM 31 GAUGE X 15/64" | 2 | PA; ST |
| RELION INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| RELION INS SYR 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| RELION INS SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| RELI-ON INSULIN 1 ML SYR 1 ML 29 GAUGE X 7/16" | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10 0.3 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10 1 ML 28 GAUGE X 1/2" | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| SAFETY PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" (Comfort EZ PRO Safety Pen Ndl) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| SAFETY PEN NEEDLE 5MM X 31G 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | PA; ST |
| SAFETY SYRINGE 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| SECURES SAFE PEN NDL 30GX5/16" OUTER 30 GAUGE X 5/16" | 2 | PA; ST |
| SECURES SAFE SYR 0.5 ML 29G 1/2" OUTER 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| SECURES SAFE SYRNG 1 ML 29G 1/2" OUTER 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| SKY SAFETY PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| SKY SAFETY PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| SM ULT CFT 0.3 ML 31GX5/16(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| STERILE PADS 2" X 2" 2 X 2 " (gauze bandage) | 1 | PA; ST |
| SURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| SURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| NEEDLES, INSULIN DISP., SAFETY (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------------------|------------------|----------------------------|
| SURE COMFORT 3/10 ML SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT 3/10 ML SYRINGE INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT 30G PEN NEEDLE 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE COMFORT ALCOHOL PREP PADS | (alcohol swabs) | 1 | PA; ST |
| SURE COMFORT INS 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT INS 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT PEN NDL 29GX1/2" 12.7MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| SURE COMFORT PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| SURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| SURE-FINE PEN NEEDLES 12.7MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| SURE-FINE PEN NEEDLES 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE-FINE PEN NEEDLES 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE-JECT INSU SYR U100 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------------------|------------------|----------------------------|
| SURE-JECT INSU SYR U100 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSU SYR U100 1 ML 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSUL SYR U100 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSULIN SYRINGE 1 ML 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-PREP ALCOHOL PREP PADS | (alcohol swabs) | 1 | PA; ST |
| TECHLITE 0.3 ML 29GX12MM (1/2) 0.3 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| TECHLITE 0.3 ML 30GX8MM (1/2) 0.3 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| TECHLITE 0.3 ML 31GX6MM (1/2) 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| TECHLITE 0.3 ML 31GX8MM (1/2) 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| TECHLITE 0.5 ML 30GX12MM (1/2) 0.5 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| TECHLITE 0.5 ML 30GX8MM (1/2) 0.5 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| TECHLITE 0.5 ML 31GX6MM (1/2) 0.5 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| TECHLITE 0.5 ML 31GX8MM (1/2) 0.5 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 29GX12MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 30GX12MM 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| TECHLITE INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 29GX3/8" 29 GAUGE X 3/8" | | 2 | PA; ST |
| TECHLITE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 32GX5/16" 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1 ML 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1 ML 1 ML 30 GAUGE X 3/8" | (Thinpro Insulin Syringe) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1/2 ML 1/2 ML 30 X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1/3 ML 0.3 ML 30 X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TERUMO INS SYRNG U100-1/2 ML 0.5 ML 29 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| THINPRO INS SYRIN U100-0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| THINPRO INS SYRIN U100-0.3 ML 0.3 ML 31 X 3/8" | 2 | PA; ST |
| THINPRO INS SYRIN U100-0.5 (insulin syringe-needle ML 0.5 ML 29 GAUGE X 1/2", 1/2 u-100) ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" | 2 | PA; ST |
| THINPRO INS SYRIN U100-0.5 ML 0.5 ML 31 X 3/8" | 2 | PA; ST |
| THINPRO INS SYRIN U100-1 ML (insulin syringe-needle 1 ML 28 GAUGE X 1/2", 1 ML 29 u-100) GAUGE X 1/2", 1 ML 30 GAUGE X 3/8" | 2 | PA; ST |
| THINPRO INS SYRIN U100-1 ML 1 ML 31 X 3/8" | 2 | PA; ST |
| TOPCARE CLICKFINE 31G X 1/4" (pen needle, diabetic) 31 GAUGE X 1/4" | 2 | PA; ST |
| TOPCARE CLICKFINE 31G X (pen needle, diabetic) 5/16" 31 GAUGE X 5/16" | 2 | PA; ST |
| TOPCARE ULTRA COMFORT (insulin syringe-needle SYRINGE 0.3 ML 29 GAUGE X u-100) 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 2 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 30G (insulin syringe-needle 5/16" 0.5 ML 30 GAUGE X 5/16" u-100) | 2 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 31G (insulin syringe-needle 5/16" 0.5 ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 32G 5/16" 1/2 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| TRUE CMFT SFTY PEN NDL 31G (pen needle, diabetic, 5MM 31 GAUGE X 3/16" safety) | 2 | PA; ST |
| TRUE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| TRUE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits | |
|--|-----------------------------------|----------------------------|--------|
| TRUE COMFORT 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 2 | PA; ST | |
| TRUE COMFORT 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST | |
| TRUE COMFORT 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | 2 | PA; ST | |
| TRUE COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT ALCOHOL 70% PADS | (alcohol swabs) | 1 | PA; ST |
| TRUE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 31GX5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 31GX6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 32GX4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| TRUE COMFORT PRO 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| TRUE COMFORT PRO ALCOHOL (alcohol swabs) PADS | 1 | PA; ST |
| TRUE COMFORT SFTY 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| TRUE COMFRT PRO 0.5 ML 30G (insulin syringe-needle 1/2" 0.5 ML 30 GAUGE X 1/2" u-100) | 2 | PA; ST |
| TRUE COMFRT SFTY 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| TRUE COMFRT SFTY 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| TRUE COMFRT SFTY 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE (pen needle, diabetic) 29GX1/2" 29 GAUGE X 1/2" | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 31G X (pen needle, diabetic) 1/4" 31 GAUGE X 1/4" | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE (pen needle, diabetic) 31GX3/16" 31 GAUGE X 3/16" | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE (pen needle, diabetic) 31GX5/16" 31 GAUGE X 5/16" | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE (pen needle, diabetic) 32GX5/32" 32 GAUGE X 5/32" | 2 | PA; ST |
| TRUEPLUS SYR 0.3 ML 29GX1/2" (insulin syringe-needle 0.3 ML 29 GAUGE X 1/2" u-100) | 2 | PA; ST |
| TRUEPLUS SYR 0.3 ML (insulin syringe-needle 30GX5/16" 0.3 ML 30 GAUGE X u-100) 5/16" | 2 | PA; ST |
| TRUEPLUS SYR 0.3 ML (insulin syringe-needle 31GX5/16" 0.3 ML 31 GAUGE X u-100) 5/16" | 2 | PA; ST |
| TRUEPLUS SYR 0.5 ML 28GX1/2" (insulin syringe-needle 1/2 ML 28 GAUGE X 1/2" u-100) | 2 | PA; ST |
| TRUEPLUS SYR 0.5 ML 29GX1/2" (insulin syringe-needle 0.5 ML 29 GAUGE X 1/2" u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-------------------------------------|------------------|----------------------------|
| TRUEPLUS SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICAR INS 0.3 ML 31GX1/4(1/2) 0.3 ML 31 GAUGE X 1/4" | (insulin syr/ndl u100 half mark) | 2 | PA; ST |
| ULTICARE INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE INS SYR 0.3 ML 30G 8MM 0.3 ML 30 GAUGE X 5/16" | (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 0.5 ML 30G 8MM (OTC) 0.5 ML 30 GAUGE X 5/16" | (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE INS SYR 0.5 ML 31G 8MM (OTC) 0.5 ML 31 GAUGE X 5/16" | (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| ULTICARE PEN NEEDLE 8MM (pen needle, diabetic) 31G 31 GAUGE X 5/16" | 2 | PA; ST |
| ULTICARE PEN NEEDLES 12MM (pen needle, diabetic) 29G 29 GAUGE X 1/2" | 2 | PA; ST |
| ULTICARE PEN NEEDLES 4MM (pen needle, diabetic) 32G MICRO, 32GX4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| ULTICARE PEN NEEDLES 6MM (pen needle, diabetic) 32G 32 GAUGE X 1/4" | 2 | PA; ST |
| ULTICARE SAFE PEN NDL 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| ULTICARE SAFE PEN NDL 5MM 30G 30 GAUGE X 3/16" | 2 | PA; ST |
| ULTICARE SAFETY 0.5 ML (Comfort EZ Insulin 29GX1/2 (RX) 0.5 ML 29 GAUGE Syringe) X 1/2" | 2 | PA; ST |
| ULTICARE SYR 0.3 ML 29G (Comfort EZ Insulin 12.7MM 0.3 ML 29 GAUGE X 1/2" Syringe) | 2 | PA; ST |
| ULTICARE SYR 0.3 ML 30GX1/2" (insulin syringe-needle 0.3 ML 30 GAUGE X 1/2" u-100) | 2 | PA; ST |
| ULTICARE SYR 0.3 ML (insulin syringe-needle 31GX5/16" SHORT NDL 0.3 ML 31 u-100) GAUGE X 5/16" | 2 | PA; ST |
| ULTICARE SYR 0.5 ML 30GX1/2" (insulin syringe-needle 0.5 ML 30 GAUGE X 1/2" u-100) | 2 | PA; ST |
| ULTICARE SYR 0.5 ML (insulin syringe-needle 31GX5/16" SHORT NDL 0.5 ML 31 u-100) GAUGE X 5/16" | 2 | PA; ST |
| ULTICARE SYR 1 ML 31GX5/16" (insulin syringe-needle 1 ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| ULTIGUARD SAFE 1 ML 30G 12.7MM 1 ML 30 X 1/2" | 2 | PA; ST |
| ULTIGUARD SAFE0.3 ML 30G 12.7MM 0.3 ML 30 X 1/2" | 2 | PA; ST |
| ULTIGUARD SAFE0.5 ML 30G 12.7MM 1/2 ML 30 X 1/2" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 1 ML 31G 8MM 1 ML 31 X 5/16" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| ULTIGUARD SAFEPACK 29G 12.7MM 29 GAUGE X 1/2" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 31G 5MM 31 GAUGE X 3/16" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 31G 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 32G 6MM 32 GAUGE X 1/4" | 2 | PA; ST |
| ULTIGUARD SAFEPK 0.3 ML 31G 8MM 0.3 ML 31 X 5/16" | 2 | PA; ST |
| ULTIGUARD SAFEPK 0.5 ML 31G 8MM 1/2 ML 31 X 5/16" | 2 | PA; ST |
| ULTILET ALCOHOL STERL (alcohol swabs) SWAB | 1 | PA; ST |
| ULTILET INSULIN SYRINGE 0.3 (insulin syringe-needle ML 0.3 ML 29 GAUGE X 1/2", 0.3 u-100) ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| ULTILET INSULIN SYRINGE 0.5 (insulin syringe-needle ML 0.5 ML 29 GAUGE X 1/2", 0.5 u-100) ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| ULTILET INSULIN SYRINGE 1 (insulin syringe-needle ML 1 ML 29 GAUGE X 1/2", 1 ML u-100) 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 2 | PA; ST |
| ULTILET PEN NEEDLE 29 GAUGE | 2 | PA; ST |
| ULTILET PEN NEEDLE 4MM 32G (pen needle, diabetic) 32 GAUGE X 5/32" | 2 | PA; ST |
| ULTRA COMFORT 0.3 ML (insulin syringe-needle SYRINGE 0.3 ML 30 GAUGE X u-100) 5/16" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| ULTRA COMFORT 0.5 ML 28GX1/2" CONVERTS TO 29G 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA COMFORT 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA COMFORT 0.5 ML SYRINGE 1/2 ML 28 GAUGE | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO 0.3 ML 30G 1/2" (1/2) 0.3 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| ULTRA FLO 0.3 ML 30G 5/16"(1/2) 0.3 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| ULTRA FLO 0.3 ML 31G 5/16"(1/2) 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO SYR 0.3 ML 30G 5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO SYR 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO SYR 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------------------|------------------|----------------------------|
| ULTRA THIN PEN NDL 32G X 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 1 ML 30G X 5/16" 1 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 1 ML 31G X 5/16" 1 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 33GX5/32" 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE 0.3 ML 30G 12.7MM 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| ULTRA-FINE 0.3 ML 31G 6MM (1/2) 0.3 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| ULTRA-FINE 0.3 ML 31G 8MM (1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| ULTRA-FINE 0.5 ML 30G 12.7MM (insulin syringe-needle 0.5 ML 30 GAUGE X 1/2" u-100) | 2 | PA; ST |
| ULTRA-FINE INS SYR 1 ML 31G (insulin syringe-needle 6MM 1 ML 31 GAUGE X 15/64" u-100) | 2 | PA; ST |
| ULTRA-FINE INS SYR 1 ML 31G (insulin syringe-needle 8MM 1 ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| ULTRA-FINE PEN NDL 29G (pen needle, diabetic) 12.7MM 29 GAUGE X 1/2" | 2 | PA; ST |
| ULTRA-FINE PEN NEEDLE 31G (pen needle, diabetic) 5MM 31 GAUGE X 3/16" | 2 | PA; ST |
| ULTRA-FINE PEN NEEDLE 31G (pen needle, diabetic) 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| ULTRA-FINE PEN NEEDLE 32G (pen needle, diabetic) 6MM 32 GAUGE X 1/4" | 2 | PA; ST |
| ULTRA-FINE SYR 0.3 ML 31G (insulin syringe-needle 8MM 0.3 ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |
| ULTRA-FINE SYR 0.5 ML 31G (insulin syringe-needle 6MM 1/2 ML 31 GAUGE X 15/64" u-100) | 2 | PA; ST |
| ULTRA-FINE SYR 0.5 ML 31G (insulin syringe-needle 8MM 0.5 ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |
| ULTRA-FINE SYR 1 ML 30G (insulin syringe-needle 12.7MM 1 ML 30 GAUGE X 1/2" u-100) | 2 | PA; ST |
| ULTRA-THIN II 1 ML 31GX5/16" 1 (insulin syringe-needle ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.3 ML 30G (insulin syringe-needle 0.3 ML 30 GAUGE X 5/16" u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.3 ML 31G (insulin syringe-needle 0.3 ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 29G (insulin syringe-needle 0.5 ML 29 GAUGE X 1/2" u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 30G (insulin syringe-needle 0.5 ML 30 GAUGE X 5/16" u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 31G (insulin syringe-needle 0.5 ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| ULTRA-THIN II INS SYR 1 ML 29G 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS SYR 1 ML 30G 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II PEN NDL 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-THIN II PEN NDL 31GX5/16 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE OTC PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE OTC PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 12MM 29G 29GX12MM, STRL 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 31GX3/16" 31GX5MM,STRL,MINI 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 33GX5/32" 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS MAX 30GX3/16" 30 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS NEEDLES 29G 29 GAUGE | | 2 | PA; ST |
| UNIFINE PENTIPS PLUS 29GX1/2" 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS PLUS 30GX3/16" 30 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 31GX1/4" ULTRA SHORT, 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 31GX3/16" MINI 31 GAUGE X 3/16" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 31GX5/16" SHORT 31 GAUGE X 5/16" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 32GX5/32" 32 GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 33GX5/32" 33 GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE PROTECT 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| UNIFINE PROTECT 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| UNIFINE PROTECT 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE SAFECONTROL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| UNIFINE SAFECONTROL 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| UNIFINE SAFECONTROL 31G (pen needle, diabetic, 5MM 31 GAUGE X 3/16" safety) | 2 | PA; ST |
| UNIFINE SAFECONTROL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| UNIFINE SAFECONTROL 31G 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| UNIFINE SAFECONTROL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G (pen needle, diabetic) 5MM 31 GAUGE X 3/16" | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G (pen needle, diabetic) 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G (pen needle, diabetic) 8MM 31 GAUGE X 5/16" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| UNIFINE ULTRA PEN NDL 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| VANISHPOINT 0.5 ML 30GX1/2" SY OUTER 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| VANISHPOINT INS 1 ML 30GX3/16" 1 ML 30 GAUGE X 3/16" | 2 | PA; ST |
| VANISHPOINT U-100 29X1/2 SYR 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE INS SYR 1 ML 29G 1/2" 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 31G X 6MM 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 32G X 5MM 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 32G 4MM-SHARPS CONTAINER 32 GAUGE X 5/32" | 2 | PA; ST |
| VERIFINE SYRING 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| VERIFINE SYRING 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE SYRNG 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE SYRNG 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY 2 X 2 " | 1 | PA; ST |
| V-GO 20 DEVICE | 3 | QL (30 per 30 days) |
| V-GO 30 DEVICE | 3 | QL (30 per 30 days) |
| V-GO 40 DEVICE | 3 | QL (30 per 30 days) |
| WEBCOL ALCOHOL PREPS 20'S,LARGE (alcohol swabs) | 1 | PA; ST |
| Enzyme Cofactors/Chaperones | | |
| Enzyme Cofactors/Chaperones | | |
| MIPLYFFA ORAL CAPSULE 124 MG, 47 MG, 62 MG, 93 MG | 5 | PA; NDS; QL (90 per 30 days) |
| Enzyme Replacement/Modifiers | | |
| Enzyme Replacement/Modifiers | | |
| CERDELGA ORAL CAPSULE 84 MG | 5 | PA; NDS |
| CREON ORAL CAPSULE,DELAYED RELEASE(DR/EC) 12,000-38,000 - 60,000 UNIT, 24,000-76,000 - 120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT | 3 | |
| GALAFOLD ORAL CAPSULE 123 MG | 5 | PA; NDS; QL (14 per 28 days) |
| <i>javygtor oral tablet,soluble 100 mg</i> (sapropterin) | 5 | PA; NDS |
| <i>miglustat oral capsule 100 mg</i> (Yargesa) | 5 | PA; NDS; QL (90 per 30 days) |
| <i>nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg</i> (Orfadin) | 5 | PA; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| ORFADIN ORAL SUSPENSION 4 MG/ML | 5 | PA; NDS |
| PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML | 5 | PA; NDS |
| PULMOZYME INHALATION SOLUTION 1 MG/ML | 5 | PA BvD; NDS |
| REVCovi INTRAMUSCULAR SOLUTION 2.4 MG/1.5 ML (1.6 MG/ML) | 5 | PA; NDS |
| <i>sapropterin oral tablet, soluble 100 mg</i> (Javygtor) | 5 | PA; NDS |
| STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML, 80 MG/0.8 ML | 5 | PA; LA; NDS |
| <i>yargesa oral capsule 100 mg</i> (miglustat) | 5 | PA; NDS; QL (90 per 30 days) |
| ZENPEP ORAL CAPSULE, DELAYED RELEASE (DR/EC) 10,000-32,000 - 42,000 UNIT, 15,000-47,000 - 63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 - 14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT | 3 | |
| Eye, Ear, Nose, Throat Agents | | |
| Eye, Ear, Nose, Throat Agents, Miscellaneous | | |
| <i>apraclonidine ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>atropine ophthalmic (eye) drops 1 %</i> (Isopto Atropine) | 2 | |
| <i>azelastine nasal spray, non-aerosol 137 mcg (0.1 %)</i> | 2 | QL (60 per 30 days) |
| <i>azelastine nasal spray, non-aerosol 205.5 mcg (0.15 %)</i> (Astepro Allergy) | 2 | QL (30 per 25 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>azelastine ophthalmic (eye) drops 0.05 %</i> | 2 | |
| <i>bepotastine besilate ophthalmic (eye) drops 1.5 %</i> (Bepreve) | 4 | ST |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | 2 | |
| <i>epinastine ophthalmic (eye) drops 0.05 %</i> | 4 | |
| <i>ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)</i> | 2 | QL (30 per 28 days) |
| <i>ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)</i> | 2 | QL (15 per 10 days) |
| MIEBO (PF) OPHTHALMIC (EYE) DROPS 100 % | 3 | QL (12 per 28 days) |
| <i>olopatadine nasal spray,non-aerosol 0.6 %</i> | 4 | QL (30.5 per 30 days) |
| <i>olopatadine ophthalmic (eye) drops 0.1 %</i> (Eye Allergy Itch-Redness Rlf) | 2 | |
| <i>olopatadine ophthalmic (eye) drops 0.2 %</i> (Advanced Eye Relief (olopatad)) | 2 | |
| Eye, Ear, Nose, Throat Anti-Infectives Agents | | |
| <i>acetic acid otic (ear) solution 2 %</i> | 2 | |
| <i>bacitracin ophthalmic (eye) ointment 500 unit/gram</i> | 2 | |
| <i>bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram</i> (Polycin) | 2 | |
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i> | 2 | |
| <i>ciprofloxacin-dexamethasone otic (ear) drops,suspension 0.3-0.1 %</i> | 3 | QL (7.5 per 7 days) |
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i> | 2 | QL (3.5 per 4 days) |
| <i>gatifloxacin ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>gentak ophthalmic (eye) ointment 0.3 % (3 mg/gram)</i> | 2 | |
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>hydrocortisone-acetic acid otic (ear) drops 1-2 %</i> | 2 | |
| <i>moxifloxacin ophthalmic (eye) drops 0.5 %</i> (Vigamox) | 2 | |
| NATACYN OPHTHALMIC (EYE) DROPS,SUSPENSION 5 % | 4 | |
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> (Neo-Polycin HC) | 2 | |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> (Neo-Polycin) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> (Maxitrol) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> | 2 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i> | 2 | |
| <i>neomycin-polymyxin-hc ophthalmic (eye) drops,suspension 3.5-10,000-10 mg-unit-mg/ml</i> | 4 | |
| <i>neomycin-polymyxin-hc otic (ear) drops,suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | |
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | |
| <i>neo-polycin hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> (neomycin-bacitracin-poly-hc) | 2 | |
| <i>neo-polycin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> (neomycin-bacitracin-polymyxin) | 2 | |
| <i>ofloxacin ophthalmic (eye) drops 0.3 %</i> (Ocuflox) | 2 | |
| <i>ofloxacin otic (ear) drops 0.3 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>polycin ophthalmic (eye) ointment</i> (bacitracin-polymyxin b) 500-10,000 unit/gram | 2 | |
| <i>polymyxin b sulf-trimethoprim ophthalmic (eye) drops</i> 10,000 unit- 1 mg/ml | 1 | |
| <i>sulfacetamide sodium ophthalmic (eye) drops</i> 10 % | 2 | |
| <i>sulfacetamide sodium ophthalmic (eye) ointment</i> 10 % | 2 | |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops</i> 10 %-0.23 % (0.25 %) | 2 | |
| <i>tobramycin ophthalmic (eye) drops</i> 0.3 % | 1 | |
| <i>tobramycin-dexamethasone ophthalmic (eye) drops,suspension</i> 0.3-0.1 % | 2 | |
| <i>trifluridine ophthalmic (eye) drops</i> 1 % | 4 | |
| XDEMVY OPHTHALMIC (EYE) DROPS 0.25 % | 5 | PA; NDS; QL (10 per 42 days) |
| ZIRGAN OPHTHALMIC (EYE) GEL 0.15 % | 4 | |
| ZYLET OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3-0.5 % (tobramycin-lotepred) | 3 | |
| Eye, Ear, Nose, Throat Anti-Inflammatory Agents | | |
| <i>bromfenac ophthalmic (eye) drops</i> (Prolensa) 0.07 % | 3 | |
| <i>bromfenac ophthalmic (eye) drops</i> (BromSite) 0.075 % | 3 | |
| <i>bromfenac ophthalmic (eye) drops</i> 0.09 % | 4 | |
| <i>cyclosporine ophthalmic (eye) dropperette</i> 0.05 % (Restasis) | 3 | QL (60 per 30 days) |
| <i>dexamethasone sodium phosphate ophthalmic (eye) drops</i> 0.1 % | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>diclofenac sodium ophthalmic (eye) drops 0.1 %</i> | 2 | |
| <i>difluprednate ophthalmic (eye) drops 0.05 %</i> (Durezol) | 4 | |
| EYSUVIS OPHTHALMIC (EYE) DROPS,SUSPENSION 0.25 % | 3 | QL (8.3 per 14 days) |
| <i>flunisolide nasal spray,non-aerosol 25 mcg (0.025 %)</i> | 4 | QL (50 per 25 days) |
| <i>fluocinolone acetonide oil otic (ear) drops 0.01 %</i> (DermOtic Oil) | 2 | |
| <i>fluorometholone ophthalmic (eye) drops,suspension 0.1 %</i> (FML Liquifilm) | 2 | |
| <i>flurbiprofen sodium ophthalmic (eye) drops 0.03 %</i> | 2 | |
| <i>fluticasone propionate nasal spray,suspension 50 mcg/actuation</i> (24 Hour Allergy Relief) | 1 | QL (16 per 30 days) |
| ILEVRO OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3 % | 3 | |
| INVELTYS OPHTHALMIC (EYE) DROPS,SUSPENSION 1 % | 3 | QL (5.6 per 14 days) |
| <i>ketorolac ophthalmic (eye) drops 0.5 %</i> (Acular) | 2 | QL (10 per 25 days) |
| LOTEMAX OPHTHALMIC (EYE) OINTMENT 0.5 % | 3 | QL (3.5 per 14 days) |
| LOTEMAX SM OPHTHALMIC (EYE) DROPS,GEL 0.38 % | 3 | QL (5 per 16 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,gel 0.5 %</i> (Lotemax) | 4 | QL (10 per 14 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.2 %</i> (Alrex) | 3 | ST |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.5 %</i> | 4 | QL (15 per 19 days) |
| <i>mometasone nasal spray,non-aerosol 50 mcg/actuation</i> (Allergy Nasal (mometasone)) | 4 | QL (34 per 30 days) |
| <i>prednisolone acetate ophthalmic (eye) drops,suspension 1 %</i> (Pred Forte) | 4 | |
| <i>prednisolone sodium phosphate ophthalmic (eye) drops 1 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------|
| XIIDRA OPHTHALMIC (EYE) DROPPERETTE 5 % | 3 | QL (60 per 30 days) |
| Gastrointestinal Agents | | |
| Antiulcer Agents And Acid Suppressants | | |
| <i>amoxicil-clarithromy-lansopraz oral combo pack 500-500-30 mg</i> | 4 | |
| <i>cimetidine hcl oral solution 300 mg/5 ml</i> | 2 | |
| <i>cimetidine oral tablet 200 mg</i> (Acid Reducer (cimetidine)) | 2 | |
| <i>cimetidine oral tablet 300 mg, 400 mg, 800 mg</i> | 2 | |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec) 20 mg</i> (Acid Reducer (esomeprazole)) | 2 | QL (30 per 30 days) |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec) 40 mg</i> (Nexium) | 2 | QL (60 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 10 mg, 20 mg</i> (Nexium Packet) | 4 | ST; QL (30 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 40 mg</i> (Nexium Packet) | 4 | ST; QL (60 per 30 days) |
| <i>famotidine oral suspension for reconstitution 40 mg/5 ml (8 mg/ml)</i> | 4 | |
| <i>famotidine oral tablet 20 mg</i> (Acid Controller) | 1 | |
| <i>famotidine oral tablet 40 mg</i> (Pepcid) | 1 | |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 15 mg</i> (Acid Reducer (lansoprazole)) | 2 | QL (30 per 30 days) |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 30 mg</i> (Prevacid) | 2 | QL (60 per 30 days) |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> (Cytotec) | 2 | |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | 2 | |
| <i>omeprazole oral capsule, delayed release(dr/ec) 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>omeprazole-sodium bicarbonate oral capsule 20-1.1 mg-gram</i> (Zegerid OTC) | 5 | ST; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>omeprazole-sodium bicarbonate oral capsule 40-1.1 mg-gram</i> | 4 | ST; QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 20 mg</i> (Protonix) | 1 | QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 40 mg</i> (Protonix) | 1 | QL (60 per 30 days) |
| <i>rabeprazole oral tablet, delayed release (dr/ec) 20 mg</i> (AcipHex) | 2 | QL (30 per 30 days) |
| <i>sucralfate oral tablet 1 gram</i> (Carafate) | 2 | |
| VOQUEZNA ORAL TABLET 10 MG, 20 MG | 4 | PA |
| Gastrointestinal Agents, Other | | |
| <i>carglumic acid oral tablet, dispersible 200 mg</i> (Carbaglu) | 5 | PA; NDS |
| <i>constulose oral solution 10 gram/15 ml</i> (lactulose) | 2 | |
| <i>cromolyn oral concentrate 100 mg/5 ml</i> (Gastrocrom) | 3 | |
| <i>dicyclomine oral capsule 10 mg</i> | 2 | |
| <i>dicyclomine oral solution 10 mg/5 ml</i> | 2 | |
| <i>dicyclomine oral tablet 20 mg</i> | 2 | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml</i> | 4 | PA; AGE (Max 64 Years) |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> (Lomotil) | 2 | PA; AGE (Max 64 Years) |
| <i>enulose oral solution 10 gram/15 ml</i> (lactulose) | 2 | |
| GATTEX 30-VIAL SUBCUTANEOUS KIT 5 MG | 5 | PA; NDS |
| <i>generlac oral solution 10 gram/15 ml</i> (lactulose) | 2 | |
| <i>glycerol phenylbutyrate oral liquid 1.1 gram/ml</i> (Ravicti) | 5 | PA; NDS |
| <i>glycopyrrolate oral tablet 1 mg</i> (Robinul) | 2 | |
| <i>glycopyrrolate oral tablet 2 mg</i> (Robinul Forte) | 2 | |
| IQIRVO ORAL TABLET 80 MG | 5 | PA; NDS; QL (30 per 30 days) |
| <i>kionex (with sorbitol) oral suspension 15-20 gram/60 ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>lactulose oral solution 10 gram/15 ml</i> (Constulose) | 2 | |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 3 | QL (30 per 30 days) |
| LIVDELZI ORAL CAPSULE 10 MG | 5 | PA; NDS; QL (30 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 10 GRAM, 5 GRAM | 3 | |
| <i>loperamide oral capsule 2 mg</i> (Anti-Diarrheal (loperamide)) | 2 | |
| <i>lubiprostone oral capsule 24 mcg</i> (Amitiza) | 2 | QL (60 per 30 days) |
| <i>lubiprostone oral capsule 8 mcg</i> (Amitiza) | 2 | QL (120 per 30 days) |
| <i>methscopolamine oral tablet 2.5 mg, 5 mg</i> | 4 | |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i> | 2 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> (Reglan) | 1 | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 3 | QL (30 per 30 days) |
| OCALIVA ORAL TABLET 10 MG, 5 MG | 5 | PA; NDS; QL (30 per 30 days) |
| RELISTOR ORAL TABLET 150 MG | 5 | PA; NDS; QL (90 per 30 days) |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6 ML | 5 | PA; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML | 5 | PA; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 8 MG/0.4 ML | 5 | PA; NDS; QL (11.2 per 28 days) |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> (Buphenyl) | 5 | PA; NDS |
| <i>sodium polystyrene sulfonate oral powder 15 gram</i> | 2 | |
| <i>sodium polystyrene sulfonate oral suspension 15 gram/60 ml</i> | 2 | |
| <i>sps (with sorbitol) oral suspension 15-20 gram/60 ml</i> | 2 | |
| TRULANCE ORAL TABLET 3 MG | 3 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>ursodiol oral capsule 200 mg, 400 mg</i> (Reltone) | 5 | NDS |
| <i>ursodiol oral capsule 300 mg</i> | 2 | |
| <i>ursodiol oral tablet 250 mg</i> | 2 | |
| <i>ursodiol oral tablet 500 mg</i> (URSO Forte) | 2 | |
| VELTASSA ORAL POWDER IN PACKET 1 GRAM, 16.8 GRAM, 25.2 GRAM, 8.4 GRAM | 3 | |
| XERMELO ORAL TABLET 250 MG | 5 | PA; NDS; QL (84 per 28 days) |
| Laxatives | | |
| <i>gavilyte-c oral recon soln 240-22.72-6.72 -5.84 gram</i> (peg 3350-electrolytes) | 2 | |
| <i>gavilyte-g oral recon soln 236-22.74-6.74 -5.86 gram</i> (peg 3350-electrolytes) | 2 | |
| <i>gavilyte-n oral recon soln 420 gram</i> (peg-electrolyte soln) | 2 | |
| <i>peg 3350-electrolytes oral recon soln 236-22.74-6.74 -5.86 gram</i> (GaviLyte-G) | 2 | |
| <i>peg-electrolyte soln oral recon soln 420 gram</i> (GaviLyte-N) | 2 | |
| <i>sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram</i> (Suprep Bowel Prep Kit) | 2 | |
| <i>sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram 2 pack (480ml)</i> | 2 | |
| Phosphate Binders | | |
| <i>calcium acetate(phosphat bind) oral capsule 667 mg</i> | 2 | |
| <i>calcium acetate(phosphat bind) oral tablet 667 mg</i> | 2 | |
| <i>lanthanum oral tablet,chewable 1,000 mg, 500 mg, 750 mg</i> (Fosrenol) | 5 | NDS |
| <i>sevelamer carbonate oral powder in packet 0.8 gram, 2.4 gram</i> (Renvela) | 3 | |
| <i>sevelamer carbonate oral tablet 800 mg</i> (Renvela) | 2 | |
| <i>sevelamer hcl oral tablet 400 mg, 800 mg</i> | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Genitourinary Agents | | |
| Antispasmodics, Urinary | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>fesoterodine oral tablet extended release 24 hr 4 mg</i> (Toviaz) | 4 | |
| <i>fesoterodine oral tablet extended release 24 hr 8 mg</i> (Toviaz) | 2 | |
| <i>flavoxate oral tablet 100 mg</i> | 2 | |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR 25 MG, 50 MG (mirabegron) | 2 | |
| <i>oxybutynin chloride oral syrup 5 mg/5 ml</i> | 2 | |
| <i>oxybutynin chloride oral tablet 2.5 mg</i> | 4 | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 2 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 15 mg, 5 mg</i> | 2 | |
| <i>solifenacin oral tablet 10 mg, 5 mg</i> (Vesicare) | 2 | |
| <i>tolterodine oral capsule, extended release 24hr 2 mg, 4 mg</i> | 2 | |
| <i>tolterodine oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>trospium oral capsule, extended release 24hr 60 mg</i> | 4 | |
| <i>trospium oral tablet 20 mg</i> | 2 | |
| Genitourinary Agents, Miscellaneous | | |
| <i>alfuzosin oral tablet extended release 24 hr 10 mg</i> (Uroxatral) | 2 | QL (30 per 30 days) |
| <i>dutasteride oral capsule 0.5 mg</i> (Avodart) | 2 | |
| <i>dutasteride-tamsulosin oral capsule, er multiphase 24 hr 0.5-0.4 mg</i> (Jalyn) | 4 | |
| <i>finasteride oral tablet 5 mg</i> (Proscar) | 1 | |
| <i>tamsulosin oral capsule 0.4 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |
| <i>tiopronin oral tablet 100 mg</i> (Thiola) | 5 | NDS |
| Heavy Metal Antagonists | | |
| Heavy Metal Antagonists | | |
| <i>deferasirox oral granules in packet 180 mg, 360 mg, 90 mg</i> (Jadenu Sprinkle) | 5 | PA; NDS |
| <i>deferasirox oral tablet 180 mg, 360 mg, 90 mg</i> (Jadenu) | 2 | PA |
| <i>deferasirox oral tablet, dispersible 125 mg</i> (Exjade) | 3 | PA |
| <i>deferasirox oral tablet, dispersible 250 mg, 500 mg</i> (Exjade) | 5 | PA; NDS |
| <i>deferiprone oral tablet 1,000 mg, 500 mg</i> (Ferriprox) | 5 | PA; NDS |
| FERRIPROX ORAL SOLUTION 100 MG/ML | 5 | PA; NDS |
| <i>penicillamine oral tablet 250 mg</i> (Depen Titratabs) | 5 | PA; NDS |
| <i>trientine oral capsule 250 mg</i> (Syprine) | 5 | PA; NDS; QL (240 per 30 days) |
| Hormonal Agents, Stimulant/Replacement/Modifying | | |
| Androgens | | |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 3 | |
| <i>oxandrolone oral tablet 10 mg, 2.5 mg</i> | 3 | PA |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml</i> (Depo-Testosterone) | 2 | PA |
| <i>testosterone cypionate intramuscular oil 200 mg/ml (1 ml)</i> | 2 | PA |
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i> | 2 | PA; QL (5 per 28 days) |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)</i> (Vogelxo) | 4 | PA; QL (300 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i> (AndroGel) | 4 | PA; QL (150 per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram)</i> | 4 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (50 mg/5 gram)</i> (Vogelxo) | 4 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal solution in metered pump w/app 30 mg/actuation (1.5 ml)</i> | 4 | PA; QL (180 per 30 days) |
| Estrogens And Antiestrogens | | |
| <i>abigale lo oral tablet 0.5-0.1 mg</i> (estradiol-norethindrone acet) | 1 | |
| <i>abigale oral tablet 1-0.5 mg</i> (estradiol-norethindrone acet) | 2 | PA; AGE (Max 64 Years) |
| <i>amabelz oral tablet 0.5-0.1 mg, 1-0.5 mg</i> (estradiol-norethindrone acet) | 2 | PA; AGE (Max 64 Years) |
| <i>conjugated estrogens oral tablet 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg</i> (Premarin) | 2 | |
| <i>dotti transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (estradiol) | 2 | QL (8 per 28 days) |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (Dotti) | 2 | QL (8 per 28 days) |
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (Climara) | 2 | QL (4 per 28 days) |
| <i>estradiol vaginal cream 0.01 % (0.1 mg/gram)</i> (Estrace) | 2 | |
| <i>estradiol vaginal tablet 10 mcg</i> (Yuvafem) | 4 | QL (18 per 28 days) |
| <i>estradiol valerate intramuscular oil 10 mg/ml, 20 mg/ml</i> (Delestrogen) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>estradiol valerate intramuscular oil</i> 40 mg/ml | 4 | |
| <i>estradiol-norethindrone acet oral</i> <i>tablet 0.5-0.1 mg</i> (Abigale Lo) | 2 | PA; AGE (Max 64 Years) |
| <i>estradiol-norethindrone acet oral</i> <i>tablet 1-0.5 mg</i> (Abigale) | 2 | PA; AGE (Max 64 Years) |
| FEMRING VAGINAL RING 0.05 MG/24 HR, 0.1 MG/24 HR | 4 | QL (1 per 84 days) |
| <i>fyavolv oral tablet 0.5-2.5 mg-mcg,</i> <i>1-5 mg-mcg</i> (norethindrone ac-eth estradiol) | 2 | PA; AGE (Max 64 Years) |
| <i>jinteli oral tablet 1-5 mg-mcg</i> (norethindrone ac-eth estradiol) | 2 | PA; AGE (Max 64 Years) |
| <i>lyllana transdermal patch</i> <i>semiweekly 0.025 mg/24 hr, 0.0375</i> <i>mg/24 hr, 0.05 mg/24 hr, 0.075</i> <i>mg/24 hr, 0.1 mg/24 hr</i> (estradiol) | 2 | QL (8 per 28 days) |
| <i>mimvey oral tablet 1-0.5 mg</i> (estradiol-norethindrone acet) | 2 | PA; AGE (Max 64 Years) |
| <i>norethindrone ac-eth estradiol oral</i> <i>tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> (Fyavolv) | 2 | PA; AGE (Max 64 Years) |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM | 3 | |
| PREMPHASE ORAL TABLET 0.625 MG (14)/ 0.625MG-5MG(14) | 3 | PA; AGE (Max 64 Years) |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 3 | PA; AGE (Max 64 Years) |
| <i>raloxifene oral tablet 60 mg</i> (Evista) | 2 | |
| <i>yuvafem vaginal tablet 10 mcg</i> (estradiol) | 4 | QL (18 per 28 days) |
| Glucocorticoids/Mineralocorticoids | | |
| <i>dexamethasone oral solution 0.5</i> <i>mg/5 ml</i> | 2 | |
| <i>dexamethasone oral tablet 0.5 mg,</i> <i>0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6</i> <i>mg</i> | 2 | |
| <i>dexamethasone sodium phosphate</i> <i>injection solution 10 mg/ml, 4 mg/ml</i> | 1 | |
| <i>fludrocortisone oral tablet 0.1 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| HEMADY ORAL TABLET 20 MG | 4 | |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> (Cortef) | 2 | |
| <i>methylprednisolone acetate injection suspension 40 mg/ml</i> (Depo-Medrol) | 2 | |
| <i>methylprednisolone oral tablet 16 mg, 4 mg, 8 mg</i> (Medrol) | 2 | |
| <i>methylprednisolone oral tablet 32 mg</i> | 2 | |
| <i>methylprednisolone oral tablets, dose pack 4 mg</i> (Medrol (Pak)) | 1 | |
| <i>prednisolone 15 mg/5 ml soln d/f 15 mg/5 ml (3 mg/ml)</i> | 2 | PA BvD |
| <i>prednisolone oral solution 15 mg/5 ml</i> | 2 | PA BvD |
| <i>prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | 2 | PA BvD |
| <i>prednisone oral solution 5 mg/5 ml</i> | 2 | PA BvD |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | PA BvD |
| <i>prednisone oral tablets, dose pack 10 mg, 10 mg (48 pack), 5 mg, 5 mg (48 pack)</i> | 2 | |
| <i>triamcinolone acetonide injection suspension 40 mg/ml</i> (Kenalog) | 2 | |
| Pituitary | | |
| CORTROPHIN GEL INJECTION GEL 80 UNIT/ML | 5 | PA; NDS; QL (35 per 28 days) |
| CORTROPHIN GEL SUBCUTANEOUS SYRINGE 40 UNIT/0.5 ML | 5 | PA; NDS; QL (15 per 30 days) |
| CORTROPHIN GEL SUBCUTANEOUS SYRINGE 80 UNIT/ML | 5 | PA; NDS; QL (30 per 30 days) |
| <i>desmopressin 10 mcg/0.1 ml spr 10 mcg/spray (0.1 ml)</i> | 3 | |
| <i>desmopressin nasal spray, non-aerosol 10 mcg/spray (0.1 ml)</i> | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg</i> (DDAVP) | 2 | |
| EGRIFTA SV SUBCUTANEOUS RECON SOLN 2 MG | 5 | PA; NDS; QL (30 per 30 days) |
| EGRIFTA WR SUBCUTANEOUS KIT 11.6 MG | 5 | PA; NDS; QL (4 per 28 days) |
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML | 5 | PA; NDS |
| <i>lanreotide subcutaneous syringe 120 mg/0.5 ml</i> (Somatuline Depot) | 5 | PA NSO; NDS; QL (0.5 per 28 days) |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG, 30 MG | 5 | PA; NDS |
| LUPRON DEPOT-PED INTRAMUSCULAR KIT 11.25 MG, 15 MG, 7.5 MG (PED) | 5 | PA; NDS |
| LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT 45 MG | 5 | PA; NDS |
| NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) | 5 | PA; NDS |
| <i>octreotide acetate injection solution 1,000 mcg/ml</i> | 5 | NDS |
| <i>octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml, 500 mcg/ml</i> (Sandostatin) | 4 | |
| <i>octreotide acetate injection solution 200 mcg/ml</i> | 4 | |
| ORGOVYX ORAL TABLET 120 MG | 5 | PA NSO; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| ORILISSA ORAL TABLET 150 MG | 5 | PA; NDS; QL (28 per 28 days) |
| ORILISSA ORAL TABLET 200 MG | 5 | PA; NDS; QL (56 per 28 days) |
| SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG | 5 | PA; NDS |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) | 5 | PA; NDS; QL (60 per 30 days) |
| SOMATULINE DEPOT (lanreotide) SUBCUTANEOUS SYRINGE 60 MG/0.2 ML | 5 | PA NSO; NDS; QL (0.2 per 28 days) |
| SOMATULINE DEPOT (lanreotide) SUBCUTANEOUS SYRINGE 90 MG/0.3 ML | 5 | PA NSO; NDS; QL (0.3 per 28 days) |
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NDS |
| SYNAREL NASAL SPRAY, NON-AEROSOL 2 MG/ML | 5 | PA; NDS |
| Progestins | | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SYRINGE 104 MG/0.65 ML | 3 | QL (0.65 per 84 days) |
| <i>gallifrey oral tablet 5 mg</i> (norethindrone acetate) | 2 | |
| <i>medroxyprogesterone intramuscular suspension 150 mg/ml</i> (Depo-Provera) | 2 | |
| <i>medroxyprogesterone intramuscular syringe 150 mg/ml</i> (Depo-Provera) | 2 | |
| <i>medroxyprogesterone oral tablet 10 mg, 2.5 mg, 5 mg</i> (Provera) | 1 | |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)</i> | 3 | PA; AGE (Max 64 Years) |
| <i>norethindrone acetate oral tablet 5 mg</i> (Gallifrey) | 2 | |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> (Prometrium) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------|
| Thyroid And Antithyroid Agents | | |
| <i>levothyroxine oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg</i> (Euthyrox) | 1 | |
| <i>levothyroxine oral tablet 300 mcg</i> (Levo-T) | 1 | |
| <i>liomny oral tablet 25 mcg, 5 mcg, 50 mcg</i> (liothyronine) | 2 | |
| <i>liothyronine oral tablet 25 mcg, 5 mcg, 50 mcg</i> (Liomny) | 2 | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>propylthiouracil oral tablet 50 mg</i> | 2 | |
| REZDIFFRA ORAL TABLET 100 MG, 60 MG, 80 MG | 5 | PA; NDS |
| Immunological Agents | | |
| Immunological Agents | | |
| ARCALYST SUBCUTANEOUS RECON SOLN 220 MG | 5 | PA; NDS |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 0.5 MG, 1 MG (tacrolimus) | 4 | PA BvD |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 5 MG (tacrolimus) | 5 | PA BvD; NDS |
| <i>auranofin oral capsule 3 mg</i> (Ridaura) | 5 | NDS |
| <i>azathioprine oral tablet 50 mg</i> (Imuran) | 2 | PA BvD |
| <i>azathioprine sodium injection recon soln 100 mg</i> | 2 | PA BvD |
| BENLYSTA SUBCUTANEOUS AUTO-INJECTOR 200 MG/ML | 5 | PA; NDS; QL (8 per 28 days) |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML | 5 | PA; NDS; QL (8 per 28 days) |
| BESREMI SUBCUTANEOUS SYRINGE 500 MCG/ML | 5 | PA NSO; NDS; QL (2 per 28 days) |
| CIMZIA 200 MG/ML SYRINGE KIT | 5 | PA; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| CIMZIA POWDER FOR RECONST SUBCUTANEOUS KIT 400 MG (200 MG X 2 VIALS) | 5 | PA; NDS |
| CIMZIA STARTER KIT SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) | 5 | PA; NDS |
| CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) | 5 | PA; NDS |
| COSENTYX (2 SYRINGES) SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NDS |
| COSENTYX PEN (2 PENS) SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5 | PA; NDS |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | 5 | PA; NDS |
| COSENTYX UNOREADY PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML | 5 | PA; NDS |
| <i>cyclosporine intravenous solution</i> (Sandimmune) <i>250 mg/5 ml</i> | 2 | PA BvD |
| <i>cyclosporine modified oral capsule</i> (Gengraf) <i>100 mg, 25 mg</i> | 2 | PA BvD |
| <i>cyclosporine modified oral capsule</i> <i>50 mg</i> | 2 | PA BvD |
| <i>cyclosporine modified oral solution</i> (Gengraf) <i>100 mg/ml</i> | 3 | PA BvD |
| <i>cyclosporine oral capsule 100 mg, 25</i> (Sandimmune) <i>mg</i> | 3 | PA BvD |
| CYLTEZO(CF) PEN CROHN'S-UC- (adalimumab-adbm) HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML | 5 | PA; NDS |
| CYLTEZO(CF) PEN PSORIASIS- (adalimumab-adbm) UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML | 5 | PA; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| CYLTEZO(CF) PEN (adalimumab-adbm) SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML | 5 | PA; NDS |
| CYLTEZO(CF) SUBCUTANEOUS (adalimumab-adbm) SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML | 5 | PA; NDS |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML | 5 | PA; NDS |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML | 5 | PA; NDS |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) | 5 | PA; NDS |
| ENBREL SUBCUTANEOUS RECON SOLN 25 MG (1 ML) | 5 | PA; NDS |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML | 5 | PA; NDS |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) | 5 | PA; NDS |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) | 5 | PA; NDS |
| <i>everolimus (immunosuppressive) oral (Zortress)</i> <i>tablet 0.25 mg</i> | 3 | PA BvD |
| <i>everolimus (immunosuppressive) oral (Zortress)</i> <i>tablet 0.5 mg, 0.75 mg, 1 mg</i> | 5 | PA BvD; NDS |
| GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RECON SOLN 10 GRAM, 5 GRAM | 5 | PA BvD; NDS |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 %, 10 % (100 ML), 10 % (200 ML) | 5 | PA BvD; NDS |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %) | 5 | PA BvD; NDS |
| <i>gengraf oral capsule 100 mg, 25 mg</i> (cyclosporine modified) | 2 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---|
| <i>gengraf oral solution 100 mg/ml</i> (cyclosporine modified) | 3 | PA BvD |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA PEN PSOR-UVEITS- ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN CROHNS-UC- HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN PEDIATRIC UC SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN PSOR-UV- ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| <i>infliximab intravenous recon soln</i> (Remicade) <i>100 mg</i> | 5 | PA; NDS |
| KINERET SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | 5 | PA; NDS |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> (Arava) | 2 | |
| <i>mycophenolate mofetil (hcl)</i> (CellCept Intravenous) <i>intravenous recon soln 500 mg</i> | 2 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>mycophenolate mofetil oral capsule 250 mg</i> (CellCept) | 2 | PA BvD |
| <i>mycophenolate mofetil oral suspension for reconstitution 200 mg/ml</i> (CellCept) | 5 | PA BvD; NDS |
| <i>mycophenolate mofetil oral tablet 500 mg</i> (CellCept) | 2 | PA BvD |
| <i>mycophenolate sodium oral tablet, delayed release (dr/ec) 180 mg, 360 mg</i> (Myfortic) | 4 | PA BvD |
| NIKTIMVO INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NDS |
| NULOJIX INTRAVENOUS RECON SOLN 250 MG | 5 | PA BvD; NDS |
| ORENCIA (WITH MALTOSE) INTRAVENOUS RECON SOLN 250 MG | 5 | PA; NDS |
| ORENCIA CLICKJECT SUBCUTANEOUS AUTO-INJECTOR 125 MG/ML | 5 | PA; NDS |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML | 5 | PA; NDS |
| OTEZLA ORAL TABLET 20 MG, 30 MG | 5 | PA; NDS |
| OTEZLA STARTER ORAL TABLETS, DOSE PACK 10 MG (4)-20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47), 10 MG (4)-20 MG (4)-30 MG(19) | 5 | PA; NDS |
| OTEZLA XR INITIATION ORAL TABLET AND TABLET ER DOSE PACK 10-20-30-75 MG | 5 | PA; NDS |
| OTEZLA XR ORAL TABLET EXTENDED RELEASE 24 HR 75 MG | 5 | PA; NDS |
| PROGRAF INTRAVENOUS SOLUTION 5 MG/ML (tacrolimus) | 4 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG | 4 | PA BvD |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML | 4 | ST |
| REZUROCK ORAL TABLET 200 MG | 5 | PA NSO; NDS |
| RIDAURA ORAL CAPSULE 3 MG (auranofin) | 5 | NDS |
| RINVOQ LQ ORAL SOLUTION 1 MG/ML | 5 | PA; NDS; QL (360 per 30 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG | 5 | PA; NDS |
| SELARSDI INTRAVENOUS SOLUTION 130 MG/26 ML | 5 | PA; NDS |
| SELARSDI SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 3 | PA |
| SELARSDI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML (ustekinumab-aekn) | 3 | PA |
| SELARSDI SUBCUTANEOUS SYRINGE 90 MG/ML (ustekinumab-aekn) | 5 | PA; NDS |
| <i>sirolimus oral solution 1 mg/ml</i> | 3 | PA BvD |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | 3 | PA BvD |
| SKYRIZI INTRAVENOUS SOLUTION 60 MG/ML | 5 | PA; NDS |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5 | PA; NDS |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NDS |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) | 5 | PA; NDS |
| STELARA INTRAVENOUS SOLUTION 130 MG/26 ML (ustekinumab) | 5 | PA; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML (ustekinumab) | 5 | PA; NDS |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML (ustekinumab) | 5 | PA; NDS |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> (Prograf) | 3 | PA BvD |
| TAVNEOS ORAL CAPSULE 10 MG | 5 | PA; NDS; QL (180 per 30 days) |
| TREMFYA INTRAVENOUS SOLUTION 200 MG/20 ML (10 MG/ML) | 5 | PA; NDS |
| TREMFYA ONE-PRESS SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; NDS |
| TREMFYA PEN INDUCTION PK(2PEN) SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML | 5 | PA; NDS |
| TREMFYA PEN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML | 5 | PA; NDS |
| TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML, 200 MG/2 ML | 5 | PA; NDS |
| TYENNE AUTOINJECTOR SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML | 5 | PA; NDS |
| TYENNE INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) | 5 | PA; NDS |
| TYENNE SUBCUTANEOUS SYRINGE 162 MG/0.9 ML | 5 | PA; NDS |
| <i>ustekinumab intravenous solution 130 mg/26 ml</i> (Stelara) | 5 | PA; NDS |
| <i>ustekinumab subcutaneous solution 45 mg/0.5 ml</i> (Stelara) | 5 | PA; NDS |
| <i>ustekinumab subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml</i> (Stelara) | 5 | PA; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| XELJANZ ORAL SOLUTION 1 MG/ML | 5 | PA; NDS |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 5 | PA; NDS |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG | 5 | PA; NDS |
| YESINTEK INTRAVENOUS SOLUTION 130 MG/26 ML | 5 | PA; NDS |
| YESINTEK SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 3 | PA |
| YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML | 3 | PA |
| YESINTEK SUBCUTANEOUS SYRINGE 90 MG/ML | 5 | PA; NDS |
| YUFLYMA(CF) AI CROHN'S-UC- (adalimumab-aaty) HS SUBCUTANEOUS AUTO-INJECTOR, KIT 80 MG/0.8 ML | 5 | PA; NDS |
| YUFLYMA(CF) AUTOINJECTOR (adalimumab-aaty) SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML | 5 | PA; NDS |
| YUFLYMA(CF) SUBCUTANEOUS (adalimumab-aaty) SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML | 5 | PA; NDS |
| Vaccines | | |
| ABRYSVO (PF) INTRAMUSCULAR RECON SOLN 120 MCG/0.5 ML | 3 | \$0 copay |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 3 | |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 3 | \$0 copay |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 3 | \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| AREXVY (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 120 MCG/0.5 ML | 3 | \$0 copay |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG | 3 | \$0 copay |
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 3 | \$0 copay |
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG-LF/0.5ML | 3 | \$0 copay |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5-8-5 LF-MCG-LF/0.5ML | 3 | \$0 copay |
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG-LF/0.5ML | 3 | |
| DENGVAXIA (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP4.5-6 CCID50/0.5 ML | 3 | QL (3 per 365 days) |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML | 3 | PA BvD; \$0 copay |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML | 3 | PA BvD; \$0 copay |
| ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML | 3 | \$0 copay |
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML | 3 | \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML | 3 | \$0 copay |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT/0.5 ML | 3 | |
| HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| HIBERIX (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 3 | |
| IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT | 3 | PA BvD; \$0 copay |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE 25-58-10 LF-MCG-LF/0.5ML | 3 | |
| IPOL INJECTION SUSPENSION 40-8-32 UNIT/0.5 ML | 3 | \$0 copay |
| IXIARO (PF) INTRAMUSCULAR SYRINGE 6 MCG/0.5 ML | 3 | \$0 copay |
| JYNNEOS (PF) SUBCUTANEOUS SUSPENSION 0.5X TO 3.95X 10EXP8 UNIT/0.5 | 3 | \$0 copay |
| KINRIX (PF) INTRAMUSCULAR SYRINGE 25 LF-58 MCG-10 LF/0.5 ML | 3 | |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION 4 MCG/0.5 ML | 3 | \$0 copay |
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML | 3 | \$0 copay |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML | 3 | \$0 copay |
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML | 3 | \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| MRESVIA (PF) INTRAMUSCULAR SYRINGE 50 MCG/0.5 ML | 3 | \$0 copay |
| PEDIARIX (PF) INTRAMUSCULAR SYRINGE 10 MCG-25LF-25 MCG-10LF/0.5 ML | 3 | |
| PEDVAX HIB (PF) INTRAMUSCULAR SOLUTION 7.5 MCG/0.5 ML | 3 | |
| PENBRAYA (PF) INTRAMUSCULAR KIT 5-120 MCG/0.5 ML | 3 | \$0 copay |
| PENBRAYA MENACWY COMPONENT(PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 5 MCG/0.5 ML | 3 | \$0 copay |
| PENBRAYA MENB COMPONENT (PF) INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 3 | \$0 copay |
| PENMENVY MEN A-B-C-W-Y (PF) INTRAMUSCULAR KIT 0.5 ML | 3 | \$0 copay |
| PENMENVY MENACWY COMPONENT(PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 10-5 MCG | 3 | \$0 copay |
| PENMENVY MENB COMPONENT (PF) INTRAMUSCULAR SYRINGE 50- 50-50-25 MCG/0.5 ML | 3 | \$0 copay |
| PENTACEL (PF) INTRAMUSCULAR KIT 15LF- 20MCG-5LF- 62 DU/0.5 ML | 3 | |
| PRIORIX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3.4-4.2- 3.3CCID50/0.5ML | 3 | \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| PROQUAD (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3-4.3-3-3.99 TCID50/0.5 | 3 | |
| QUADRACEL (PF) INTRAMUSCULAR SUSPENSION 15 LF-48 MCG- 5 LF UNIT/0.5ML | 3 | |
| QUADRACEL (PF) INTRAMUSCULAR SYRINGE 15 LF-48 MCG- 5 LF UNIT/0.5ML | 3 | |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT | 3 | PA BvD; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| ROTARIX ORAL SUSPENSION 10EXP6 CCID50 /1.5 ML | 3 | |
| ROTARIX ORAL SUSPENSION FOR RECONSTITUTION 10EXP6 CCID50/ML | 3 | |
| ROTATEQ VACCINE ORAL SOLUTION 2 ML | 3 | |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 50 MCG/0.5 ML | 3 | \$0 copay; QL (2 per 365 days) |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF UNIT/0.5 ML | 3 | \$0 copay |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML | 3 | \$0 copay |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML | 3 | \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits | |
|--|-----------------------------------|----------------------------|-----------|
| TICOVAC INTRAMUSCULAR SYRINGE 1.2 MCG/0.25 ML | 3 | | |
| TICOVAC INTRAMUSCULAR SYRINGE 2.4 MCG/0.5 ML | 3 | \$0 copay | |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 3 | \$0 copay | |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML | 3 | \$0 copay | |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5 ML | 3 | \$0 copay | |
| TYPHIM VI INTRAMUSCULAR SYRINGE 25 MCG/0.5 ML | (typhoid vi polysacch vaccine) | 3 | \$0 copay |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML | 3 | | |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 50 UNIT/ML | 3 | \$0 copay | |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML | 3 | | |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 50 UNIT/ML | 3 | \$0 copay | |
| VARIVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 1,350 UNIT/0.5 ML | 3 | \$0 copay | |
| VAXCHORA VACCINE ORAL SUSPENSION FOR RECONSTITUTION 4X10EXP8 TO 2X 10EXP9 CF UNIT | 3 | \$0 copay | |
| VIMKUNYA INTRAMUSCULAR SYRINGE 40 MCG/0.8 ML | 3 | \$0 copay | |
| VIVOTIF ORAL CAPSULE,DELAYED RELEASE(DR/EC) 2 BILLION UNIT | 3 | \$0 copay | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------|
| YF-VAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10 EXP4.74 UNIT/0.5 ML, 10 EXP4.74 UNIT/0.5 ML(2.5 ML IN 1 VIAL) | 3 | \$0 copay |
| Inflammatory Bowel Disease Agents | | |
| Inflammatory Bowel Disease Agents | | |
| <i>alose tron oral tablet 0.5 mg</i> (Lotronex) | 3 | |
| <i>alose tron oral tablet 1 mg</i> (Lotronex) | 5 | NDS |
| <i>balsalazide oral capsule 750 mg</i> (Colazal) | 2 | |
| <i>budesonide oral capsule, delayed, extend. release 3 mg</i> | 4 | |
| <i>budesonide rectal foam 2 mg/actuation</i> (Uceris) | 3 | |
| DIPENTUM ORAL CAPSULE 250 MG | 5 | ST; NDS |
| <i>hydrocortisone rectal enema 100 mg/60 ml</i> (Cortenema) | 3 | |
| <i>mesalamine oral capsule (with del rel tablets) 400 mg</i> | 4 | |
| <i>mesalamine oral capsule, extended release 500 mg</i> (Pentasa) | 3 | |
| <i>mesalamine oral capsule, extended release 24hr 0.375 gram</i> (Apriso) | 4 | |
| <i>mesalamine oral tablet, delayed release (dr/ec) 1.2 gram</i> (Lialda) | 4 | QL (120 per 30 days) |
| <i>mesalamine oral tablet, delayed release (dr/ec) 800 mg</i> | 4 | |
| <i>mesalamine rectal enema 4 gram/60 ml</i> (Rowasa) | 3 | |
| <i>mesalamine rectal suppository 1,000 mg</i> (Canasa) | 3 | |
| <i>sulfasalazine oral tablet 500 mg</i> (Azulfidine) | 2 | |
| <i>sulfasalazine oral tablet, delayed release (dr/ec) 500 mg</i> (Azulfidine EN-tabs) | 4 | |
| Metabolic Bone Disease Agents | | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| Metabolic Bone Disease Agents | | |
| <i>alendronate oral solution 70 mg/75 ml</i> | 4 | QL (300 per 28 days) |
| <i>alendronate oral tablet 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>alendronate oral tablet 35 mg</i> | 1 | QL (4 per 28 days) |
| <i>alendronate oral tablet 70 mg</i> (Fosamax) | 1 | QL (4 per 28 days) |
| <i>calcitonin (salmon) nasal spray, non-aerosol 200 unit/actuation</i> | 2 | |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 2 | |
| <i>calcitriol oral solution 1 mcg/ml</i> (Rocaltrol) | 4 | |
| <i>cinacalcet oral tablet 30 mg, 60 mg</i> (Sensipar) | 3 | QL (60 per 30 days) |
| <i>cinacalcet oral tablet 90 mg</i> (Sensipar) | 2 | QL (120 per 30 days) |
| <i>doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg</i> | 4 | |
| <i>ibandronate oral tablet 150 mg</i> | 2 | QL (1 per 28 days) |
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE | 5 | PA; NDS; QL (2 per 28 days) |
| OSENVELT SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | 5 | PA; NDS |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg</i> (Zemplar) | 4 | |
| <i>paricalcitol oral capsule 4 mcg</i> | 4 | |
| RAYALDEE ORAL CAPSULE, EXTENDED RELEASE 24 HR 30 MCG | 5 | NDS; QL (60 per 30 days) |
| <i>risedronate oral tablet 150 mg</i> (Actonel) | 2 | QL (1 per 28 days) |
| <i>risedronate oral tablet 30 mg, 5 mg</i> | 4 | QL (30 per 30 days) |
| <i>risedronate oral tablet 35 mg</i> (Actonel) | 2 | QL (4 per 28 days) |
| <i>risedronate oral tablet 35 mg (12 pack), 35 mg (4 pack)</i> | 2 | QL (4 per 28 days) |
| <i>risedronate oral tablet, delayed release (dr/ec) 35 mg</i> (Atelvia) | 4 | QL (4 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| STOBOCLO SUBCUTANEOUS SYRINGE 60 MG/ML | 3 | QL (1 per 180 days) |
| <i>teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)</i> (Bonsity) | 5 | PA; NDS; QL (2.24 per 28 days) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) | 5 | PA; NDS; QL (1.56 per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | 5 | PA; NDS |
| Miscellaneous Therapeutic Agents | | |
| Miscellaneous Therapeutic Agents | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML | 5 | PA; NDS |
| ANDEMBRY AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 200 MG/1.2 ML | 5 | PA; NDS |
| BAQSIMI NASAL SPRAY, NON-AEROSOL 3 MG/ACTUATION | 3 | |
| <i>betaine oral powder 1 gram/scoop</i> (Cystadane) | 5 | PA; NDS |
| <i>bupirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | |
| <i>diazoxide oral suspension 50 mg/ml</i> (Proglycem) | 5 | NDS |
| ELMIRON ORAL CAPSULE 100 MG | 4 | |
| EVRYSDI ORAL RECON SOLN 0.75 MG/ML | 5 | PA; NDS |
| EVRYSDI ORAL TABLET 5 MG | 5 | PA; NDS; QL (30 per 30 days) |
| <i>glucagon emergency kit (human) injection recon soln 1 mg</i> | 3 | |
| <i>glutamine (sickle cell) oral powder in packet 5 gram</i> (Endari) | 5 | PA; NDS; QL (180 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO- INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| GVOKE SUBCUTANEOUS SOLUTION 1 MG/0.2 ML | 3 | |
| <i>hydroxyzine pamoate oral capsule 100 mg</i> | 2 | |
| <i>hydroxyzine pamoate oral capsule 25 mg, 50 mg</i> | 1 | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 2 | |
| <i>levocarnitine (with sugar) oral solution 100 mg/ml</i> (Carnitor) | 2 | |
| <i>levocarnitine oral tablet 330 mg</i> (Carnitor) | 4 | |
| <i>mesna oral tablet 400 mg</i> (Mesnex) | 5 | NDS |
| <i>nitroglycerin rectal ointment 0.4 % (w/w)</i> (Rectiv) | 3 | QL (30 per 30 days) |
| <i>pyridostigmine bromide oral syrup 60 mg/5 ml</i> (Mestinon) | 4 | |
| <i>pyridostigmine bromide oral tablet 30 mg</i> | 4 | |
| <i>pyridostigmine bromide oral tablet 60 mg</i> (Mestinon) | 2 | |
| <i>pyridostigmine bromide oral tablet extended release 180 mg</i> (Mestinon Timespan) | 4 | |
| RIVFLOZA SUBCUTANEOUS SOLUTION 80 MG/0.5 ML (160 MG/ML) | 5 | PA; NDS |
| RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML | 5 | PA; NDS |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2 ML (150 MG/ML) | 5 | PA; NDS; QL (4 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NDS; QL (2 per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 300 MG/2 ML (150 MG/ML) | 5 | PA; NDS; QL (4 per 28 days) |
| THALOMID ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| THALOMID ORAL CAPSULE 150 MG, 200 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| THALOMID ORAL CAPSULE 50 MG | 5 | PA NSO; NDS; QL (224 per 28 days) |
| TYBOST ORAL TABLET 150 MG | 3 | QL (30 per 30 days) |
| VEOZAH ORAL TABLET 45 MG | 4 | PA; QL (30 per 30 days) |
| VOWST ORAL CAPSULE | 5 | PA; NDS; QL (12 per 30 days) |

Ophthalmic Agents

Antiglaucoma Agents

| | | |
|--|---|----------------------|
| <i>acetazolamide oral capsule, extended release 500 mg</i> | 2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 2 | |
| <i>acetazolamide sodium injection recon soln 500 mg</i> | 2 | |
| <i>betaxolol ophthalmic (eye) drops 0.5 %</i> | 4 | |
| <i>bimatoprost ophthalmic (eye) drops 0.03 %</i> | 4 | QL (2.5 per 25 days) |
| <i>brimonidine ophthalmic (eye) drops 0.1 %</i> (Alphagan P) | 4 | |
| <i>brimonidine ophthalmic (eye) drops 0.15 %</i> (Alphagan P) | 2 | |
| <i>brimonidine ophthalmic (eye) drops 0.2 %</i> | 2 | |
| <i>brimonidine-timolol ophthalmic (eye) drops 0.2-0.5 %</i> (Combigan) | 4 | |
| <i>brinzolamide ophthalmic (eye) drops, suspension 1 %</i> (Azopt) | 3 | |
| <i>carteolol ophthalmic (eye) drops 1 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|----------------------------------|----------------------------|
| <i>dorzolamide ophthalmic (eye) drops</i> 2 % | 2 | |
| <i>dorzolamide-timolol ophthalmic (eye) drops</i> (Cosopt) 22.3-6.8 mg/ml | 2 | |
| <i>latanoprost ophthalmic (eye) drops</i> (Xalatan) 0.005 % | 1 | QL (2.5 per 25 days) |
| <i>levobunolol ophthalmic (eye) drops</i> 0.5 % | 2 | |
| LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 % | 3 | QL (2.5 per 25 days) |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 4 | |
| <i>pilocarpine hcl ophthalmic (eye) drops</i> 1 %, 2 %, 4 % | 2 | |
| RHOPRESSA OPHTHALMIC (EYE) DROPS 0.02 % | 3 | QL (2.5 per 25 days) |
| ROCKLATAN OPHTHALMIC (EYE) DROPS 0.02-0.005 % | 3 | QL (2.5 per 25 days) |
| SIMBRINZA OPHTHALMIC (EYE) DROPS,SUSPENSION 1-0.2 % | 3 | |
| <i>tafluprost (pf) ophthalmic (eye) dropperette</i> 0.0015 % (Zioptan (PF)) | 4 | QL (30 per 30 days) |
| <i>timolol maleate ophthalmic (eye) drops</i> 0.25 %, 0.5 % | 1 | |
| <i>timolol maleate ophthalmic (eye) gel forming solution</i> 0.25 %, 0.5 % | 4 | |
| <i>timolol ophthalmic (eye) drops</i> 0.5 % (Betimol) | 1 | |
| <i>travoprost ophthalmic (eye) drops</i> 0.004 % (Travatan Z) | 4 | QL (2.5 per 25 days) |
| VYZULTA OPHTHALMIC (EYE) DROPS 0.024 % | 4 | QL (5 per 30 days) |
| Replacement Preparations | | |
| Replacement Preparations | | |
| <i>d5 % (d-glucose)-0.9 % sodchlr intravenous parenteral solution</i> | (d5 % and 0.9 % sodium chloride) | 2 |
| <i>d5 % and 0.9 % sodium chloride intravenous parenteral solution</i> | (D5 % (d-glucose)-0.9 % sodchlr) | 2 |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>d5 %-0.45 % sodium chloride intravenous parenteral solution</i> | 2 | |
| ISOLYTE S IV SOLUTION-EXCEL SINGLE USE | 4 | |
| ISOLYTE S PH 7.4 INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | |
| <i>klor-con m10 oral tablet,er particles/crystals 10 meq</i> (potassium chloride) | 2 | |
| <i>klor-con m15 oral tablet,er particles/crystals 15 meq</i> (potassium chloride) | 2 | |
| <i>klor-con m20 oral tablet,er particles/crystals 20 meq</i> (potassium chloride) | 2 | |
| <i>magnesium sulfate injection solution 500 mg/ml (50 %)</i> | 4 | |
| <i>magnesium sulfate injection syringe 500 mg/ml (50 %)</i> | 2 | |
| PLASMA-LYTE A INTRAVENOUS PARENTERAL SOLUTION (electrolyte-a) | 4 | |
| <i>potassium chloride intravenous solution 2 meq/ml</i> | 2 | |
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i> | 2 | |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i> | 4 | |
| <i>potassium chloride oral tablet extended release 10 meq</i> (Klor-Con 10) | 2 | |
| <i>potassium chloride oral tablet extended release 15 meq</i> | 3 | |
| <i>potassium chloride oral tablet extended release 20 meq</i> | 2 | |
| <i>potassium chloride oral tablet extended release 8 meq</i> (Klor-Con 8) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>potassium chloride oral tablet,er particles/crystals 10 meq</i> (Klor-Con M10) | 2 | |
| <i>potassium chloride oral tablet,er particles/crystals 15 meq</i> (Klor-Con M15) | 2 | |
| <i>potassium chloride oral tablet,er particles/crystals 20 meq</i> (Klor-Con M20) | 2 | |
| <i>potassium chloride-0.45 % nacl intravenous parenteral solution 20 meq/l</i> | 2 | |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg)</i> (Urocit-K 10) | 2 | |
| <i>potassium citrate oral tablet extended release 15 meq</i> (Urocit-K 15) | 2 | |
| <i>potassium citrate oral tablet extended release 5 meq (540 mg)</i> | 2 | |
| <i>sodium chloride 0.45 % intravenous parenteral solution 0.45 %</i> | 2 | |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i> | 2 | |
| <i>sodium chloride 0.9% solution mini-bag, single use</i> | 2 | |
| Respiratory Tract Agents | | |
| Anti-Inflammatories, Inhaled Corticosteroids | | |
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION (fluticasone propion-salmeterol) | 3 | QL (12 per 30 days) |
| AIRSUPRA 90-80 MCG INHALER 90-80 MCG/ACTUATION | 3 | QL (32.1 per 30 days) |
| ARNUITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION (fluticasone furoate) | 3 | QL (30 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE (fluticasone furoate-vilanterol) | 3 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 50-25 MCG/DOSE | 3 | QL (60 per 30 days) |
| <i>breyana inhalation hfa aerosol inhaler</i> (budesonide-formoterol) 160-4.5 mcg/actuation, 80-4.5 mcg/actuation | 4 | QL (30.9 per 30 days) |
| <i>budesonide inhalation suspension for nebulization</i> 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml (Pulmicort) | 3 | PA BvD; QL (120 per 30 days) |
| <i>budesonide-formoterol inhalation hfa aerosol inhaler</i> 160-4.5 mcg/actuation, 80-4.5 mcg/actuation (Breyna) | 4 | QL (30.6 per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler</i> 110 mcg/actuation | 4 | QL (12 per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler</i> 220 mcg/actuation | 4 | QL (24 per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler</i> 44 mcg/actuation | 4 | QL (21.2 per 30 days) |
| <i>fluticasone propion-salmeterol inhalation blister with device</i> 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose (Wixela Inhub) | 2 | QL (60 per 30 days) |
| <i>wixela inhub inhalation blister with device</i> 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose (fluticasone propion-salmeterol) | 2 | QL (60 per 30 days) |
| Antileukotrienes | | |
| <i>montelukast oral tablet</i> 10 mg (Singulair) | 1 | |
| <i>montelukast oral tablet, chewable</i> 4 mg, 5 mg (Singulair) | 2 | |
| <i>zafirlukast oral tablet</i> 10 mg, 20 mg (Accolate) | 4 | |
| Bronchodilators | | |
| AIRSUPRA INHALATION HFA AEROSOL INHALER 90-80 MCG/ACTUATION | 3 | QL (32.1 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler</i> 90 mcg/actuation (Ventolin HFA) | 2 | QL (17 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler</i> 90 mcg/actuation (nda020503) | 2 | QL (13.4 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)</i> | 4 | QL (36 per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml</i> | 2 | PA BvD |
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i> | 2 | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 4 | |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION (umeclidinium-vilanterol) | 3 | QL (60 per 30 days) |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION | 4 | QL (25.8 per 28 days) |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION | 3 | QL (10.7 per 30 days) |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION | 3 | QL (8 per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 2 | PA BvD |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | 2 | PA BvD; QL (540 per 30 days) |
| PROAIR RESPICLICK INHALATION AEROSOL POWDR BREATH ACTIVATED 90 MCG/ACTUATION | 4 | QL (2 per 30 days) |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE | 3 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION | 3 | QL (4 per 30 days) |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION | 3 | QL (4 per 30 days) |
| STRIVERDI RESPIMAT INHALATION MIST 2.5 MCG/ACTUATION | 3 | QL (4 per 28 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i> | 3 | |
| <i>theophylline oral solution 80 mg/15 ml</i> | 3 | |
| <i>theophylline oral tablet extended release 12 hr 100 mg, 200 mg, 300 mg, 450 mg</i> | 4 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | 2 | |
| <i>tiotropium bromide inhalation</i> (Spiriva with <i>capsule, w/inhalation device 18 mcg</i> HandiHaler) | 3 | QL (30 per 30 days) |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200- 62.5-25 MCG | 3 | QL (60 per 30 days) |
| Respiratory Tract Agents, Other | | |
| <i>acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)</i> | 2 | PA BvD |
| ALYFTREK ORAL TABLET 10- 50-125 MG | 5 | PA; NDS; QL (60 per 30 days) |
| ALYFTREK ORAL TABLET 4-20- 50 MG | 5 | PA; NDS; QL (90 per 30 days) |
| BRONCHITOL INHALATION CAPSULE, W/INHALATION DEVICE 40 MG | 5 | NDS; QL (560 per 28 days) |
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i> | 2 | PA BvD |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML | 5 | PA; NDS; QL (1 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML | 5 | PA; NDS; QL (1 per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG | 5 | PA; NDS; QL (56 per 28 days) |
| KALYDECO ORAL TABLET 150 MG | 5 | PA; NDS; QL (56 per 28 days) |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG | 5 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML | 5 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | 5 | PA; LA; NDS; QL (0.4 per 28 days) |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5 | PA; NDS; QL (60 per 30 days) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG, 75-94 MG | 5 | PA; NDS; QL (56 per 28 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5 | PA; NDS; QL (112 per 28 days) |
| <i>pirfenidone oral capsule 267 mg</i> | 5 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 267 mg</i> (Esbriet) | 5 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 534 mg</i> | 5 | PA; NDS; QL (90 per 30 days) |
| <i>pirfenidone oral tablet 801 mg</i> (Esbriet) | 5 | PA; NDS; QL (90 per 30 days) |
| PROLASTIN-C INTRAVENOUS SOLUTION 1,000 MG (+/-)/20 ML | 5 | PA BvD; NDS |
| <i>roflumilast oral tablet 250 mcg</i> (Daliresp) | 3 | QL (28 per 28 days) |
| <i>roflumilast oral tablet 500 mcg</i> (Daliresp) | 3 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------|
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) | 5 | PA; NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 100-50- 75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) | 5 | PA; NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) | 5 | PA; NDS; QL (84 per 28 days) |
| WINREVAIR SUBCUTANEOUS KIT 120 MG (60 MG X 2), 45 MG, 60 MG, 90 MG (45 MG X 2) | 5 | PA; NDS; QL (1 per 21 days) |
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 5 | PA; NDS |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG | 5 | PA; NDS |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 5 | PA; NDS |

Skeletal Muscle Relaxants

Skeletal Muscle Relaxants

| | | |
|---|---|--|
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>dantrolene oral capsule 100 mg, 50 mg</i> | 4 | |
| <i>dantrolene oral capsule 25 mg</i> (Dantrium) | 4 | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>tizanidine oral tablet 2 mg</i> | 2 | |
| <i>tizanidine oral tablet 4 mg</i> (Zanaflex) | 2 | |

Sleep Disorder Agents

Sleep Disorder Agents

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> (Nuvigil) | 2 | PA; QL (30 per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>doxepin oral tablet 3 mg, 6 mg</i> (Silenor) | 2 | QL (30 per 30 days) |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> (Lunesta) | 2 | QL (30 per 30 days) |
| HETLIOZ LQ ORAL SUSPENSION 4 MG/ML | 5 | PA; NDS; QL (150 per 30 days) |
| <i>modafinil oral tablet 100 mg</i> (Provigil) | 2 | PA; QL (30 per 30 days) |
| <i>modafinil oral tablet 200 mg</i> (Provigil) | 2 | PA; QL (60 per 30 days) |
| <i>sodium oxybate oral solution 500 mg/ml</i> (Xyrem) | 5 | PA; LA; NDS; QL (540 per 30 days) |
| <i>tasimelteon oral capsule 20 mg</i> (Hetlioz) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>zolpidem oral tablet 10 mg, 5 mg</i> (Ambien) | 1 | QL (30 per 30 days) |
| <i>zolpidem oral tablet,ext release multiphase 12.5 mg, 6.25 mg</i> (Ambien CR) | 2 | QL (30 per 30 days) |
| Vasodilating Agents | | |
| Vasodilating Agents | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 5 | PA; NDS; QL (90 per 30 days) |
| <i>alyq oral tablet 20 mg</i> (tadalafil (pulm. hypertension)) | 2 | PA; QL (60 per 30 days) |
| <i>ambriasantan oral tablet 10 mg, 5 mg</i> (Letairis) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> (Tracleer) | 5 | PA; LA; NDS; QL (60 per 30 days) |
| OPSUMIT ORAL TABLET 10 MG | 5 | PA; NDS; QL (30 per 30 days) |
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> (Revatio) | 2 | PA; QL (360 per 30 days) |
| <i>sildenafil oral tablet 100 mg, 25 mg, 50 mg</i> (Viagra) | 1 | EX; CB (6 EA per 30 days) |
| <i>tadalafil oral tablet 2.5 mg</i> | 2 | PA; QL (30 per 30 days) |
| <i>tadalafil oral tablet 5 mg</i> (Cialis) | 2 | PA; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| <i>treprostinil sodium injection solution</i> (Remodulin) 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml | 5 | PA; NDS |
| TYVASO INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) | 5 | PA; NDS |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG | 5 | PA; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 200 MCG | 5 | PA; NDS; QL (240 per 30 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)- 800 MCG (60) | 5 | PA; NDS |

Vitamins And Minerals

Vitamins And Minerals

| | | |
|--|---|--|
| <i>bal-care dha combo pack 27-1-430 mg</i> | 1 | |
| <i>bal-care dha essential pack 27 mg iron-1 mg -374 mg</i> | 1 | |
| <i>c-nate dha softgel 28 mg iron-1 mg - 200 mg</i> | 1 | |
| <i>completenate tablet chew 29 mg iron-1 mg</i> | 1 | |
| <i>folivane-ob capsule 85-1 mg</i> | 1 | |
| <i>kosher prenatal plus iron tab 30 mg iron- 1 mg</i> | 1 | |
| <i>marnatal-f capsule 60 mg iron-1 mg</i> | 1 | |
| <i>m-natal plus tablet 27 mg iron- 1 mg</i> (pnv,calcium 72-iron-folic acid) | 1 | |
| <i>mynatal advance oral tablet 90-1-50 mg</i> | 1 | |
| <i>mynatal capsule 65 mg iron- 1 mg</i> | 1 | |
| <i>mynatal oral tablet 90-1-50 mg</i> | 1 | |
| <i>mynatal plus captab 65 mg iron- 1 mg</i> | 1 | |
| <i>mynatal-z captab 65 mg iron- 1 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|---|---------------------------------------|----------------------------|
| <i>mynate 90 plus oral tablet extended release 90 mg iron-1 mg</i> | 1 | |
| <i>newgen tablet 32-1,000 mg-mcg</i> | 1 | |
| <i>niva-plus tablet 27 mg iron- 1 mg</i> | 1 | |
| <i>obstetrix dha combo pack 29 mg iron- 1,700 mcg dfe</i> | 1 | |
| <i>obstetrix dha oral combo pack,tablet and cap,dr 29 mg iron-1 mg -50 mg</i> | 1 | |
| <i>pnv 29-1 oral tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>pnv prenatal plus multivit tab gluten-free (rx) 27 mg iron- 1 mg</i> | (pnv,calcium 72-iron-folic acid) 1 | |
| <i>pnv-dha + docusate oral capsule 27-1.25-55-300 mg</i> | 1 | |
| <i>pnv-omega softgel 28-1-300 mg</i> | 1 | |
| <i>pr natal 400 combo pack 29-1-400 mg</i> | 1 | |
| <i>pr natal 400 ec combo pack 29-1-400 mg</i> | 1 | |
| <i>pr natal 430 combo pack 29 mg iron-1 mg -430 mg</i> | 1 | |
| <i>pr natal 430 ec combo pack 29-1-430 mg</i> | 1 | |
| <i>prenal true combo pack 30 mg iron-1.4 mg-300 mg</i> | 1 | |
| <i>prenaissance oral capsule 29-1.25-55-325 mg</i> | 1 | |
| <i>prenaissance plus oral capsule 28-1-50-250 mg</i> | 1 | |
| <i>prenatabs fa tablet 29-1 mg</i> | 1 | |
| <i>prenatal 19 (with docusate) oral tablet 29 mg iron- 1 mg-25 mg</i> | 1 | |
| <i>prenatal 19 chewable tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>prenatal plus iron tablet (rx) 29 mg iron- 1 mg</i> | (pnv,calcium 72-iron,carb-folic) 1 | |
| <i>prenatal vitamin plus low iron oral tablet 27 mg iron- 1 mg</i> | (pnv,calcium 72-iron-folic acid) 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>prenatal-u capsule 106.5-1 mg</i> | 1 | |
| <i>preplus oral tablet 27 mg iron- 1 mg (pnv,calcium 72-iron-folic acid)</i> | 1 | |
| <i>pretab oral tablet 29-1 mg</i> | 1 | |
| <i>r-natal ob softgel 20 mg iron- 1 mg-320 mg</i> | 1 | |
| <i>select-ob chewable caplet 29 mg iron- 1 mg</i> | 1 | |
| <i>select-ob chewable caplet 29 mg iron- 1 mg</i> | 1 | |
| <i>se-natal 19 chewable tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>taron-c dha capsule 35-1-200 mg</i> | 1 | |
| <i>taron-prex prenatal-dha oral capsule 30 mg iron-1.2 mg-55 mg-265 mg</i> | 1 | |
| <i>virt-c dha oral capsule 35-1-200 mg</i> | 1 | |
| <i>virt-nate dha softgel 28 mg iron-1 mg -200 mg</i> | 1 | |
| <i>virt-pn dha softgel (rx) 27 mg iron-1 mg -300 mg</i> | 1 | |
| <i>virt-pn plus oral capsule 28-1-300 mg</i> | 1 | |
| <i>vitafol gummies 3.33 mg iron- 0.33 mg</i> | 1 | |
| <i>vitafol nano oral tablet 18 mg iron- 1 mg</i> | 1 | |
| <i>vitafol-ob+dha combo pack 65-1-250 mg</i> | 1 | |
| <i>vp-ch-pnv oral capsule 30 mg iron-1 mg -50 mg-260 mg</i> | 1 | |
| <i>vp-pnv-dha oral capsule 28 mg iron-1 mg-200 mg</i> | 1 | |
| <i>zatean-pn dha capsule 27 mg iron-1 mg -300 mg</i> | 1 | |
| <i>zatean-pn plus softgel 28-1-300 mg</i> | 1 | |
| <i>zingiber tablet 1.2 mg-40 mg- 124.1 mg-100 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

02/01/2026

INDEX

| | | |
|--|----------|-----|
| 1 | | |
| 1ST TIER UNIFINE PENTIPS | | |
| | 115 | |
| 1ST TIER UNIFINE PENTIPS PLUS | | 115 |
| A | | |
| <i>abacavir</i> | 71 | |
| <i>abacavir-lamivudine</i> | 71 | |
| ABELCET..... | 54 | |
| <i>abigale</i> | 172 | |
| <i>abigale lo</i> | 172 | |
| ABILIFY ASIMTUFII..... | 64 | |
| ABILIFY MAINTENA..... | 64 | |
| <i>abiraterone</i> | 19 | |
| <i>abiraterone, submicronized</i> | 19 | |
| <i>abirtega</i> | 19 | |
| ABOUTTIME PEN NEEDLE | | 115 |
| ABRYSVO (PF)..... | 184 | |
| <i>acamprosate</i> | 8 | |
| <i>acarbose</i> | 48 | |
| <i>accutane</i> | 110 | |
| <i>acebutolol</i> | 86 | |
| <i>acetaminophen-codeine</i> | 3 | |
| <i>acetazolamide</i> | 194 | |
| <i>acetazolamide sodium</i> | 194 | |
| <i>acetic acid</i> | 162 | |
| <i>acetylcysteine</i> | 200 | |
| <i>acitretin</i> | 110 | |
| ACTHIB (PF)..... | 184 | |
| ACTIMMUNE..... | 192 | |
| <i>acyclovir</i> | 77, 110 | |
| <i>acyclovir sodium</i> | 77 | |
| ADACEL(TDAP | | |
| ADOLESN/ADULT)(PF) | 184 | |
| <i>adapalene</i> | 114 | |
| <i>adefovir</i> | 77 | |
| ADEMPAS..... | 203 | |
| <i>adrucil</i> | 19 | |
| ADVAIR HFA..... | 197 | |
| ADVOCATE PEN NEEDLE | | 116 |
| ADVOCATE SYRINGES.. | 115, | |
| 116 | | |
| <i>afirmelle</i> | 99 | |
| AIMOVIQ AUTOINJECTOR | | 58 |
| AIRSUPRA..... | 197, 198 | |
| AKEEGA..... | 19 | |
| <i>ala-cort</i> | 111 | |
| <i>ala-scalp</i> | 111 | |
| <i>albendazole</i> | 61 | |
| <i>albuterol sulfate</i> | 198, 199 | |
| <i>alclometasone</i> | 111, 112 | |
| ALCOHOL PADS..... | 116 | |
| ALCOHOL PREP PADS | 136 | |
| ALCOHOL PREP SWABS. | 116 | |
| ALCOHOL SWABS..... | 132 | |
| ALCOHOL WIPES..... | 116 | |
| ALECENSA..... | 19 | |
| <i>alendronate</i> | 191 | |
| <i>alfuzosin</i> | 170 | |
| <i>aliskiren</i> | 94 | |
| <i>allopurinol</i> | 56 | |
| <i>alose tron</i> | 190 | |
| <i>alprazolam</i> | 9, 10 | |
| <i>altavera (28)</i> | 99 | |
| ALTRENO..... | 114 | |
| ALUNBRIG..... | 19 | |
| ALVAIZ..... | 79 | |
| <i>alyacen 1/35 (28)</i> | 99 | |
| <i>alyacen 7/7/7 (28)</i> | 99 | |
| ALYFTREK..... | 200 | |
| <i>alyq</i> | 203 | |
| <i>amabelz</i> | 172 | |
| <i>amantadine hcl</i> | 62 | |
| <i>ambrisentan</i> | 203 | |
| <i>amethia</i> | 99 | |
| <i>amethyst (28)</i> | 99 | |
| <i>amikacin</i> | 11 | |
| <i>amiloride</i> | 90 | |
| <i>amiloride-hydrochlorothiazide</i> | | 90 |
| <i>amiodarone</i> | 85 | |
| <i>amitriptyline</i> | 45 | |
| <i>amitriptyline-chlordiazepoxide</i> | | 45 |
| <i>amlodipine</i> | 89 | |
| <i>amlodipine-atorvastatin</i> | 91 | |
| <i>amlodipine-benazepril</i> | 89 | |
| <i>amlodipine-olmesartan</i> | 89 | |
| <i>amlodipine-valsartan</i> | 89 | |
| <i>amlodipine-valsartan-hcthiazid</i> | | 90 |
| <i>ammonium lactate</i> | 110 | |
| <i>amoxapine</i> | 45 | |
| <i>amoxicil-clarithromy-lansopraz</i> | | 166 |
| <i>amoxicillin</i> | 15, 16 | |
| <i>amoxicillin-pot clavulanate</i> .. | 16 | |
| <i>amphotericin b</i> | 54 | |
| <i>amphotericin b liposome</i> | 54 | |
| <i>ampicillin</i> | 16 | |
| <i>ampicillin sodium</i> | 16 | |
| <i>ampicillin-sulbactam</i> | 16 | |
| <i>anagrelide</i> | 80 | |
| <i>anastrozole</i> | 19 | |
| ANDEMBRY | | |
| AUTOINJECTOR..... | 192 | |
| ANKTIVA..... | 19 | |
| ANORO ELLIPTA..... | 199 | |

| | | | | | |
|--------------------------------------|--------|--------------------------------------|----------|-------------------------------------|---------|
| <i>apomorphine</i> | 62 | <i>aurovela 24 fe</i> | 100 | BD INSULIN SYRINGE | |
| <i>apraclonidine</i> | 161 | <i>aurovela fe 1.5/30 (28)</i> | 100 | ULTRA-FINE..... | 117 |
| <i>aprepitant</i> | 59, 60 | <i>aurovela fe 1-20 (28)</i> | 100 | BD LO-DOSE ULTRA-FINE | |
| <i>apri</i> | 100 | AUSTEDO..... | 94 | | 118 |
| APTIVUS..... | 71 | AUSTEDO XR..... | 95 | BD NANO 2ND GEN PEN | |
| AQINJECT PEN NEEDLE.. | 116 | AUSTEDO XR TITRATION | | NEEDLE..... | 118 |
| <i>aranelle (28)</i> | 100 | KT(WK1-4)..... | 95 | BD SAFETYGLIDE INSULIN | |
| ARCALYST..... | 177 | AUTOSHIELD DUO PEN | | SYRINGE..... | 118 |
| AREXVY (PF)..... | 185 | NEEDLE..... | 117 | BD SAFETYGLIDE SYRINGE | |
| ARIKAYCE..... | 11 | AUVELITY..... | 45 | | 118 |
| <i>aripiprazole</i> | 64 | <i>aviane</i> | 100 | BD ULTRA-FINE MICRO | |
| ARISTADA..... | 64, 65 | AVMAPKI..... | 20 | PEN NEEDLE..... | 118 |
| ARISTADA INITIO..... | 64 | AVMAPKI-FAKZYNJA..... | 20 | BD ULTRA-FINE MINI PEN | |
| <i>armodafinil</i> | 203 | AVONEX..... | 95 | NEEDLE..... | 118 |
| ARNUITY ELLIPTA..... | 197 | AXTLE..... | 20 | BD ULTRA-FINE NANO PEN | |
| <i>ascomp with codeine</i> | 3 | <i>ayuna</i> | 100 | NEEDLE..... | 118 |
| <i>asenapine maleate</i> | 65 | AYVAKIT..... | 20 | BD ULTRA-FINE ORIG PEN | |
| <i>ashlyna</i> | 100 | <i>azacitidine</i> | 20 | NEEDLE..... | 119 |
| <i>aspirin-dipyridamole</i> | 80 | <i>azathioprine</i> | 177 | BD ULTRA-FINE SHORT | |
| ASSURE ID DUO PRO SFTY | | <i>azathioprine sodium</i> | 177 | PEN NEEDLE..... | 119 |
| PEN NDL..... | 116 | <i>azelastine</i> | 161, 162 | BD VEO INSULIN SYR | |
| ASSURE ID DUO-SHIELD | 117 | <i>azithromycin</i> | 14 | (HALF UNIT)..... | 119 |
| ASSURE ID INSULIN | | <i>aztreonam</i> | 15 | BD VEO INSULIN SYRINGE | |
| SAFETY..... | 117 | <i>azurette (28)</i> | 100 | UF..... | 119 |
| ASSURE ID PEN NEEDLE | 117 | B | | BELSOMRA..... | 203 |
| ASSURE ID PRO PEN | | <i>bacitracin</i> | 162 | <i>benazepril</i> | 84 |
| NEEDLE..... | 117 | <i>bacitracin-polymyxin b</i> | 162 | | 84 |
| ASTAGRAF XL..... | 177 | <i>baclofen</i> | 202 | <i>bendamustine</i> | 20 |
| <i>atazanavir</i> | 71 | <i>bal-care dha</i> | 204 | BENDAMUSTINE..... | 20 |
| <i>atenolol</i> | 86 | <i>bal-care dha essential</i> | 204 | BENDEKA..... | 20 |
| <i>atenolol-chlorthalidone</i> | 86 | <i>balsalazide</i> | 190 | BENLYSTA..... | 177 |
| <i>atomoxetine</i> | 94 | BALVERSA..... | 20 | <i>benztropine</i> | 62 |
| <i>atorvastatin</i> | 91 | <i>balziva (28)</i> | 100 | <i>bepotastine besilate</i> | 162 |
| <i>atovaquone</i> | 61 | BAQSIMI..... | 192 | BESREMI..... | 177 |
| <i>atovaquone-proguanil</i> | 61 | BCG VACCINE, LIVE (PF) | 185 | <i>betaine</i> | 192 |
| <i>atropine</i> | 161 | BD ALCOHOL SWABS..... | 118 | <i>betamethasone dipropionate</i> | 112 |
| ATROVENT HFA..... | 199 | BD AUTOSHIELD DUO PEN | | | 112 |
| <i>aubra eq</i> | 100 | NEEDLE..... | 117 | <i>betamethasone valerate</i> | 112 |
| AUGTYRO..... | 19 | BD ECLIPSE LUER-LOK.. | 117 | <i>betamethasone, augmented</i> .. | 112 |
| <i>auranofin</i> | 177 | BD INSULIN SYRINGE | 118 | BETASERON..... | 95 |
| <i>aurovela 1.5/30 (21)</i> | 100 | BD INSULIN SYRINGE | | <i>betaxolol</i> | 86, 194 |
| <i>aurovela 1/20 (21)</i> | 100 | (HALF UNIT)..... | 117 | <i>bethanechol chloride</i> | 170 |

| | | | | | |
|--|----------|--|--------|---------------------------------------|----------|
| <i>bexarotene</i> | 20 | <i>buspirone</i> | 192 | CARETOUCH PEN NEEDLE | |
| BEXSERO..... | 185 | <i>butalbital-acetaminop-caf-cod</i> 3 | | | 119, 120 |
| <i>bicalutamide</i> | 20 | <i>butalbital-acetaminophen-caff.</i> 3 | | <i>carglumic acid</i> | 167 |
| BICILLIN L-A | 16 | <i>butalbital-aspirin-caffeine</i> | 3 | <i>carteolol</i> | 194 |
| BIKTARVY | 71 | <i>butorphanol</i> | 3 | <i>cartia xt</i> | 87 |
| <i>bimatoprost</i> | 194 | C | | <i>carvedilol</i> | 86 |
| <i>bisoprolol fumarate</i> | 86 | CABENUVA | 71 | CAYSTON..... | 15 |
| <i>bisoprolol-hydrochlorothiazide</i> | | <i>cabergoline</i> | 62 | <i>cefaclor</i> | 13 |
| | 86 | CABLIVI..... | 80 | <i>cefadroxil</i> | 13 |
| BIZENGRI | 20 | CABOMETYX..... | 21 | <i>cefazolin</i> | 13 |
| <i>bleomycin</i> | 20 | <i>cabotegravir</i> | 71 | <i>cefdinir</i> | 13 |
| <i>blisovi 24 fe</i> | 100 | <i>calcipotriene</i> | 110 | <i>cefepime</i> | 13 |
| <i>blisovi fe 1.5/30 (28)</i> | 100 | <i>calcitonin (salmon)</i> | 191 | <i>cefixime</i> | 13 |
| <i>blisovi fe 1/20 (28)</i> | 100 | <i>calcitriol</i> | 191 | <i>cefoxitin</i> | 13 |
| BOOSTRIX TDAP | 185 | <i>calcium acetate(phosphat bind)</i> | | <i>cefpodoxime</i> | 13 |
| BORDERED GAUZE..... | 119 | | 169 | <i>cefprozil</i> | 13 |
| <i>bortezomib</i> | 20 | CALQUENCE | 21 | <i>ceftazidime</i> | 14 |
| BORUZU | 20 | CALQUENCE | | <i>ceftriaxone</i> | 14 |
| <i>bosentan</i> | 203 | (ACALABRUTINIB MAL) | | <i>cefuroxime axetil</i> | 14 |
| BOSULIF | 21 | | 21 | <i>cefuroxime sodium</i> | 14 |
| BRAFTOVI..... | 21 | CAMCEVI (6 MONTH) | 21 | <i>celecoxib</i> | 6 |
| BREO ELLIPTA | 197, 198 | <i>camila</i> | 100 | <i>cephalexin</i> | 14 |
| <i>breyna</i> | 198 | CAMZYOS..... | 88 | CERDELGA | 160 |
| BREZTRI AEROSPHERE .. | 199 | <i>candesartan</i> | 83 | <i>cevimeline</i> | 109 |
| <i>briellyn</i> | 100 | <i>candesartan-hydrochlorothiazid</i> | | <i>chateal eq (28)</i> | 100 |
| BRILINTA | 80 | | 83 | <i>chlordiazepoxide hcl</i> | 10 |
| <i>brimonidine</i> | 194 | CAPLYTA..... | 65 | <i>chlorhexidine gluconate</i> | 109 |
| <i>brimonidine-timolol</i> | 194 | CAPRELSA..... | 21 | <i>chloroquine phosphate</i> | 61 |
| <i>brinzolamide</i> | 194 | <i>captopril</i> | 84 | <i>chlorpromazine</i> | 65 |
| BRIVIACT | 38 | <i>carbamazepine</i> | 38, 39 | <i>chlorthalidone</i> | 90 |
| <i>bromfenac</i> | 164 | <i>carbidopa</i> | 62 | <i>cholestyramine (with sugar)</i> .. | 91 |
| <i>bromocriptine</i> | 62 | <i>carbidopa-levodopa</i> | 62 | <i>cholestyramine light</i> | 91 |
| BRONCHITOL | 200 | <i>carbidopa-levodopa-entacapone</i> | | <i>ciclopirox</i> | 54 |
| BRUKINSA | 21 | | 63 | <i>cilostazol</i> | 80 |
| <i>budesonide</i> | 190, 198 | <i>carbinoxamine maleate</i> | 57 | CIMDUO | 71 |
| <i>budesonide-formoterol</i> | 198 | <i>carboplatin</i> | 21 | <i>cimetidine</i> | 166 |
| <i>bumetanide</i> | 90 | CAREFINE PEN NEEDLE. 119 | | <i>cimetidine hcl</i> | 166 |
| <i>buprenorphine</i> | 3 | CARETOUCH ALCOHOL | | CIMZIA | 177, 178 |
| <i>buprenorphine hcl</i> | 9 | PREP PAD..... | 119 | CIMZIA POWDER FOR | |
| <i>buprenorphine-naloxone</i> | 9 | CARETOUCH INSULIN | | RECONST | 178 |
| <i>bupropion hcl</i> | 45 | SYRINGE | 120 | CIMZIA STARTER KIT | 178 |
| <i>bupropion hcl (smoking deter)</i> . | 9 | | | <i>cinacalcet</i> | 191 |

| | | | | | |
|--|----------|--|---------------|---------------------------------------|---------------|
| CINRYZE..... | 79 | CLINIMIX E 5%/D20W | | <i>constulose</i> | 167 |
| <i>ciprofloxacin hcl</i> | 17, 162 | SULFIT FREE..... | 82 | COPIKTRA..... | 22 |
| <i>ciprofloxacin in 5 % dextrose</i> | 17 | CLINIMIX E 8%-D10W | | CORLANOR..... | 88 |
| <i>ciprofloxacin-dexamethasone</i> | | SULFITEFREE..... | 82 | CORTROPHIN GEL..... | 174 |
| | 162 | CLINIMIX E 8%-D14W | | COSENTYX..... | 178 |
| <i>citalopram</i> | 45 | SULFITEFREE..... | 82 | COSENTYX (2 SYRINGES) | |
| <i>cladribine</i> | 21 | <i>clobazam</i> | 39 | | 178 |
| <i>clarithromycin</i> | 14, 15 | <i>clobetasol</i> | 112 | COSENTYX PEN (2 PENS) | 178 |
| <i>clemastine</i> | 57 | <i>clobetasol-emollient</i> | 112 | COSENTYX UNOREADY | |
| <i>clemasz</i> | 57 | <i>clomipramine</i> | 45 | PEN..... | 178 |
| <i>clemsza</i> | 57 | <i>clonazepam</i> | 10 | COTELLIC..... | 22 |
| CLICKFINE PEN NEEDLE | | <i>clonidine</i> | 82 | CREON..... | 160 |
| | 120, 132 | <i>clonidine hcl</i> | 82, 95 | CRESEMBA..... | 55 |
| <i>clindamycin hcl</i> | 11 | <i>clopidogrel</i> | 81 | <i>cromolyn</i> | 162, 167, 200 |
| <i>clindamycin pediatric</i> | 12 | <i>clorazepate dipotassium</i> | 10 | <i>cryselle (28)</i> | 101 |
| <i>clindamycin phosphate</i> | 12, 57, | <i>clotrimazole</i> | 54, 55 | CURAD GAUZE PAD..... | 123 |
| 111 | | <i>clotrimazole-betamethasone</i> .. | 55 | CURITY ALCOHOL SWABS | |
| <i>clindamycin-benzoyl peroxide</i> | | <i>clozapine</i> | 65 | | 123 |
| | 111 | <i>c-nate dha</i> | 204 | CURITY GAUZE..... | 123 |
| CLINIMIX 5%/D15W | | COARTEM..... | 61 | <i>cyclobenzaprine</i> | 202 |
| SULFITE FREE..... | 81 | COBENFY..... | 65 | <i>cyclophosphamide</i> | 22 |
| CLINIMIX 4.25%/D10W SULF | | COBENFY STARTER PACK | | <i>cyclosporine</i> | 164, 178 |
| FREE..... | 81 | | 65 | <i>cyclosporine modified</i> | 178 |
| CLINIMIX 4.25%/D5W | | <i>codeine sulfate</i> | 3, 4 | CYLTEZO(CF)..... | 179 |
| SULFIT FREE..... | 81 | <i>codeine-butalbital-asa-caff</i> | 4 | CYLTEZO(CF) PEN..... | 179 |
| CLINIMIX 5%- | | <i>colchicine</i> | 57 | CYLTEZO(CF) PEN | |
| D20W(SULFITE-FREE) ... | 81 | <i>colesevelam</i> | 92 | CROHN'S-UC-HS..... | 178 |
| CLINIMIX 6%-D5W | | <i>colestipol</i> | 92 | CYLTEZO(CF) PEN | |
| (SULFITE-FREE)..... | 81 | <i>colistin (colistimethate na)</i> ... | 12 | PSORIASIS-UV..... | 178 |
| CLINIMIX 8%- | | COMBIVENT RESPIMAT..... | 199 | <i>cyproheptadine</i> | 57 |
| D10W(SULFITE-FREE) ... | 81 | COMETRIQ..... | 21 | <i>cyred eq</i> | 101 |
| CLINIMIX 8%- | | COMFORT EZ INSULIN | | D | |
| D14W(SULFITE-FREE) ... | 81 | SYRINGE..... | 120, 121, 122 | <i>d5 % (d-glucose)-0.9 % sodchlr</i> | |
| CLINIMIX E 2.75%/D5W | | COMFORT EZ PEN NEEDLES | | | 195 |
| SULF FREE..... | 81 | | 121 | <i>d5 % and 0.9 % sodium chloride</i> | |
| CLINIMIX E 4.25%/D10W | | COMFORT EZ PRO SAFETY | | | 195 |
| SUL FREE..... | 81 | PEN NDL..... | 121, 122 | <i>d5 %-0.45 % sodium chloride</i> | |
| CLINIMIX E 4.25%/D5W | | COMFORT TOUCH PEN | | | 196 |
| SULF FREE..... | 82 | NEEDLE..... | 122, 123 | <i>dabigatran etexilate</i> | 77 |
| CLINIMIX E 5%/D15W | | <i>completenate</i> | 204 | <i>dalfampridine</i> | 95 |
| SULFIT FREE..... | 82 | <i>compro</i> | 60 | <i>danazol</i> | 171 |
| | | <i>conjugated estrogens</i> | 172 | <i>dantrolene</i> | 202 |

| | | | | | |
|--|----------|---|-----------|---------------------------------------|----------|
| DANYELZA | 22 | <i>dexamethasone sodium phosphate</i> | 164, 173 | <i>dorzolamide</i> | 195 |
| DANZITEN..... | 22 | <i>dexmethylphenidate</i> | 95 | <i>dorzolamide-timolol</i> | 195 |
| <i>dapagliflozin propanediol</i> | 48 | <i>dextroamphetamine sulfate</i> ... 95, | 96 | <i>dotti</i> | 172 |
| <i>dapsone</i> | 59 | <i>dextroamphetamine-</i> | | DOVATO..... | 71 |
| DAPTACEL (DTAP | | <i>amphetamine</i> | 96 | <i>doxazosin</i> | 82 |
| PEDIATRIC) (PF)..... | 185 | <i>dextrose 5 % in water (d5w)</i> .. | 82 | <i>doxepin</i> | 46, 203 |
| <i>daptomycin</i> | 12 | DIACOMIT | 39 | <i>doxercalciferol</i> | 191 |
| <i>darunavir</i> | 71 | <i>diazepam</i> | 10, 39 | <i>doxorubicin, peg-liposomal</i> ... | 22 |
| DARZALEX | 22 | <i>diazepam intensol</i> | 10 | <i>doxy-100</i> | 18 |
| DARZALEX FASPRO | 22 | <i>diazoxide</i> | 192 | <i>doxycycline hyclate</i> | 18 |
| <i>dasatinib</i> | 22 | <i>diclofenac epolamine</i> | 6 | <i>doxycycline monohydrate</i> | 18 |
| <i>dasetta 1/35 (28)</i> | 101 | <i>diclofenac potassium</i> | 6 | DRIZALMA SPRINKLE | 46 |
| <i>dasetta 7/7/7 (28)</i> | 101 | <i>diclofenac sodium</i> | 6, 7, 165 | <i>dronabinol</i> | 60 |
| DATROWAY..... | 22 | <i>diclofenac-misoprostol</i> | 7 | DROPLET INSULIN | |
| DAURISMO..... | 22 | <i>dicloxacillin</i> | 16 | SYR(HALF UNIT).. | 123, 124 |
| DAWNZERA..... | 88 | <i>dicyclomine</i> | 167 | DROPLET INSULIN | |
| <i>daysee</i> | 101 | <i>didanosine</i> | 71 | SYRINGE | 124, 125 |
| <i>deblitane</i> | 101 | DIFICID..... | 15 | DROPLET MICRON PEN | |
| <i>decitabine</i> | 22 | <i>diflorasone</i> | 113 | NEEDLE | 125 |
| <i>deferasirox</i> | 171 | <i>diflunisal</i> | 7 | DROPLET PEN NEEDLE . | 125, |
| <i>deferiprone</i> | 171 | <i>difluprednate</i> | 165 | 126 | |
| DELSTRIGO..... | 71 | <i>digoxin</i> | 88 | DROPSAFE ALCOHOL PREP | |
| <i>demeclocycline</i> | 18 | <i>dihydroergotamine</i> | 58 | PADS | 126 |
| DENGVAXIA (PF)..... | 185 | DILANTIN | 39 | DROPSAFE INSULIN | |
| <i>denta 5000 plus</i> | 109 | <i>diltiazem hcl</i> | 87, 88 | SYRINGE | 126 |
| <i>dentagel</i> | 109 | <i>dilt-xr</i> | 88 | DROPSAFE PEN NEEDLE | 126 |
| DEPO-SUBQ PROVERA | 104 | <i>dimethyl fumarate</i> | 96 | <i>drosiprenone-ethinyl estradiol</i> | |
| | 176 | DIPENTUM..... | 190 | | 101 |
| DERMACEA | 123 | <i>diphenoxylate-atropine</i> | 167 | DROXIA | 80 |
| DERMACEA NON-WOVEN | | <i>dipyridamole</i> | 81 | <i>droxidopa</i> | 82, 83 |
| | 123 | <i>disopyramide phosphate</i> | 85 | <i>duloxetine</i> | 46 |
| <i>dermacinrx lidocan</i> | 8 | <i>disulfiram</i> | 9 | DUPIXENT PEN | 179 |
| DESCOVY | 71 | <i>divalproex</i> | 39 | DUPIXENT SYRINGE | 179 |
| <i>desipramine</i> | 45, 46 | <i>dofetilide</i> | 85 | <i>dutasteride</i> | 170 |
| <i>desmopressin</i> | 174, 175 | <i>dolishale</i> | 101 | <i>dutasteride-tamsulosin</i> | 170 |
| <i>desog-e.estradiol/e.estradiol</i> | 101 | <i>donepezil</i> | 44 | E | |
| <i>desogestrel-ethinyl estradiol</i> | 101 | DOPTELET (10 TAB PACK)79 | | EASY COMFORT ALCOHOL | |
| <i>desonide</i> | 112, 113 | DOPTELET (15 TAB PACK)79 | | PAD..... | 127 |
| <i>desoximetasone</i> | 113 | DOPTELET (30 TAB PACK)79 | | EASY COMFORT INSULIN | |
| <i>desvenlafaxine succinate</i> | 46 | DOPTELET SPRINKLE..... | 79 | SYRINGE | 127, 128 |
| <i>dexamethasone</i> | 173 | | | EASY COMFORT PEN | |
| | | | | NEEDLES..... | 127, 128 |

| | | | | |
|--|---|-----|---|----------|
| EASY COMFORT SAFETY | <i>elinest</i> | 101 | <i>epinastine</i> | 162 |
| PEN NEEDLE..... | ELIQUIS..... | 78 | <i>epinephrine</i> | 89 |
| EASY GLIDE INSULIN | ELIQUIS DVT-PE TREAT 30D | | <i>epitol</i> | 40 |
| SYRINGE..... | START..... | 77 | EPIVIR HBV | 72 |
| EASY GLIDE PEN NEEDLE | ELIQUIS SPRINKLE..... | 78 | EPKINLY | 23 |
| | ELMIRON..... | 192 | <i>eplerenone</i> | 94 |
| EASY TOUCH..... | ELREXFIO | 23 | ERBITUX | 23 |
| EASY TOUCH ALCOHOL | <i>eltrombopag olamine</i> | 79 | <i>ergoloid</i> | 44 |
| PREP PADS | <i>eluryng</i> | 101 | ERIVEDGE..... | 23 |
| EASY TOUCH FLIPLOCK | EMBRACE PEN NEEDLE. | 131 | ERLEADA..... | 23 |
| INSULIN..... | EMCYT | 23 | <i>erlotinib</i> | 23 |
| EASY TOUCH FLIPLOCK | EMEND | 60 | <i>errin</i> | 101 |
| SYRINGE..... | EMGALITY PEN..... | 58 | <i>ertapenem</i> | 15 |
| EASY TOUCH INSULIN | EMGALITY SYRINGE | 58 | <i>ery pads</i> | 111 |
| SAFETY SYR..... | EMRELIS | 23 | <i>erythromycin</i> | 15, 162 |
| EASY TOUCH INSULIN | EMSAM..... | 46 | <i>erythromycin ethylsuccinate</i> .. | 15 |
| SYRINGE.128, 129, 130, 131 | <i>emtricitabine</i> | 72 | <i>erythromycin with ethanol</i> .. | 111 |
| EASY TOUCH LUER LOCK | <i>emtricitabine-tenofovir (tdf)</i> .. | 72 | <i>erythromycin-benzoyl peroxide</i> | |
| INSULIN..... | <i>emtricitabine-tenofovir (tdf)</i> .. | 72 | | 111 |
| EASY TOUCH PEN NEEDLE | EMTRIVA | 72 | ERZOFRI..... | 65, 66 |
| | <i>emzahh</i> | 101 | <i>escitalopram oxalate</i> | 46 |
| EASY TOUCH SAFETY PEN | <i>enalapril maleate</i> | 84 | <i>eslicarbazepine</i> | 40 |
| NEEDLE | <i>enalapril-hydrochlorothiazide</i> 84 | | <i>esomeprazole magnesium</i> | 166 |
| EASY TOUCH | ENBREL..... | 179 | <i>estarylla</i> | 102 |
| SHEATHLOCK INSULIN | ENBREL MINI..... | 179 | <i>estazolam</i> | 10 |
| | ENBREL SURECLICK | 179 | <i>estradiol</i> | 172 |
| EASY TOUCH UNI-SLIP ... | <i>endocet</i> | 4 | <i>estradiol valerate</i> | 172, 173 |
| <i>econazole nitrate</i> | ENGERIX-B (PF)..... | 185 | <i>estradiol-norethindrone acet</i> | 173 |
| EDURANT..... | ENGERIX-B PEDIATRIC (PF) | | <i>eszopiclone</i> | 203 |
| EDURANT PED | | 185 | <i>ethambutol</i> | 59 |
| <i>efavirenz</i> | <i>enilloring</i> | 101 | <i>ethosuximide</i> | 40 |
| <i>efavirenz-emtricitabin-tenofov</i> 72 | <i>enoxaparin</i> | 78 | <i>ethynodiol diac-eth estradiol</i> | 102 |
| <i>efavirenz-lamivu-tenofov disop</i> | <i>enpresse</i> | 101 | <i>etodolac</i> | 7 |
| | <i>enskyce</i> | 101 | <i>etonogestrel-ethinyl estradiol</i> | |
| EGRIFTA SV..... | ENSPRYNG | 96 | | 102 |
| EGRIFTA WR..... | <i>entacapone</i> | 63 | ETOPOPHOS | 23 |
| ELAHERE..... | <i>entecavir</i> | 77 | <i>etoposide</i> | 24 |
| ELEPSIA XR | ENTRESTO..... | 83 | <i>etravirine</i> | 72 |
| ELIGARD | ENTRESTO SPRINKLE..... | 83 | EUCRISA | 113 |
| ELIGARD (3 MONTH)..... | <i>enulose</i> | 167 | EULEXIN | 24 |
| ELIGARD (4 MONTH)..... | EPCLUSA | 76 | <i>everolimus (antineoplastic)</i> | 24 |
| ELIGARD (6 MONTH)..... | EPIDIOLEX | 39 | | |

| | | | | |
|---|---|---------|---------------------------------------|----------|
| <i>everolimus</i> | FETZIMA | 46 | <i>folivane-ob</i> | 204 |
| (<i>immunosuppressive</i>)..... | FIASP FLEXTOUCH U-100 | | <i>fondaparinux</i> | 78 |
| EVOTAZ..... | INSULIN | 51 | <i>fosamprenavir</i> | 72 |
| EVRYSDI..... | FIASP PENFILL U-100 | | <i>fosfomycin tromethamine</i> | 12 |
| EXEL INSULIN..... | INSULIN | 51 | <i>fosinopril</i> | 84 |
| <i>exemestane</i> | FIASP PUMPCART | 51 | <i>fosinopril-hydrochlorothiazide</i> | |
| EXTENCILLINE | FIASP U-100 INSULIN | 51 | | 84 |
| EXXUA..... | <i>fidaxomicin</i> | 15 | <i>fosphenytoin</i> | 40 |
| EYSUVIS..... | <i>finasteride</i> | 170 | FOTIVDA..... | 24 |
| EZALLOR SPRINKLE..... | <i>fungolimod</i> | 96 | FREESTYLE PRECISION. 131, | |
| <i>ezetimibe</i> | FINTEPLA | 40 | 132 | |
| <i>ezetimibe-simvastatin</i> | <i>fioricet</i> | 4 | FRUZAQLA | 24 |
| F | FIRMAGON KIT W DILUENT | | <i>fulvestrant</i> | 24 |
| FAKZYNJA | SYRINGE | 24 | <i>furosemide</i> | 90 |
| <i>falmina (28)</i> | <i>flavoxate</i> | 170 | FUZEON..... | 72 |
| <i>famciclovir</i> | <i>flecainide</i> | 85 | FYARRO | 25 |
| <i>famotidine</i> | <i>floxuridine</i> | 24 | <i>fyavolv</i> | 173 |
| FANAPT | <i>fluconazole</i> | 55 | FYCOMPA | 40 |
| FANAPT TITRATION PACK | <i>fluconazole in nacl (iso-osm)</i> . 55 | | G | |
| A..... | <i>flucytosine</i> | 55 | <i>gabapentin</i> | 40 |
| FANAPT TITRATION PACK | <i>fludrocortisone</i> | 173 | GALAFOLD | 160 |
| B..... | <i>flunisolide</i> | 165 | <i>galantamine</i> | 44 |
| FANAPT TITRATION PACK | <i>fluocinolone</i> | 113 | <i>gallifrey</i> | 176 |
| C | <i>fluocinolone acetonide oil</i> ... 165 | | GAMMAGARD S-D (IGA < 1 | |
| FARXIGA | <i>fluocinonide</i> | 113 | MCG/ML)..... | 179 |
| FASENRA..... | <i>fluocinonide-emollient</i> | 113 | GAMMAPLEX..... | 179 |
| FASENRA PEN | <i>fluoride (sodium)</i> | 109 | GAMUNEX-C | 179 |
| <i>febuxostat</i> | <i>fluorometholone</i> | 165 | GARDASIL 9 (PF) | 185 |
| <i>feirza</i> | <i>fluorouracil</i> | 24, 110 | <i>gatifloxacin</i> | 162 |
| <i>felbamate</i> | <i>flouxetine</i> | 46, 47 | GATTEX 30-VIAL..... | 167 |
| <i>felodipine</i> | <i>fluphenazine decanoate</i> | 66 | GAUZE BANDAGE | 132 |
| FEMRING..... | <i>fluphenazine hcl</i> | 66 | GAUZE PAD | 132 |
| <i>femynor</i> | <i>flurazepam</i> | 10 | <i>gavilyte-c</i> | 169 |
| <i>fenofibrate</i> | <i>flurbiprofen</i> | 7 | <i>gavilyte-g</i> | 169 |
| <i>fenofibrate micronized</i> | <i>flurbiprofen sodium</i> | 165 | <i>gavilyte-n</i> | 169 |
| <i>fenofibrate nanocrystallized</i> ...92 | <i>flutamide</i> | 24 | GAVRETO | 25 |
| <i>fenofibric acid (choline)</i> | <i>fluticasone propionate</i> 113, 165, | | <i>gefitinib</i> | 25 |
| <i>fenoprofen</i> | 198 | | <i>gemcitabine</i> | 25 |
| <i>fentanyl</i> | <i>fluticasone propion-salmeterol</i> | | <i>gemfibrozil</i> | 92 |
| <i>fentanyl citrate</i> | | 198 | <i>gemmily</i> | 102 |
| FERRIPROX..... | <i>fluvastatin</i> | 92 | <i>generlac</i> | 167 |
| <i>fesoterodine</i> | <i>fluvoxamine</i> | 47 | <i>gengraf</i> | 179, 180 |

| | | | | | |
|--|--------------|--------------------------------------|----------------|---------------------------------------|----------|
| <i>gentak</i> | 162 | HAVRIX (PF)..... | 186 | <i>hydrocortisone valerate</i> | 114 |
| <i>gentamicin</i> | 11, 111, 162 | HEALTHWISE INSULIN | | <i>hydrocortisone-acetic acid</i> ... | 163 |
| <i>gentamicin sulfate (ped) (pf)</i> .. | 11 | SYRINGE..... | 133 | <i>hydromorphone</i> | 5 |
| <i>gentamicin sulfate (pf)</i> | 11 | HEALTHWISE PEN NEEDLE | | <i>hydromorphone (pf)</i> | 5 |
| GENVOYA | 72 | | 133 | <i>hydroxychloroquine</i> | 61 |
| GILOTRIF..... | 25 | HEALTHY ACCENTS | | <i>hydroxyurea</i> | 25 |
| <i>glatiramer</i> | 96 | UNIFINE PENTIP..... | 133 | <i>hydroxyzine hcl</i> | 57 |
| <i>glatopa</i> | 96 | <i>heather</i> | 102 | <i>hydroxyzine pamoate</i> | 193 |
| <i>glimepiride</i> | 54 | HEMADY | 174 | HYRNUO | 25 |
| <i>glipizide</i> | 54 | <i>heparin (porcine)</i> | 78 | I | |
| <i>glipizide-metformin</i> | 54 | HEPLISAV-B (PF)..... | 186 | <i>ibandronate</i> | 191 |
| <i>glucagon emergency kit</i> | | HERCEPTIN HYLECTA..... | 25 | IBRANCE | 25 |
| (<i>human</i>) | 192 | HERNEXEOS | 25 | IBTROZI..... | 25 |
| <i>glutamine (sickle cell)</i> | 192 | HETLIOZ LQ | 203 | <i>ibu</i> | 7 |
| <i>glyburide</i> | 54 | HIBERIX (PF)..... | 186 | <i>ibuprofen</i> | 7 |
| <i>glyburide micronized</i> | 54 | HUMIRA | 180 | <i>ibuprofen-famotidine</i> | 7 |
| <i>glyburide-metformin</i> | 54 | HUMIRA PEN | 180 | <i>icatibant</i> | 89 |
| <i>glycerol phenylbutyrate</i> | 167 | HUMIRA PEN CROHNS-UC- | | <i>iclevia</i> | 102 |
| <i>glycopyrrolate</i> | 167 | HS START | 180 | ICLUSIG..... | 25 |
| <i>glydo</i> | 8 | HUMIRA PEN PSOR- | | <i>icosapent ethyl</i> | 92 |
| GLYXAMBI | 49 | UVEITS-ADOL HS | 180 | IDHIFA | 26 |
| GOMEKLI | 25 | HUMIRA(CF) | 180 | <i>ifosfamide</i> | 26 |
| <i>granisetron hcl</i> | 60 | HUMIRA(CF) PEDI CROHNS | | ILEVRO..... | 165 |
| <i>griseofulvin microsize</i> | 55 | STARTER | 180 | <i>imatinib</i> | 26 |
| <i>griseofulvin ultramicrosize</i> | 55 | HUMIRA(CF) PEN..... | 180 | IMBRUVICA..... | 26 |
| <i>guanfacine</i> | 83, 96 | HUMIRA(CF) PEN CROHNS- | | IMDELLTRA | 26 |
| GVOKE..... | 193 | UC-HS | 180 | <i>imipenem-cilastatin</i> | 15 |
| GVOKE HYOPEN 2-PACK | | HUMIRA(CF) PEN | | <i>imipramine hcl</i> | 47 |
| | 193 | PEDIATRIC UC..... | 180 | <i>imipramine pamoate</i> | 47 |
| GVOKE PFS 1-PACK | | HUMIRA(CF) PEN PSOR-UV- | | <i>imiquimod</i> | 110 |
| SYRINGE..... | 193 | ADOL HS | 180 | IMJUDO | 26 |
| H | | HUMULIN R U-500 (CONC) | | IMKELDI..... | 26 |
| HAEGARDA | 79 | INSULIN | 51 | IMOVAX RABIES VACCINE | |
| <i>hailey 24 fe</i> | 102 | HUMULIN R U-500 (CONC) | | (PF) | 186 |
| <i>hailey fe 1.5/30 (28)</i> | 102 | KWIKPEN..... | 51 | IMPAVIDO..... | 61 |
| <i>hailey fe 1/20 (28)</i> | 102 | <i>hydralazine</i> | 89 | INBRIJA | 63 |
| <i>halobetasol propionate</i> | 113 | <i>hydrochlorothiazide</i> | 90, 91 | <i>incassia</i> | 102 |
| <i>haloette</i> | 102 | <i>hydrocodone-acetaminophen</i> ... | 4 | INCONTROL ALCOHOL | |
| <i>haloperidol</i> | 66 | <i>hydrocodone-ibuprofen</i> | 4 | PADS | 133 |
| <i>haloperidol decanoate</i> | 66 | <i>hydrocortisone</i> | 113, 114, 174, | INCONTROL PEN NEEDLE | |
| <i>haloperidol lactate</i> | 66 | 190 | | | 133, 134 |
| HARVONI | 76 | <i>hydrocortisone butyrate</i> | 113, 114 | INCRELEX..... | 175 |

| | | | | | |
|---|--|--|--------|--|--------|
| <i>indapamide</i> | 91 | <i>ipratropium-albuterol</i> | 199 | <i>jolessa</i> | 103 |
| <i>indomethacin</i> | 7 | IQIRVO..... | 167 | <i>juleber</i> | 103 |
| INFANRIX (DTAP) (PF)..... | 186 | <i>irbesartan</i> | 83 | JULUCA..... | 73 |
| <i>infliximab</i> | 180 | <i>irbesartan-hydrochlorothiazide</i> | 83 | <i>junel 1.5/30 (21)</i> | 103 |
| INGREZZA..... | 97 | <i>irinotecan</i> | 26, 27 | <i>junel 1/20 (21)</i> | 103 |
| INGREZZA INITIATION PK(TARDIV)..... | 97 | ISENTRESS..... | 72, 73 | <i>junel fe 1.5/30 (28)</i> | 103 |
| INGREZZA SPRINKLE..... | 97 | ISENTRESS HD..... | 72 | <i>junel fe 1/20 (28)</i> | 103 |
| INLEXZO..... | 26 | <i>isibloom</i> | 102 | <i>junel fe 24</i> | 103 |
| INLURIYO..... | 26 | ISOLYTE S PH 7.4..... | 196 | JUXTAPID..... | 92, 93 |
| INLYTA..... | 26 | ISOLYTE-P IN 5 % DEXTROSE..... | 196 | JYLAMVO..... | 27 |
| INPEN (FOR HUMALOG) BLUE..... | 134 | ISOLYTE-S..... | 196 | JYNARQUE..... | 91 |
| INPEN (NOVOLOG OR FIASP) BLUE..... | 134 | <i>isoniazid</i> | 59 | JYNNEOS (PF)..... | 186 |
| INQOVI..... | 26 | <i>isosorbide dinitrate</i> | 94 | K | |
| INREBIC..... | 26 | <i>isosorbide mononitrate</i> | 94 | KALETRA..... | 73 |
| <i>insulin asp prt-insulin aspart</i> 51, 52 | | <i>isosorbide-hydralazine</i> | 94 | KALYDECO..... | 201 |
| <i>insulin aspart u-100</i> | 52 | <i>isradipine</i> | 90 | <i>kariva (28)</i> | 103 |
| <i>insulin glargine-yfgn</i> | 52 | ITOVEBI..... | 27 | KATERZIA..... | 90 |
| <i>insulin lispro</i> | 52 | <i>itraconazole</i> | 55 | <i>kelnor 1/35 (28)</i> | 103 |
| INSULIN SYR/NDL U100 HALF MARK..... | 134 | IV PREP WIPES..... | 136 | <i>kelnor 1/50 (28)</i> | 103 |
| INSULIN SYRINGE MICROFINE..... | 118 | <i>ivabradine</i> | 89 | KERENDIA..... | 94 |
| INSULIN SYRINGE NEEDLELESS..... | 135 | <i>ivermectin</i> | 61 | KESIMPTA PEN..... | 97 |
| INSULIN SYRINGE-NEEDLE U-100..... | 131, 134, 135, 139, 141, 143, 147, 151, 152 | IWILFIN..... | 27 | <i>ketoconazole</i> | 55 |
| INSULIN U-500 SYRINGE- NEEDLE..... | 135 | IXIARO (PF)..... | 186 | <i>ketoprofen</i> | 7 |
| INSUPEN PEN NEEDLE.... | 135 | J | | <i>ketorolac</i> | 7, 165 |
| INTELENCE..... | 72 | <i>jaimiess</i> | 102 | KEYTRUDA..... | 27 |
| <i>introvale</i> | 102 | JAKAFI..... | 27 | KEYTRUDA QLEX..... | 27 |
| INVEGA HAFYERA..... | 67 | <i>jantoven</i> | 78 | KIMMTRAK..... | 27 |
| INVEGA SUSTENNA..... | 67 | JANUMET..... | 49 | KINERET..... | 180 |
| INVEGA TRINZA..... | 67 | JANUMET XR..... | 49 | KINRIX (PF)..... | 186 |
| INVELTYS..... | 165 | JANUVIA..... | 49 | <i>kionex (with sorbitol)</i> | 167 |
| IPOL..... | 186 | JARDIANCE..... | 49 | KISQALI..... | 27, 28 |
| <i>ipratropium bromide</i> | 162, 199 | <i>jasmiel (28)</i> | 103 | KISQALI FEMARA CO-PACK | 27 |
| | | JAVADIN..... | 86 | KLISYRI (250 MG)..... | 110 |
| | | <i>javygtor</i> | 160 | <i>klor-con m10</i> | 196 |
| | | JAYPIRCA..... | 27 | <i>klor-con m15</i> | 196 |
| | | JEMPERLI..... | 27 | <i>klor-con m20</i> | 196 |
| | | <i>jencycla</i> | 103 | KLOXXADO..... | 9 |
| | | JENTADUETO..... | 49 | KOSELUGO..... | 28 |
| | | JENTADUETO XR..... | 49 | <i>kosher prenatal plus iron</i> | 204 |
| | | <i>jinteli</i> | 173 | KRAZATI..... | 28 |
| | | | | <i>kurvelo (28)</i> | 103 |

| | | | | | |
|---|--------|---|----------|-------------------------------------|---------|
| KYLEENA..... | 103 | <i>levofloxacin in d5w</i> | 17 | <i>losartan</i> | 83 |
| KYNMOBI..... | 63 | <i>levonest (28)</i> | 104 | <i>losartan-hydrochlorothiazide</i> | 83 |
| L | | <i>levonorgest-eth.estradiol-iron</i> | 104 | LOTEMAX..... | 165 |
| <i>l norgest/e.estradiol-e.estradiol</i> | 103 | | 104 | LOTEMAX SM..... | 165 |
| <i>labetalol</i> | 86 | <i>levonorgestrel-ethinyl estradiol</i> | 104 | <i>loteprednol etabonate</i> | 165 |
| <i>lacosamide</i> | 40 | <i>levonorg-eth estrad triphasic</i> | 104 | <i>lovastatin</i> | 93 |
| <i>lactulose</i> | 168 | <i>levora-28</i> | 104 | <i>low-ogestrel (28)</i> | 104 |
| <i>lagevrio (eua)</i> | 77 | <i>levothyroxine</i> | 177 | <i>loxapine succinate</i> | 67 |
| <i>lamivudine</i> | 73 | LEXIVA..... | 73 | <i>lo-zumandimine (28)</i> | 104 |
| <i>lamivudine-zidovudine</i> | 73 | LIBERVANT..... | 41 | <i>lubiprostone</i> | 168 |
| <i>lamotrigine</i> | 40, 41 | <i>lidocaine</i> | 8 | <i>luizza</i> | 105 |
| <i>lanreotide</i> | 175 | <i>lidocaine hcl</i> | 8 | LUMAKRAS..... | 29 |
| <i>lansoprazole</i> | 166 | <i>lidocaine viscous</i> | 8 | LUMIGAN..... | 195 |
| <i>lanthanum</i> | 169 | <i>lidocaine-prilocaine</i> | 8 | LUNSUMIO..... | 29 |
| LANTUS SOLOSTAR U-100 | | <i>lidocan iii</i> | 8 | LUPRON DEPOT..... | 29, 175 |
| INSULIN..... | 52 | LILETTA..... | 104 | LUPRON DEPOT (3 MONTH) | |
| LANTUS U-100 INSULIN..... | 52 | <i>linezolid</i> | 12 | | 29, 175 |
| <i>lapatinib</i> | 28 | <i>linezolid in dextrose 5%</i> | 12 | LUPRON DEPOT (4 MONTH) | |
| <i>larin 1.5/30 (21)</i> | 104 | LINZESS..... | 168 | | 29 |
| <i>larin 1/20 (21)</i> | 104 | <i>liomny</i> | 177 | LUPRON DEPOT (6 MONTH) | |
| <i>larin 24 fe</i> | 104 | <i>liothyronine</i> | 177 | | 29 |
| <i>larin fe 1.5/30 (28)</i> | 104 | LISCO..... | 136 | LUPRON DEPOT-PED..... | 175 |
| <i>larin fe 1/20 (28)</i> | 104 | <i>lisinopril</i> | 85 | LUPRON DEPOT-PED (3 | |
| <i>latanoprost</i> | 195 | <i>lisinopril-hydrochlorothiazide</i> | 85 | MONTH)..... | 175 |
| LAZCLUZE..... | 28 | LITE TOUCH INSULIN PEN | | <i>lurasidone</i> | 67 |
| <i>leflunomide</i> | 180 | NEEDLES..... | 136 | <i>lutera (28)</i> | 105 |
| <i>lenalidomide</i> | 28 | LITE TOUCH INSULIN | | LUTRATE DEPOT (3 | |
| LENTOCILIN S..... | 17 | SYRINGE..... | 136, 137 | MONTH)..... | 29 |
| LENVIMA..... | 28 | <i>lithium carbonate</i> | 97 | LYBALVI..... | 68 |
| <i>lessina</i> | 104 | <i>lithium citrate</i> | 97 | <i>lyleq</i> | 105 |
| <i>letrozole</i> | 28 | LIVDELZI..... | 168 | <i>lyllana</i> | 173 |
| <i>leucovorin calcium</i> | 193 | LIVTENCITY..... | 75 | LYNOZYFIC..... | 29 |
| LEUKERAN..... | 28 | LOKELMA..... | 168 | LYNPARZA..... | 30 |
| LEUKINE..... | 80 | <i>lomustine</i> | 28 | LYSODREN..... | 30 |
| <i>leuprolide</i> | 28 | LONSURF..... | 29 | LYTGOBI..... | 30 |
| <i>leuprolide acetate (3 month)</i> | 28 | <i>loperamide</i> | 168 | <i>lyza</i> | 105 |
| <i>levetiracetam</i> | 41 | <i>lopinavir-ritonavir</i> | 73 | M | |
| <i>levobunolol</i> | 195 | LOQTORZI..... | 29 | MAGELLAN INSULIN | |
| <i>levocarnitine</i> | 193 | <i>lorazepam</i> | 10 | SAFETY SYRNG..... | 137 |
| <i>levocarnitine (with sugar)</i> | 193 | <i>lorazepam intensol</i> | 10 | MAGELLAN SYRINGE..... | 137 |
| <i>levocetirizine</i> | 57 | LORBRENA..... | 29 | <i>magnesium sulfate</i> | 196 |
| <i>levofloxacin</i> | 17 | <i>loryna (28)</i> | 104 | <i>malathion</i> | 115 |

| | | | | | |
|----------------------------------|---------|---------------------------------------|-------------|--|----------|
| <i>maraviroc</i> | 73 | MEKINIST | 30 | MICRODOT INSULIN PEN | |
| MARGENZA | 30 | MEKTOVI..... | 30 | NEEDLE | 137, 138 |
| <i>marlissa (28)</i> | 105 | <i>meleya</i> | 105 | MICRODOT READYGARD | |
| <i>marnatal-f</i> | 204 | <i>meloxicam</i> | 7 | PEN NEEDLE | 138 |
| MARPLAN | 47 | <i>memantine</i> | 44 | <i>microgestin 1.5/30 (21)</i> | 105 |
| MATULANE | 30 | <i>memantine-donepezil</i> | 45 | <i>microgestin 1/20 (21)</i> | 105 |
| <i>matzim la</i> | 88 | MENACTRA (PF)..... | 186 | <i>microgestin 24 fe</i> | 105 |
| MAVENCLAD (10 TABLET | | MENQUADFI (PF)..... | 186 | <i>microgestin fe 1.5/30 (28)</i> | 105 |
| PACK)..... | 97 | MENVEO A-C-Y-W-135-DIP | | <i>microgestin fe 1/20 (28)</i> | 105 |
| MAVENCLAD (4 TABLET | | (PF)..... | 186 | <i>midodrine</i> | 83 |
| PACK)..... | 97 | <i>mercaptapurine</i> | 30 | MIEBO (PF)..... | 162 |
| MAVENCLAD (5 TABLET | | <i>meropenem</i> | 15 | <i>mifepristone</i> | 49 |
| PACK)..... | 97 | <i>merzee</i> | 105 | <i>miglitol</i> | 49 |
| MAVENCLAD (6 TABLET | | <i>mesalamine</i> | 190 | <i>miglustat</i> | 160 |
| PACK)..... | 97 | <i>mesna</i> | 193 | <i>mili</i> | 105 |
| MAVENCLAD (7 TABLET | | <i>metadate er</i> | 98 | <i>mimvey</i> | 173 |
| PACK)..... | 97 | <i>metformin</i> | 49 | MINI ULTRA-THIN II..... | 138 |
| MAVENCLAD (8 TABLET | | <i>methadone</i> | 5 | <i>minocycline</i> | 19 |
| PACK)..... | 97 | <i>methazolamide</i> | 195 | <i>minoxidil</i> | 94 |
| MAVENCLAD (9 TABLET | | <i>methenamine hippurate</i> | 12 | MIPLYFFA..... | 160 |
| PACK)..... | 97 | <i>methimazole</i> | 177 | MIRENA..... | 105 |
| MAVYRET | 77 | <i>methocarbamol</i> | 202 | <i>mirtazapine</i> | 47 |
| MAXICOMFORT II PEN | | <i>methotrexate sodium</i> | 30 | <i>misoprostol</i> | 166 |
| NEEDLE | 137 | <i>methotrexate sodium (pf)</i> | 30 | <i>mitoxantrone</i> | 30 |
| MAXICOMFORT INSULIN | | <i>methoxsalen</i> | 110 | M-M-R II (PF) | 186 |
| SYRINGE..... | 137 | <i>methscopolamine</i> | 168 | <i>m-natal plus</i> | 204 |
| MAXI-COMFORT INSULIN | | <i>methsuximide</i> | 41 | <i>modafinil</i> | 203 |
| SYRINGE..... | 137 | <i>methylphenidate hcl</i> | 98, 99 | MODEYSO..... | 30 |
| MAXI-COMFORT INSULIN | | <i>methylprednisolone</i> | 174 | <i>moexipril</i> | 85 |
| SYRINGE..... | 137 | <i>methylprednisolone acetate</i> . | 174 | <i>molindone</i> | 68 |
| MAXICOMFORT SAFETY | | <i>metoclopramide hcl</i> | 168 | <i>mometasone</i> | 114, 165 |
| PEN NEEDLE..... | 137 | <i>metolazone</i> | 91 | MONOJECT INSULIN | |
| MAYZENT | 97, 98 | <i>metoprolol succinate</i> | 86 | SAFETY SYRING..... | 139 |
| MAYZENT STARTER(FOR | | <i>metoprolol ta-hydrochlorothiaz</i> | | MONOJECT INSULIN | |
| 1MG MAINT)..... | 98 | | 86 | SYRINGE | 138, 139 |
| MAYZENT STARTER(FOR | | <i>metoprolol tartrate</i> | 86 | MONOJECT SYRINGE..... | 138 |
| 2MG MAINT)..... | 98 | <i>metronidazole</i> | 12, 57, 111 | MONOJECT ULTRA | |
| <i>meclizine</i> | 60 | <i>metronidazole in nacl (iso-os)</i> | 12 | COMFORT INSULIN | 154 |
| <i>medroxyprogesterone</i> | 176 | <i>metyrosine</i> | 89 | <i>mono-lynyah</i> | 105 |
| <i>mefenamic acid</i> | 7 | <i>mexiletine</i> | 85 | <i>montelukast</i> | 198 |
| <i>mefloquine</i> | 61 | <i>miconazole-3</i> | 56 | <i>morphine</i> | 5 |
| <i>megestrol</i> | 30, 176 | | | MORPHINE..... | 5 |

| | | |
|---|--|---------------------------------------|
| <i>morphine concentrate</i>5 | <i>neomycin-polymyxin b-</i> | <i>norethindrone-e.estradiol-iron</i> |
| MOUNJARO.....50 | <i>dexameth</i> 163 | 106 |
| MOVANTIK.....168 | <i>neomycin-polymyxin-gramicidin</i> | <i>norgestimate-ethinyl estradiol</i> |
| <i>moxifloxacin</i>17, 163 | 163 | 106 |
| <i>moxifloxacin-sod.ace,sul-water</i> | <i>neomycin-polymyxin-hc</i> 163 | <i>nortrel 1/35 (21)</i> 106 |
| 17 | <i>neo-polycin</i> 163 | <i>nortrel 1/35 (28)</i> 106 |
| <i>moxifloxacin-sod.chloride(iso)</i> | <i>neo-polycin hc</i> 163 | <i>nortrel 7/7/7 (28)</i> 106 |
| 17 | NERLYNX..... 31 | <i>nortriptyline</i> 47 |
| MRESVIA (PF).....187 | NEUPRO..... 63 | NORVIR..... 73 |
| MULTAQ.....85 | <i>nevirapine</i> 73 | NOVOFINE 30..... 139 |
| <i>mupirocin</i>111 | <i>newgen</i> 205 | NOVOFINE 32..... 139 |
| <i>mycophenolate mofetil</i>181 | NEXLETOL..... 93 | NOVOFINE PLUS..... 139 |
| <i>mycophenolate mofetil (hcl)</i> .180 | NEXLIZET..... 93 | NOVOLIN 70/30 U-100 |
| <i>mycophenolate sodium</i>181 | NEXPLANON..... 105 | INSULIN..... 52 |
| <i>mynatal</i>204 | <i>niacin</i> 93 | NOVOLIN 70-30 FLEXPEN U- |
| <i>mynatal advance</i>204 | <i>niacor</i> 93 | 100..... 52 |
| <i>mynatal plus</i>204 | <i>nicardipine</i> 90 | NOVOLIN N FLEXPEN..... 52 |
| <i>mynatal-z</i>204 | NICOTROL..... 9 | NOVOLIN N NPH U-100 |
| <i>mynate 90 plus</i>205 | NICOTROL NS..... 9 | INSULIN..... 53 |
| MYRBETRIQ.....170 | <i>nifedipine</i> 90 | NOVOLIN R FLEXPEN..... 53 |
| N | <i>nikki (28)</i> 105 | NOVOLIN R REGULAR U100 |
| <i>nabumetone</i>7 | NIKTIMVO..... 181 | INSULIN..... 53 |
| <i>nadolol</i>86 | <i>nilutamide</i> 31 | NOVOLOG FLEXPEN U-100 |
| <i>nafcillin</i>17 | NINLARO..... 31 | INSULIN..... 53 |
| <i>naloxone</i>9 | <i>nitazoxanide</i> 61 | NOVOLOG MIX 70-30 U-100 |
| <i>naltrexone</i>9 | <i>nitisinone</i> 160 | INSULN..... 53 |
| NAMZARIC.....45 | <i>nitrofurantoin macrocrystal</i> .. 12 | NOVOLOG MIX 70- |
| NANO 2ND GEN PEN | <i>nitrofurantoin monohyd/m-cryst</i> | 30FLEXPEN U-100..... 53 |
| NEEDLE..... 139 | 12 | NOVOLOG PENFILL U-100 |
| NANO PEN NEEDLE.....139 | <i>nitroglycerin</i> 94, 193 | INSULIN..... 53 |
| <i>naproxen</i>7, 8 | <i>niva-plus</i> 205 | NOVOLOG U-100 INSULIN |
| <i>naratriptan</i>58 | NIVESTYM..... 80 | ASPART..... 53 |
| NATACYN.....163 | <i>nizatidine</i> 166 | NOVOTWIST..... 139 |
| <i>nateglinide</i>50 | NORDITROPIN FLEXPRO 175 | NOXAFIL..... 56 |
| NATPARA.....191 | <i>norelgestromin-ethin.estradiol</i> | NUBEQA..... 31 |
| NAYZILAM.....41 | 105 | NUCALA..... 201 |
| <i>nebivolol</i>87 | <i>norethindrone (contraceptive)</i> | NULOJIX..... 181 |
| <i>nefazodone</i>47 | 106 | NUPLAZID..... 68 |
| <i>neomycin</i>11 | <i>norethindrone acetate</i> 176 | NURTEC ODT..... 58 |
| <i>neomycin-bacitracin-poly-hc</i> 163 | <i>norethindrone ac-eth estradiol</i> | <i>nyamyc</i> 56 |
| <i>neomycin-bacitracin-polymyxin</i> | 106, 173 | <i>nylia 1/35 (28)</i> 106 |
|163 | | <i>nylia 7/7/7 (28)</i> 106 |

| | | | | | | |
|--|----------|---|--------|---|-----------------------|----|
| <i>nymyo</i> | 106 | OMNIPOD DASH INTRO KIT (GEN 4) | 140 | P | <i>pacerone</i> | 85 |
| <i>nystatin</i> | 56 | OMNIPOD DASH PDM KIT (GEN 4) | 140 | <i>paclitaxel</i> | 32 | |
| <i>nystatin-triamcinolone</i> | 56 | OMNIPOD DASH PODS (GEN 4)..... | 140 | <i>paclitaxel protein-bound</i> | 32 | |
| <i>nystop</i> | 56 | ONAPGO..... | 63 | <i>paliperidone</i> | 68 | |
| NYVEPRIA..... | 80 | <i>ondansetron</i> | 60 | PALYNZIQ..... | 161 | |
| O | | <i>ondansetron hcl</i> | 60 | PANRETIN..... | 110 | |
| <i>obstetrix dha</i> | 205 | ONGENTYS..... | 63 | <i>pantoprazole</i> | 167 | |
| <i>obstetrix dha prenatal duo</i> | 205 | ONUREG..... | 31 | <i>paricalcitol</i> | 191 | |
| OICALIVA | 168 | OPDIVO | 31 | <i>paroxetine hcl</i> | 47 | |
| <i>octreotide acetate</i> | 175 | OPDIVO QVANTIG..... | 31 | PAXLOVID | 76 | |
| ODEFSEY | 74 | OPDUALAG | 31 | <i>pazopanib</i> | 32 | |
| ODOMZO | 31 | OPIPZA | 68 | PEDIARIX (PF)..... | 187 | |
| OFEV | 201 | OPSUMIT..... | 203 | PEDVAX HIB (PF) | 187 | |
| <i>ofloxacin</i> | 163 | ORENCIA | 181 | <i>peg 3350-electrolytes</i> | 169 | |
| OGIVRI..... | 31 | ORENCIA (WITH MALTOSE) | 181 | PEGASYS..... | 77 | |
| OGSIVEO | 31 | ORENCIA CLICKJECT | 181 | <i>peg-electrolyte soln</i> | 169 | |
| OJEMDA..... | 31 | ORFADIN | 161 | PEMAZYRE..... | 32 | |
| OJJAARA..... | 31 | ORGOVYX | 175 | <i>pemetrexed disodium</i> | 32 | |
| <i>olanzapine</i> | 68 | ORILISSA | 176 | PEMRYDI RTU..... | 32 | |
| <i>olmesartan</i> | 83 | ORKAMBI | 201 | PEN NEEDLE | 140, 141 | |
| <i>olmesartan-amlodipin-hcthiazid</i> | 83 | <i>orquidea</i> | 106 | PEN NEEDLE, DIABETIC 122, 132, 138, 140, 143 | | |
| <i>olmesartan-hydrochlorothiazide</i> | 83 | ORSERDU..... | 31 | PEN NEEDLE, DIABETIC, SAFETY | 143 | |
| <i>olopatadine</i> | 162 | <i>oseltamivir</i> | 75, 76 | PENBRAYA (PF)..... | 187 | |
| <i>omega-3 acid ethyl esters</i> | 93 | OSEVELT..... | 191 | PENBRAYA MENACWY COMPONENT(PF)..... | 187 | |
| <i>omeprazole</i> | 166 | OSMOLEX ER..... | 63 | PENBRAYA MENB COMPONENT (PF)..... | 187 | |
| <i>omeprazole-sodium bicarbonate</i> | 166, 167 | OTEZLA..... | 181 | <i>penciclovir</i> | 110 | |
| OMNIPOD 5 (G6/LIBRE 2 PLUS)..... | 140 | OTEZLA STARTER..... | 181 | <i>penicillamine</i> | 171 | |
| OMNIPOD 5 G6-G7 INTRO KT(GEN5)..... | 140 | OTEZLA XR..... | 181 | <i>penicillin g potassium</i> | 17 | |
| OMNIPOD 5 G6-G7 PODS (GEN 5)..... | 140 | OTEZLA XR INITIATION | 181 | <i>penicillin g procaine</i> | 17 | |
| OMNIPOD 5 INTRO(G6/LIBRE2PLUS) | 140 | <i>oxaliplatin</i> | 32 | <i>penicillin v potassium</i> | 17 | |
| OMNIPOD CLASSIC PDM KIT(GEN 3) | 140 | <i>oxandrolone</i> | 171 | PENMENVY MEN A-B-C-W- Y (PF)..... | 187 | |
| OMNIPOD CLASSIC PODS (GEN 3)..... | 140 | <i>oxazepam</i> | 11 | PENMENVY MENACWY COMPONENT(PF)..... | 187 | |
| | | <i>oxcarbazepine</i> | 41 | PENMENVY MENB COMPONENT (PF)..... | 187 | |
| | | <i>oxybutynin chloride</i> | 170 | PENTACEL (PF)..... | 187 | |
| | | <i>oxycodone</i> | 5 | | | |
| | | <i>oxycodone-acetaminophen</i> .. | 5, 6 | | | |
| | | <i>oxymorphone</i> | 6 | | | |
| | | OZEMPIC..... | 50 | | | |

| | | | | | |
|--|----------|---|----------|--|----------|
| <i>pentamidine</i> | 61, 62 | <i>portia 28</i> | 107 | PREZISTA | 74 |
| PENTIPS PEN NEEDLE | 141 | <i>posaconazole</i> | 56 | PRIFTIN | 59 |
| <i>pentoxifylline</i> | 81 | <i>potassium chloride</i> | 196, 197 | PRIMAQUINE | 62 |
| <i>perampanel</i> | 41 | <i>potassium chloride-0.45 % nacl</i> | 197 | <i>primidone</i> | 42 |
| <i>perindopril erbumine</i> | 85 | | 197 | PRIORIX (PF) | 187 |
| <i>periogard</i> | 109 | <i>potassium citrate</i> | 197 | PRO COMFORT ALCOHOL | |
| <i>permethrin</i> | 115 | <i>pr natal 400</i> | 205 | PADS | 142 |
| <i>perphenazine</i> | 68 | <i>pr natal 400 ec</i> | 205 | PRO COMFORT INSULIN | |
| <i>perphenazine-amitriptyline</i> | 47 | <i>pr natal 430</i> | 205 | SYRINGE | 141, 142 |
| PERSERIS..... | 68 | <i>pr natal 430 ec</i> | 205 | PRO COMFORT PEN | |
| <i>phenelzine</i> | 47 | <i>pramipexole</i> | 63 | NEEDLE | 142 |
| <i>phenobarbital</i> | 42 | <i>prasugrel hcl</i> | 81 | PROAIR RESPICLICK | 199 |
| <i>phenytek</i> | 42 | <i>pravastatin</i> | 93 | <i>probenecid</i> | 57 |
| <i>phenytoin</i> | 42 | <i>praziquantel</i> | 62 | <i>probenecid-colchicine</i> | 57 |
| <i>phenytoin sodium</i> | 42 | <i>prazosin</i> | 83 | <i>prochlorperazine</i> | 60 |
| <i>phenytoin sodium extended</i> | 42 | <i>prednisolone</i> | 174 | <i>prochlorperazine edisylate</i> | 60, |
| <i>philith</i> | 106 | <i>prednisolone acetate</i> | 165 | 68 | |
| PIFELTRO | 74 | <i>prednisolone sodium phosphate</i> | 165, 174 | <i>prochlorperazine maleate</i> | 60 |
| <i>pilocarpine hcl</i> | 109, 195 | | 165, 174 | <i>procto-med hc</i> | 114 |
| <i>pimecrolimus</i> | 114 | <i>prednisone</i> | 174 | <i>proctosol hc</i> | 114 |
| <i>pimozide</i> | 68 | <i>pregabalin</i> | 42 | <i>proctozone-hc</i> | 114 |
| <i>pimtree (28)</i> | 107 | PREMARIN..... | 173 | PRODIGY INSULIN | |
| <i>pindolol</i> | 87 | PREMPHASE..... | 173 | SYRINGE | 142 |
| <i>pioglitazone</i> | 50 | PREMPRO..... | 173 | <i>progesterone micronized</i> | 176 |
| <i>pioglitazone-metformin</i> | 50 | <i>prenal true</i> | 205 | PROGRAF | 181, 182 |
| PIP PEN NEEDLE | 141 | <i>prenaissance</i> | 205 | PROLASTIN-C..... | 201 |
| <i>piperacillin-tazobactam</i> | 17 | <i>prenaissance plus</i> | 205 | <i>promethazine</i> | 57, 60 |
| PIQRAY | 32 | <i>prenatabs fa</i> | 205 | <i>promethegan</i> | 61 |
| <i>pirfenidone</i> | 201 | <i>prenatal 19</i> | 205 | <i>propafenone</i> | 85 |
| <i>piroxicam</i> | 8 | <i>prenatal 19 (with docusate)</i> . | 205 | <i>propranolol</i> | 87 |
| <i>pitavastatin calcium</i> | 93 | <i>prenatal plus</i> | 205 | <i>propylthiouracil</i> | 177 |
| PLASMA-LYTE A | 196 | <i>prenatal plus (calcium carb)</i> 205 | | PROQUAD (PF) | 188 |
| PLEGRIDY | 99 | <i>prenatal vitamin plus low iron</i> | 205 | PROSOL 20 %..... | 82 |
| <i>pnv 29-1</i> | 205 | | 205 | <i>protriptyline</i> | 47 |
| <i>pnv-dha + docusate</i> | 205 | <i>prenatal-u</i> | 206 | PULMOZYME | 161 |
| <i>pnv-omega</i> | 205 | <i>preplus</i> | 206 | PURE COMFORT ALCOHOL | |
| <i>podofilox</i> | 110 | <i>pretab</i> | 206 | PADS | 142 |
| <i>polycin</i> | 164 | <i>prevalite</i> | 93 | PURE COMFORT PEN | |
| <i>polymyxin b sulfate</i> | 12 | PREVENT DROPSAFE PEN | | NEEDLE | 142, 143 |
| <i>polymyxin b sulf-trimethoprim</i> | 164 | NEEDLE..... | 141 | PURE COMFORT SAFETY | |
| POMALYST | 32 | PREVYMIS | 76 | PEN NEEDLE | 142 |
| | | PREZCOBIX..... | 74 | <i>pyrazinamide</i> | 59 |

| | | | | | |
|--------------------------------------|--------|---------------------------------------|-----|---------------------------------------|--------|
| <i>pyridostigmine bromide</i> | 193 | <i>ribavirin</i> | 77 | SAFESNAP INSULIN | |
| <i>pyrimethamine</i> | 62 | RIDAURA..... | 182 | SYRINGE..... | 143 |
| Q | | <i>rifabutin</i> | 59 | SAFETY PEN NEEDLE..... | 144 |
| QINLOCK..... | 32 | <i>rifampin</i> | 59 | <i>sajazir</i> | 89 |
| QUADRACEL (PF)..... | 188 | <i>rilpivirine</i> | 74 | SANTYL..... | 110 |
| <i>quetiapine</i> | 68, 69 | <i>riluzole</i> | 99 | <i>sapropterin</i> | 161 |
| <i>quinapril</i> | 85 | <i>rimantadine</i> | 76 | SCSEMBLIX..... | 33, 34 |
| <i>quinapril-hydrochlorothiazide</i> | 85 | RINVOQ..... | 182 | <i>scopolamine base</i> | 61 |
| <i>quinidine gluconate</i> | 86 | RINVOQ LQ..... | 182 | SECUADO..... | 69 |
| <i>quinidine sulfate</i> | 86 | <i>risedronate</i> | 191 | SECURESAFE INSULIN | |
| <i>quinine sulfate</i> | 62 | <i>risperidone</i> | 69 | SYRINGE..... | 144 |
| QULIPTA..... | 58 | <i>risperidone microspheres</i> | 69 | SECURESAFE PEN NEEDLE | |
| R | | <i>ritonavir</i> | 74 | | 144 |
| RABAVERT (PF)..... | 188 | RITUXAN HYCELA..... | 33 | SELARSDI..... | 182 |
| <i>rabeprazole</i> | 167 | <i>rivaroxaban</i> | 78 | <i>select-ob</i> | 206 |
| RALDESY..... | 47 | <i>rivastigmine</i> | 45 | <i>select-ob (folic acid)</i> | 206 |
| <i>raloxifene</i> | 173 | <i>rivastigmine tartrate</i> | 45 | <i>selegiline hcl</i> | 63 |
| <i>ramipril</i> | 85 | RIVFLOZA..... | 193 | <i>selenium sulfide</i> | 111 |
| <i>ranolazine</i> | 89 | <i>rizatriptan</i> | 58 | SELZENTRY..... | 74 |
| <i>rasagiline</i> | 63 | <i>r-natal ob</i> | 206 | <i>se-natal 19 chewable</i> | 206 |
| RASUVO (PF)..... | 182 | ROCKLATAN..... | 195 | SEREVENT DISKUS..... | 199 |
| RAYALDEE..... | 191 | <i>roflumilast</i> | 201 | SEROSTIM..... | 176 |
| <i>reclipsen (28)</i> | 107 | ROLVEDON..... | 80 | <i>sertraline</i> | 47 |
| RECOMBIVAX HB (PF)..... | 188 | ROMVIMZA..... | 33 | <i>setlakin</i> | 107 |
| REGRANEX..... | 110 | <i>ropinirole</i> | 63 | <i>sevelamer carbonate</i> | 169 |
| RELENZA DISKHALER..... | 76 | <i>rosadan</i> | 111 | <i>sevelamer hcl</i> | 169 |
| RELISTOR..... | 168 | <i>rosuvastatin</i> | 93 | SEZABY..... | 42 |
| <i>repaglinide</i> | 50 | <i>rosyrah</i> | 107 | <i>sf 5000 plus</i> | 109 |
| REPATHA PUSHTRONEX..... | 93 | ROTARIX..... | 188 | <i>sharobel</i> | 107 |
| REPATHA SURECLICK..... | 93 | ROTATEQ VACCINE..... | 188 | SHINGRIX (PF)..... | 188 |
| REPATHA SYRINGE..... | 93 | ROZLYTREK..... | 33 | SIGNIFOR..... | 176 |
| RETACRIT..... | 80 | RUBRACA..... | 33 | <i>sildenafil</i> | 203 |
| RETEVMO..... | 32, 33 | <i>rufinamide</i> | 42 | <i>sildenafil (pulm.hypertension)</i> | |
| RETROVIR..... | 74 | RUKOBIA..... | 74 | | 203 |
| REVCOVI..... | 161 | RYBELSUS..... | 50 | <i>silver sulfadiazine</i> | 111 |
| REVUFORJ..... | 33 | RYBREVANT..... | 33 | SIMBRINZA..... | 195 |
| REXULTI..... | 69 | RYBREVANT FASPRO..... | 33 | <i>simliya (28)</i> | 107 |
| REYATAZ..... | 74 | RYDAPT..... | 33 | <i>simpesse</i> | 107 |
| REZDIFFRA..... | 177 | RYKINDO..... | 69 | SIMPLI PEN NEEDLE..... | 132 |
| REZLIDHIA..... | 33 | RYTELO..... | 33 | <i>simvastatin</i> | 93 |
| REZUROCK..... | 182 | S | | <i>sirolimus</i> | 182 |
| RHOPRESSA..... | 195 | <i>sacubitril-valsartan</i> | 83 | SIRTURO..... | 59 |

| | | | |
|--|----------|---------------------------------------|----------|
| SKY SAFETY PEN NEEDLE | | TABRECTA | 34 |
| | 144 | <i>tacrolimus</i> | 114, 183 |
| SKYLA | 107 | <i>adalafil</i> | 203 |
| SKYRIZI | 182 | TAFINLAR | 34 |
| <i>sodium chloride 0.45 %</i> | 197 | <i>tafluprost (pf)</i> | 195 |
| <i>sodium chloride 0.9 %</i> | 197 | TAGRISO | 34 |
| <i>sodium fluoride-pot nitrate</i> | 109 | TAKHZYRO | 193, 194 |
| <i>sodium oxybate</i> | 203 | TALVEY | 34 |
| <i>sodium phenylbutyrate</i> | 168 | TALZENNA | 34 |
| <i>sodium polystyrene sulfonate</i> | 168 | <i>tamoxifen</i> | 34 |
| <i>sodium, potassium, mag sulfates</i> | 169 | <i>tamsulosin</i> | 170 |
| <i>solifenacin</i> | 170 | <i>tarina 24 fe</i> | 107 |
| SOLQUA 100/33 | 53 | <i>tarina fe 1-20 eq (28)</i> | 107 |
| SOLTAMOX | 34 | <i>taron-c dha</i> | 206 |
| SOMATULINE DEPOT | 176 | <i>taron-prex prenatal-dha</i> | 206 |
| SOMAVERT | 176 | TASIGNA | 34 |
| <i>sorafenib</i> | 34 | <i>tasimelteon</i> | 203 |
| <i>sorine</i> | 87 | TAVALISSE | 80 |
| <i>sotalol</i> | 87 | TAVNEOS | 183 |
| <i>sotalol af</i> | 87 | <i>taysofy</i> | 107 |
| SPIRIVA RESPIMAT | 200 | <i>tazarotene</i> | 115 |
| <i>spironolactone</i> | 91, 94 | <i>tazicef</i> | 14 |
| <i>spironolacton-hydrochlorothiaz</i> | 91 | <i>taztia xt</i> | 88 |
| SPRAVATO | 48 | TAZVERIK | 34 |
| <i>sprintec (28)</i> | 107 | TDVAX | 188 |
| SPRITAM | 42 | TECENTRIQ | 35 |
| <i>sps (with sorbitol)</i> | 168 | TECENTRIQ HYBREZA | 34 |
| <i>sronyx</i> | 107 | TECHLITE INSULIN | |
| <i>ssd</i> | 111 | SYRINGE | 146, 147 |
| <i>stavudine</i> | 74 | TECHLITE INSULN | |
| STELARA | 182, 183 | SYR(HALF UNIT) | 146 |
| STERILE PADS | 144 | TECHLITE PEN NEEDLE | 147 |
| STIOLTO RESPIMAT | 200 | TECHLITE PLUS PEN | |
| STIVARGA | 34 | NEEDLE | 147 |
| STOBOCLO | 192 | TECVAYLI | 35 |
| STRENSIQ | 161 | TEFLARO | 14 |
| <i>streptomycin</i> | 11 | <i>telmisartan</i> | 84 |
| STRIBILD | 74 | <i>telmisartan-amlodipine</i> | 84 |
| STRIVERDI RESPIMAT | 200 | <i>telmisartan-hydrochlorothiazid</i> | 84 |
| <i>subvenite</i> | 42 | <i>temazepam</i> | 11 |
| | | TEMIXYS | 75 |
| | | | |
| <i>sucralfate</i> | 167 | | |
| <i>sulfacetamide sodium</i> | 164 | | |
| <i>sulfacetamide sodium (acne)</i> | 111 | | |
| <i>sulfacetamide-prednisolone</i> | 164 | | |
| <i>sulfadiazine</i> | 18 | | |
| <i>sulfamethoxazole-trimethoprim</i> | 18 | | |
| | 18 | | |
| <i>sulfasalazine</i> | 190 | | |
| <i>sulindac</i> | 8 | | |
| <i>sumatriptan</i> | 58 | | |
| <i>sumatriptan succinate</i> | 58, 59 | | |
| <i>sumatriptan-naproxen</i> | 59 | | |
| <i>sunitinib malate</i> | 34 | | |
| SUNLENCA | 74 | | |
| SURE COMFORT ALCOHOL | | | |
| PREP PADS | 145 | | |
| SURE COMFORT INS. SYR. | | | |
| U-100 | 144 | | |
| SURE COMFORT INSULIN | | | |
| SYRINGE | 144, 145 | | |
| SURE COMFORT PEN | | | |
| NEEDLE | 145 | | |
| SURE COMFORT SAFETY | | | |
| PEN NEEDLE | 144 | | |
| SURE-FINE PEN NEEDLES | | | |
| | 145 | | |
| SURE-JECT INSULIN | | | |
| SYRINGE | 145, 146 | | |
| SURE-PREP ALCOHOL PREP | | | |
| PADS | 146 | | |
| <i>syeda</i> | 107 | | |
| SYMDEKO | 202 | | |
| SYMPAZAN | 43 | | |
| SYMTUZA | 75 | | |
| SYNAREL | 176 | | |
| SYNJARDY | 50 | | |
| SYNJARDY XR | 50 | | |
| SYNRIBO | 34 | | |
| SYRINGE WITH NEEDLE, | | | |
| SAFETY | 144 | | |
| T | | | |
| TABLOID | 34 | | |

| | | | | | |
|--|----------|---|---------|--------------------------------|---------------|
| <i>tencon</i> | 6 | <i>tobramycin</i> | 11, 164 | <i>triazolam</i> | 11 |
| TENIVAC (PF) | 188 | <i>tobramycin in 0.225 % nacl</i> ... | 11 | <i>tridacaine ii</i> | 8 |
| <i>tenofovir disoproxil fumarate</i> | 75 | <i>tobramycin sulfate</i> | 11 | <i>trientine</i> | 171 |
| TEPMETKO..... | 35 | <i>tobramycin-dexamethasone</i> . | 164 | <i>tri-estarylla</i> | 107 |
| <i>terazosin</i> | 171 | <i>tolterodine</i> | 170 | <i>trifluoperazine</i> | 69 |
| <i>terbinafine hcl</i> | 56 | <i>tolvaptan (polycys kidney dis)</i> | 91 | <i>trifluridine</i> | 164 |
| <i>terbutaline</i> | 200 | TOPCARE CLICKFINE | 148 | <i>trihexyphenidyl</i> | 63, 64 |
| <i>terconazole</i> | 58 | TOPCARE ULTRA | | TRIJARDY XR..... | 50 |
| <i>teriflunomide</i> | 99 | COMFORT | 148 | TRIKAFTA..... | 202 |
| <i>teriparatide</i> | 192 | <i>topiramate</i> | 43 | <i>tri-legend fe</i> | 108 |
| TERUMO INSULIN SYRINGE | | <i>toposar</i> | 35 | <i>tri-linyah</i> | 108 |
| | 147 | <i>toremifene</i> | 35 | <i>tri-lo-estarylla</i> | 108 |
| <i>testosterone</i> | 171, 172 | <i>torpenz</i> | 35 | <i>tri-lo-marzia</i> | 108 |
| <i>testosterone cypionate</i> | 171 | <i>torse mide</i> | 91 | <i>tri-lo-mili</i> | 108 |
| <i>testosterone enanthate</i> | 171 | TOUJEO MAX U-300 | | <i>tri-lo-sprintec</i> | 108 |
| <i>tetrabenazine</i> | 99 | SOLOSTAR..... | 53 | <i>trimethoprim</i> | 12 |
| <i>tetracycline</i> | 19 | TOUJEO SOLOSTAR U-300 | | <i>tri-mili</i> | 108 |
| TEVIMBRA..... | 35 | INSULIN | 53 | <i>trimipramine</i> | 48 |
| THALOMID..... | 194 | TRADJENTA | 50 | TRINTELLIX | 48 |
| <i>theophylline</i> | 200 | <i>tramadol</i> | 6 | <i>tri-nymyo</i> | 108 |
| THINPRO INSULIN SYRINGE | | <i>tramadol-acetaminophen</i> | 6 | <i>tri-sprintec (28)</i> | 108 |
| | 147, 148 | <i>trandolapril</i> | 85 | TRIUMEQ | 75 |
| <i>thioridazine</i> | 69 | <i>tranexamic acid</i> | 80 | TRIUMEQ PD | 75 |
| <i>thiothixene</i> | 69 | <i>tranylcypromine</i> | 48 | <i>trivora (28)</i> | 108 |
| <i>tiadylt er</i> | 88 | TRAVASOL 10 %..... | 82 | <i>tri-vylibra</i> | 108 |
| <i>tiagabine</i> | 43 | <i>travoprost</i> | 195 | <i>tri-vylibra lo</i> | 108 |
| TIBSOVO..... | 35 | <i>trazodone</i> | 48 | TRIZIVIR | 75 |
| <i>ticagrelor</i> | 81 | TRECTOR | 59 | TROGARZO..... | 75 |
| TICE BCG..... | 35 | TRELEGY ELLIPTA..... | 200 | TROPHAMINE 10 %..... | 82 |
| TICOVAC | 189 | TRELSTAR..... | 35 | <i>trospium</i> | 170 |
| <i>tigecycline</i> | 19 | TREMFYA | 183 | TRUE COMFORT ALCOHOL | |
| <i>tilia fe</i> | 107 | TREMFYA ONE-PRESS.... | 183 | PADS | 149 |
| <i>timolol</i> | 195 | TREMFYA PEN..... | 183 | TRUE COMFORT INSULIN | |
| <i>timolol maleate</i> | 87, 195 | TREMFYA PEN INDUCTION | | SYRINGE | 149 |
| <i>tinidazole</i> | 62 | PK(2PEN)..... | 183 | TRUE COMFORT PEN | |
| <i>tiopronin</i> | 171 | <i>treprostinil sodium</i> | 204 | NEEDLE..... | 149 |
| <i>tiotropium bromide</i> | 200 | <i>tretinoin</i> | 115 | TRUE COMFORT PRO | |
| TIVDAK..... | 35 | <i>tretinoin (antineoplastic)</i> | 35 | ALCOHOL PADS | 150 |
| TIVICAY | 75 | <i>triamcinolone acetonide</i> | 109, | TRUE COMFORT PRO INS | |
| TIVICAY PD | 75 | 114, 174 | | SYRINGE | 148, 149, 150 |
| <i>tizanidine</i> | 202 | <i>triamterene-hydrochlorothiazid</i> | | TRUE COMFORT SAFE | |
| TOBI PODHALER | 11 | | 91 | INSULIN SYRG..... | 149, 150 |

| | | | | | |
|--|----------|---|--------------------|--|----------|
| TRUE COMFORT SAFETY PEN NEEDLE..... | 148 | ULTRA CMFT INS SYR (HALF UNIT)..... | 132, 144 | UNIFINE SAFECONTROL PEN NEEDLE | 158 |
| TRUEPLUS INSULIN..... | 150, 151 | ULTRA COMFORT INSULIN SYRINGE..... | 126, 132, 153, 154 | UNIFINE ULTRA PEN NEEDLE | 158, 159 |
| TRUEPLUS PEN NEEDLE..... | 150 | ULTRA FLO INSUL SYR(HALF UNIT)..... | 154 | UPTRAVI | 204 |
| TRULANCE..... | 168 | ULTRA FLO INSULIN SYRINGE..... | 154 | <i>ursodiol</i> | 169 |
| TRULICITY..... | 51 | ULTRA FLO PEN NEEDLE | 154 | <i>ustekinumab</i> | 183 |
| TRUMENBA | 189 | ULTRA THIN PEN NEEDLE | 155 | UZEDY | 69, 70 |
| TRUQAP | 35 | ULTRACARE INSULIN SYRINGE..... | 155 | V | |
| TRUXIMA | 35 | ULTRACARE PEN NEEDLE | 155 | <i>valacyclovir</i> | 77 |
| TUKYSA..... | 35 | ULTRA-FINE INS SYR (HALF UNIT) | 156 | VALCHLOR..... | 110 |
| TURALIO | 36 | ULTRA-FINE INSULIN SYRINGE..... | 155, 156 | <i>valganciclovir</i> | 77 |
| <i>turqoz (28)</i> | 108 | ULTRA-FINE PEN NEEDLE | 156 | <i>valproate sodium</i> | 43 |
| TWINRIX (PF) | 189 | ULTRA-THIN II (SHORT) INS SYR | 156, 157 | <i>valproic acid</i> | 43 |
| TYBOST | 194 | ULTRA-THIN II (SHORT) PEN NDL | 157 | <i>valproic acid (as sodium salt)</i> | 43 |
| TYENNE..... | 183 | ULTRA-THIN II INS PEN NEEDLES | 157 | <i>valsartan</i> | 84 |
| TYENNE AUTOINJECTOR | 183 | ULTRA-THIN II INSULIN SYRINGE..... | 156, 157 | <i>valsartan-hydrochlorothiazide</i> | 84 |
| TYMLOS | 192 | UNIFINE OTC PEN NEEDLE | 157 | VALTOCO | 43 |
| TYPHIM VI | 189 | UNIFINE PEN NEEDLE | 157 | <i>valtya</i> | 108 |
| TYVASO..... | 204 | UNIFINE PENTIPS | 140, 157 | <i>vancomycin</i> | 12 |
| U | | UNIFINE PENTIPS MAXFLOW..... | 157 | VANFLYTA..... | 36 |
| UBRELVY..... | 59 | UNIFINE PENTIPS PLUS..... | 157, 158 | VANISHPOINT INSULIN SYRINGE | 159 |
| UDENYCA ONBODY | 80 | UNIFINE PENTIPS PLUS MAXFLOW..... | 157 | VANISHPOINT SYRINGE..... | 159 |
| ULTICARE | 151, 152 | UNIFINE PROTECT | 158 | VAQTA (PF) | 189 |
| ULTICARE INSULIN SYRINGE..... | 151 | | | <i>varenicline tartrate</i> | 9 |
| ULTICARE INSULN SYR(HALF UNIT) | 151 | | | VARIVAX (PF)..... | 189 |
| ULTICARE PEN NEEDLE..... | 151, 152 | | | VAXCHORA VACCINE ... | 189 |
| ULTICARE SAFETY PEN NEEDLE | 152 | | | <i>velivet triphasic regimen (28)</i> | 108 |
| ULTIGUARD SAFEPACK- INSULIN SYR | 152, 153 | | | VELTASSA | 169 |
| ULTIGUARD SAFEPACK- PEN NEEDLE..... | 153 | | | VEMLIDY | 75 |
| ULTILET ALCOHOL SWAB | 153 | | | VENCLEXTA..... | 36 |
| ULTILET INSULIN SYRINGE | 134, 153 | | | VENCLEXTA STARTING PACK..... | 36 |
| ULTILET PEN NEEDLE | 153 | | | <i>venlafaxine</i> | 48 |
| | | | | <i>venlafaxine besylate</i> | 48 |
| | | | | VEOZAH | 194 |
| | | | | <i>verapamil</i> | 88 |
| | | | | VERIFINE INSULIN SYRINGE | 159, 160 |

| | | |
|----------------------------------|---|---|
| VERIFINE PEN NEEDLE... 159 | <i>voriconazole</i> 56 | <i>xulane</i> 109 |
| VERIFINE PLUS PEN | VOSEVI..... 77 | XULTOPHY 100/3.6..... 53 |
| NEEDLE 159 | VOWST 194 | Y |
| VERIFINE PLUS PEN | <i>vp-ch-pnv</i> 206 | <i>yargesa</i> 161 |
| NEEDLE-SHARP 159 | <i>vp-pnv-dha</i> 206 | YERVOY 37 |
| VERQUVO 89 | VRAYLAR..... 70 | YESINTEK..... 184 |
| VERSACLOZ 70 | VUMERITY 99 | YF-VAX (PF) 190 |
| VERSALON..... 160 | VYALEV..... 64 | YONSA..... 38 |
| VERZENIO..... 36 | <i>vyfemla (28)</i> 109 | YUFLYMA(CF) 184 |
| <i>vestura (28)</i> 108 | <i>vylibra</i> 109 | YUFLYMA(CF) AI CROHN'S- UC-HS..... 184 |
| V-GO 20..... 160 | VYLOY 37 | YUFLYMA(CF) AUTOINJECTOR..... 184 |
| V-GO 30..... 160 | VYZULTA 195 | <i>yuvafem</i> 173 |
| V-GO 40..... 160 | W | Z |
| <i>vienva</i> 108 | <i>warfarin</i> 78 | <i>zafemy</i> 109 |
| <i>vigabatrin</i> 43 | WEBCOL 160 | <i>zafirlukast</i> 198 |
| <i>vigadrone</i> 43 | WELIREG 37 | <i>zaleplon</i> 203 |
| <i>vigpoder</i> 43 | WINREVAIR 202 | <i>zatean-pn dha</i> 206 |
| <i>vilazodone</i> 48 | <i>wixela inhub</i> 198 | <i>zatean-pn plus</i> 206 |
| VIMKUNYA..... 189 | X | <i>zebutal</i> 6 |
| <i>vinblastine</i> 36 | XALKORI 37 | ZEJULA 38 |
| <i>vincasar pfs</i> 36 | <i>xarah fe</i> 109 | ZELBORAF 38 |
| <i>vincristine</i> 36 | XARELTO..... 79 | <i>zenatane</i> 110 |
| <i>vinorelbine</i> 36 | XARELTO DVT-PE TREAT 30D START..... 79 | ZENPEP..... 161 |
| <i>violele (28)</i> 108 | XATMEP..... 37 | <i>zidovudine</i> 75 |
| VIRACEPT 75 | XCOPRI..... 43, 44 | ZIIHERA..... 38 |
| VIREAD..... 75 | XCOPRI MAINTENANCE PACK..... 43 | <i>zingiber</i> 206 |
| <i>virt-c dha</i> 206 | XCOPRI TITRATION PACK 44 | <i>ziprasidone hcl</i> 70 |
| <i>virt-nate dha</i> 206 | XDEMVI 164 | <i>ziprasidone mesylate</i> 70 |
| <i>virt-pn dha</i> 206 | XELJANZ..... 184 | ZIRABEV 38 |
| <i>virt-pn plus</i> 206 | XELJANZ XR..... 184 | ZIRGAN 164 |
| <i>vitafol gummies</i> 206 | XERMELO 169 | ZOLADEX..... 38 |
| <i>vitafol nano</i> 206 | XGEVA 192 | ZOLINZA 38 |
| <i>vitafol-ob+dha</i> 206 | XIFAXAN 13 | <i>zolmitriptan</i> 59 |
| VITRAKVI..... 36 | XIGDUO XR..... 51 | <i>zolpidem</i> 203 |
| VIVIMUSTA 36 | XIIDRA 166 | ZONISADE..... 44 |
| VIVOTIF..... 189 | XOLAIR 202 | <i>zonisamide</i> 44 |
| VIZIMPRO..... 36 | XOSPATA..... 37 | <i>zovia 1/35e (28)</i> 109 |
| VOCABRIA..... 75 | XPOVIO 37 | <i>zovia 1-35 (28)</i> 109 |
| <i>volnea (28)</i> 108 | XTANDI..... 37 | ZTALMY 44 |
| VONJO..... 36 | | ZTLIDO 8 |
| VOQUEZNA..... 167 | | |
| VORANIGO..... 36 | | |

| | | | | | |
|-------------------------------|-----|----------------|-----|------------------------|----|
| <i>zumandimine (28)</i> | 109 | ZYKADIA..... | 38 | ZYNYZ..... | 38 |
| ZURZUVAE | 48 | ZYLET..... | 164 | ZYPREXA RELPREVV | 70 |
| ZYDELIG..... | 38 | ZYNLONTA | 38 | | |

VILLAGE CARE MAX

Llámenos al 1-855-296-8800

sin cargo TTY 711

7 días a la semana de

8:00 am a 8:00 pm

www.villagecaremax.org

Este formulario fue actualizado el 01/23/2026. Si desea información más reciente o tiene otras preguntas, por favor llame a Servicios a Miembros de VillageCareMAX al 855-296-8800 (usuarios de TTY llaman al 711), de 8:00 am a 8:00 pm, los 7 días de la semana o visite www.villagecaremax.org.